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Abstract
Due to the side-effects caused by regular chemotherapy, the development of drug delivery
systems that can specifically target cancer cells and deliver the therapeutic dose is required.
In this study, a folate-derivative of β-cyclodextrin has been studied as a vehicle for targeting
folate receptors (FR) and delivering the chemotherapeutic drug methotrexate (MTX). FRs can
be considered key cell membrane targets since they are commonly over-expressed in cancer
cells and play an important role in cancer development and progression. Cyclodextrins (CDs)
are cyclic oligosaccharides with a unique structure that allows them to form inclusion
complexes with guest molecules, increasing their aqueous solubility and efficacy. MTX is a
chemotherapeutic drug that acts by inhibiting folate metabolism and is used worldwide for
the treatment of different types of cancer.
Cellular uptake of folic acid is mediated with high affinity by FRs while the cellular uptake of
antifolates, such as MTX, is mediated with high affinity by the reduced folate carriers
(RFCs). This study addresses the gene (mRNA) and protein expression levels of FRs and
RFCs in the carcinoma cell lines KB (cervical carcinoma), CaCo-2 (colon), SKOV-3
(ovarian), HeLa (cervical), MCF-7 (breast), A549 (lung) and the normal cell line BEAS-2B
(bronchial epithelial), quantified by real-time polymerase chain reaction (real-time PCR) and
flow cytometry, respectively. Real-time PCR and flow cytometry data demonstrated that
levels of FR protein in KB and CaCo-2 cells are high, while levels in SKOV-3, HeLa and
MCF-7 cells are moderate. A549 and BEAS-2B cells express low levels of FR protein. These
experiments have also shown that all cell lines ubiquitously express moderate levels of RFC.
The cell lines KB, CaCo-2, MCF-7, A549 and BEAS-2B were used in cell viability assays to
assess the cytotoxicity of the carrier CDEnFA, the free drug MTX and the drug complex
CDEnFA:MTX. A 48-hour exposure to the compounds demonstrated that the carrier
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CDEnFA caused minor cytotoxicity towards all cells indicating it is biocompatible to the
cells tested. Free MTX is more toxic than the complex CDEnFA:MTX towards cell lines
expressing low levels of FR, such as the BEAS-2B. More importantly, the results have
demonstrated that the complex CDEnFA:MTX showed greater cytotoxicity than the free drug
towards the high FR expressing KB and CaCo-2 cells, indicating that it has potential to target
this receptor, enhancing the specificity and the efficiency of the drug.
Protein inhibition was used to better understand the role of FRs and RFCs in the uptake and
internalisation of the drug MTX from the complex CDEnFA:MTX. To elucidate whether the
FR captures and internalises the whole complex or the β-cyclodextrin remains extracellular
and the RFC is the responsible for the internalisation of the MTX, the drugs fumonisin-B1
and sulfasalazine were used to inhibit FRs and RFCs, respectively. After a pre-treatment with
these drugs, KB cells, which are high FR-expressing cells, were treated with MTX and
CDEnFA:MTX to assess if the cytotoxicity caused by these compounds was decreased after
inhibition of each transporter. The results demonstrated a decreased cytotoxicity caused by
the MTX after inhibition of RFCs, confirming its internalisation through this transporter. The
results also demonstrated that the cytotoxicity caused by CDEnFA:MTX is decreased after
inhibition of each receptor and significantly decreased after a co-treatment that inhibits both
transporters. This indicates that the cytotoxic effect from the complex CDEnFA:MTX can be
a result of the drug uptake and internalisation through two routes: (1) after CDEnFA:MTX
binds to the folate receptor on the cell membrane, MTX is released from the cyclodextrin
cavity and internalised through the RFC. (2) The CDEnFA:MTX binds to the FR on the cell
membrane and this receptor internalises the whole complex by endocytosis. By using both of
these routes of internalisation, CDEnFA:MTX can amplify the cytotoxic effect of the drug
MTX.
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In vivo studies in the larvae of the greater wax moth Galleria mellonella were performed to
evaluate how tolerant the larvae were to the carrier CDEnFA, and also to compare its
tolerance to the complex and the free drug. The results have demonstrated that CDEnFA
treatment did not result in the death of the organism and did not increase the larval immune
response. This is a positive result and indicates that CDEnFA is not toxic and therefore, is a
safe drug carrier to be used with in vivo models. Mortality assays have also shown that the
complex CDEnFA:MTX caused slightly more toxicity towards the larvae than the free drug.
However, G. mellonella are strongly resistant to the drug MTX, and for that reason,
mammalian studies would be necessary to further evaluate the in vivo response to
CDEnFA:MTX and its comparison to the effect of MTX alone.

Keywords: cancer, chemotherapy, cyclodextrins, folates, folate receptors, methotrexate,
reduced folate carriers, targeted therapy.
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1.1 Introduction to cancer therapy
The defining feature of cancer is the rapid replication of abnormal cells, which proliferate
uncontrollably, can invade adjoining parts of the body and spread to other organs. Cancer is a
leading cause of death worldwide and was responsible for 8.9 million deaths in 2016.1
According to the World Health Organisation, cancer of the lung, liver, colorectum, stomach
and breast cause the most cancer deaths every year.2
Under normal conditions, cells from a specific tissue can exchange information with other
cell types. However, genetic mutations can disrupt intercellular signals, which can lead to a
change in the proliferation profile of cells.3 Figure 1.1 displays the structure of DNA at
nucleotide base level and shows the structure of genes as compacted strands of DNA called
chromosomes within the nuclei of cells. The mutations involved in cancer development
include the mispairing of nucleotide base pairs, insertions or deletions of nucleotides or
various chemical base changes. Alteration of larger segments of DNA, often at a
chromosomal level, includes rearrangements, deletions, or duplications of DNA segments.
Other modifications related to cancer do not involve a mutation of the DNA itself but can
involve the addition or removal of chemical markers, which can influence gene expression.4
These changes and mutations may be inherited, induced by environmental factors, or result
from endogenous DNA replication errors or metabolic processes.5 Abnormal conditions can
be temporary and reversible, but under persistent inflammation, there is an upregulation of
enzymes that can disrupt the extracellular matrix, and thus, invading immune cells can
overproduce factors that promote abnormal proliferation.6 Cancer cells interact with their
micro- and macro-environments changing surrounding tissues and enhancing abnormal
interactions, as malignancy progresses. At this point, the tumour becomes its own organ, with
distinct characteristics that now defines all its cellular responses.7
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Figure 1.1. Nucleus of the cell with the genes arranged in long strands of tightly packed
DNA called chromosomes. DNA is made up of four nucleotides: adenine (A), thymine (T),
guanine (G), and cytosine (C). A binds with T, and G binds with C to form base pairs, which
connect the two DNA strands.8

As a result of the uncontrolled cellular replication, there is the formation of an initial visible
mass, called the "primary" tumour. Cells from a primary tumour can colonise the same or
different organ sites in a process called metastasis.9,10 Metastasis remains the principal cause
of mortality in cancer patients despite decades of research aimed at restricting tumour
growth.11 The type of cancer is determined by the organ in which the cancer starts, as well as
the morphological cell type from which the cancer is derived i.e. cancers from connective
tissue are known as sarcomas, cancers of epithelial cells are known as carcinomas and
carcinoma derived from cells of glandular origin are called adenocarcinoma.9
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Based on tumour behaviour, cancers can be classified according to their stage. Cancer staging
systems describe how far the cancer has spread anatomically and attempt to characterise
patients with a similar prognosis into the same staging group. There are generally five
progressive stages for carcinoma, 0, I, II, III and IV. Stage I are small localized cancers, II
and III are locally advanced and/or involve lymph nodes, while stage IV are inoperable or
metastatic. There is also an additional staging system for some cancers, such as in colorectal
carcinomas, which is denominated as “TNM”.9 The system describes three events, as they
appear on clinical examination and indicates the anatomic extent of the cancer, where T
represents local Tumour growth, N represents spread to regional lymph Nodes and M is
metastasis. A number is added to each letter to indicate the size and/or extent of the primary
tumour and the degree of cancer spread.12

1.1.1 Cancer treatment options
Cancer therapy is usually more effective when the cancer is diagnosed at an early stage of the
disease and when the treatment option is specific for the diagnosed tumour. Combinations of
treatments can be administered depending on the type of cancer and given at different times.
Neoadjuvant and adjuvant therapies are combined therapies that have been shown as
promising approaches in the search for curative treatments. Neoadjuvant therapy is the
administration of therapeutic agents before the main treatment and aims to downstage the
primary tumour by an early attack on systemic micro-metastatic disease. Adjuvant therapy is
a strategy in which a treatment is given, in addition to and usually after, the primary or main
therapy to maximize its effectiveness.13
The most commonly used treatment options are surgery, radiotherapy, immunotherapy,
hormone therapy and chemotherapy. Surgery can be used to remove or shrink the tumour and
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works best for solid tumours that are contained in one area. For example, the primary
treatment for invasive breast cancers is by surgical removal of the tumour. Surgery is also the
first step in brain tumour treatment to remove as much of the tumour as is safe without
affecting normal brain function.14 Radiation therapy is the use of high-energy particles or
waves, such as x-rays, gamma rays, electron beams, or protons, to destroy or damage cancer
cells. Radiation works by directly targeting cellular DNA, causing induced-cell death to
eradicate or shrink the tumours.15 Radiotherapy can also help to reduce problems that may be
caused by a growing tumour, such as breathing issues or loss of bowel and bladder control.
Tumours are successfully treated with radiotherapy if they are at an early stage. It is
commonly used to treat non-melanoma skin cancer, head and neck cancer, breast cancer, nonsmall cell lung cancer, cervical and prostate cancer. Metastatic cancers are generally
incurable with radiation therapy because it is not possible to treat the whole body.16
Immunotherapy is a type of cancer treatment that activates and helps the cells from the
immune system to fight cancer. The transfer of anticancer monoclonal antibodies and T cells
from a donor to a cancer patient has been an effective treatment for a variety of
haematological and solid malignancies.17 The success of immunotherapy reflects the ability
of the donor cells or antibodies to induce an immediate immune reaction against the cancer,
bypassing the requirement to activate endogenous immunity.18 A promising technology in
immunotherapy that has shown impressive results in clinical trials for leukaemia, lymphoma
and myeloma, is the use of genetically engineered T cells that express a Chimeric Antigen
Receptor (CAR) on their membrane. These cells are designed to recognise a specific tumour
antigen and combined with the T cell signalling domains, these cells can effectively target the
tumour and activate the immune response.19 Hormone therapy is a treatment that can block
the body’s ability to produce hormones, or can interfere with how hormones behave in the
body. Hormone therapy is commonly used to treat some breast and prostate cancers. It is also
5
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used for the treatment of endometrial cancer, as it is a hormone-dependent malignancy that
proliferates in response to estrogen exposure. Hormones such as progesterone can be used to
stop the estrogen to be released, and consequently, reduce the cancer’s proliferation
response.20 Hormone therapy can stop cancer progression, slow its growth or reduce the
chance of the cancer returning. It can also ease cancer symptoms, for example, hormone
therapy may be used to reduce or prevent symptoms in men with prostate cancer who are not
able to have surgery or radiation therapy.21
Chemotherapy is the use of drugs to treat a disease. Some chemicals can kill cancer cells and
can be used as a treatment for primary tumours, and also when cancer has metastasized and
has spread.22 Paul Ehrlich was the first researcher to coin the term “chemotherapy” as he used
chemicals to treat infectious diseases, for example, arsphenamine (Salvarsan) to treat syphilis.
He postulated that many more drugs could be synthesized chemically and be directed
specifically against microbes or even against cancer cells.23 One of the first uses of a
chemical to treat cancer was after World War I, when it was recognised that mustard gas (2chloroethyl sulphide), used as a weapon in the war, subsequently caused lymphoid and
myeloid suppression in humans. 2-Chloroethyl sulphide was then used in a patient with
lymphoma and it caused a high anti-tumour effect, but failed to produce durable
remission.24,25 In 1948, folic acid was observed to stimulate cancer cell proliferation in
children with leukaemia, and therefore, drugs with the ability to inhibit folic acid metabolism,
such as aminopterin and methotrexate were introduced as chemotherapeutic agents.24 Folate
and antifolate metabolism are discussed in more detail at the end of this chapter. In 1965,
cisplatin was discovered by Barnett Rosenberg as a drug that could restrict cell division in
bacterial cells and later reduce tumours and treat leukaemia in mice. This led to the use of
cisplatin for a range of cancer types, but it was particularly effective for testicular cancer.26
The mechanism of action reported for cisplatin was its ability to bind to DNA and cause cell
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death.27 Since then, several other chemotherapeutic drugs have been identified for the
management of cancer, with the majority of them used to damage DNA.24,28 These include
cisplatin, doxorubicin, 5-fluorouracil, etoposide, and gemcitabine.29 DNA integrity is critical
for cellular function and regular cell proliferation. Damage to DNA is detected by cell-cycle
checkpoint proteins, whose activation induces cell-cycle arrest to prevent the transmission of
damaged DNA during mitosis. DNA lesions that occur during the DNA synthesis phase can
block replication progression and can lead to replication-associated DNA double-strand
breaks. If the damaged DNA cannot be repaired, cell death can occur.30
There are, however, limitations to chemotherapy, which include negative side effects and
individual patient sensitivities to treatment. Table 1.1 below displays some examples of
chemotherapeutic agents that affect DNA, their mode of action and their major side effects.
These limitations occur due to a lack of specificity in delivery, as most chemotherapeutic
agents target healthy and cancerous cells alike. As a consequence of this, the patient may
suffer from side effects such as hair loss, appetite loss, fatigue, pain, diarrhoea, nausea, blood
disorders etc. If the side effects are too severe, the patient may not be able to continue the
treatment, and hence, chemotherapy can have an enormous impact on the control of cancer
progression.31

Table 1.1. Properties of DNA-damaging compounds used in the treatment of cancer.29
Drug

Mode of Action

Major Side Effects
Myelosuppression; pulmonary toxicity;
gastrointestinal toxicity; hepatotoxicity;
nephrotoxicity; neurotoxicity

Methotrexate

Prevents DNA synthesis by inhibiting
dihydrofolate reductase (DHFR)

Cisplatin

DNA crosslinker

Nephrotoxicity; neurotoxicity;
ototoxicity

Doxorubicin

Topoisomerase II poison

Cardiotoxicity; myelosuppression;
neurotoxicity

5-Fluorouracil

Prevents DNA synthesis by inhibiting
thymidylate synthase (TS)

Neurotoxicity; gastrointestinal toxicity
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Methotrexate (MTX) is the model drug that was applied in this work to damage and eliminate
cancer cells. MTX is a chemotherapeutic drug used worldwide, on its own or combined with
other chemotherapeutic agents, for the treatment of different types of cancer, such as breast
cancer, osteosarcoma, head and neck cancers, lymphoma and leukaemia.32 MTX was
originally developed in 1950 and its chemical structure is displayed in figure 1.2.

Figure 1.2. Chemical structure of methotrexate.

In low doses, it can also be used to treat autoimmune diseases, such as rheumatoid arthritis,
lupus and Crohn’s disease. In 1951, Jane Wright demonstrated the use of MTX in solid
tumours and reported remission of a breast tumour.33 Since then, there have been reports of
MTX in the successful treatment of cancer of the marrow, choriocarcinoma and
chorioadenoma.34
Understanding the importance of folate for cell replication led researchers to speculate that
folate analogues such as MTX could be useful in treating malignant tissues. MTX is a
competitive inhibitor that stops folic acid metabolism by preferentially binding to the
enzymes related to its metabolism. As shown in figure 1.3, MTX enters cells through the
reduced folate carrier (SLC19A1) and acts by inhibiting the enzyme dihydrofolate reductase
(DHFR), which results in accumulation of dihydrofolate (DHF) and depletion of cellular
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folates. Cytosolic folylpolyglutamyl

synthase (FPGS) adds

glutamate residues to

methotrexate to produce methotrexate polyglutamates (MTXPGs). The addition of glutamate
residues to methotrexate increases its affinity for enzymes such as the thymidylate synthetase
(TYMS) and enzymes of the de novo purine-synthesis pathway such as phosphoribosyl
pyrophosphate amidotransferase (PPAT), phosphoribosylglycinamide formyltransferase
(GAR transformylase), and IMP cyclohydrolase (ATIC). Other enzymes that are indirectly
affected by methotrexate are 5,10-methylenetetrahydrofolate reductase (MTHFR) and
methylenetetrahydrofolate dehydrogenase (MTHFD1). Hence, MTX interrupts the DNA
synthesis process, and consequently, single (SSB) and double strand breaks (DSB) occur in
the DNA helix. Repair mechanisms remove the damaged DNA and cell death then occurs via
necrosis or apoptosis pathways.35

Figure 1.3. Overview of methotrexate mechanism of action. Drugs and drug metabolites are
indicated in yellow, transporters in pink, enzymes in green and cellular metabolites in blue.
dTMP = deoxythymidine monophosphate; dUMP = deoxyuridine monophosphate; THF =
tetrahydrofolate.36
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However, to achieve high efficacy, high doses of MTX are required. To be effective MTX
must be internalised into cells. However, MTX is anionic and cannot permeate negatively
charged cell membranes due to repulsion, unless a high concentration is used. Also, the
enzyme DHFR has a greater affinity for folate than for MTX unless the concentration of
MTX is high.37 Besides the need for high doses, MTX has a narrow tumour spectrum and
also does not cross the blood-brain barrier and therefore cannot be used for solid tumours and
brain tumours. Resistance to MTX is also possible. A system for the delivery of MTX to the
required site of action may avoid some of these disadvantages.
To overcome the limitations of chemotherapy, drug delivery systems have been extensively
studied, along with the identification of molecular biomarkers in cancer cells for targeted
drug delivery systems. These targeted systems provide a novel exciting alternative
therapeutic approach with long-term future benefits for cancer treatment.

1.2 Drug delivery systems
Drug delivery systems (DDS) can be used to increase the efficiency and specificity of the
delivery process. DDS involve targeted delivery and/or controlled release of therapeutic
agents. The efficiency of a treatment can be improved with the use of DDS as they may allow
an increase in drug bioavailability, stability and aqueous solubility, improve cellular
distribution and metabolic control. Higher specificity of the treatment can be achieved by
targeting specific sites and pathways in the cells to be treated. These properties, when
optimised, may help to reduce the side effects of the treatment.38
The significant impact of targeted drug delivery lies in the ability to specifically guide a drug
or drug carrier to minimize systemic toxic effects.39 In 1900, Paul Ehrlich postulated the
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existence of specific cellular receptors and studied the possibility of binding to drugs. That
was when he created the concept of a “magic bullet” to first describe targeted drug delivery.
He envisioned that just like a bullet fired from a gun to hit a specific target, there could be a
way to target microbes, or cancer cells, with the use of molecules or receptors.23,24 Specific
properties of the targeted cells, the presence of molecular markers, characteristics of the
environment and localisation of the cells are important factors that must be considered for the
development of targeted DDS.
The recognition of the target may be on various levels, including a whole organ, certain cells
in an organ, or even individual components of specific cells, such as cell surface proteins.
Recognition of the target on the molecular level is certainly the main form of recognition.40
Molecular targets normally include receptors that are overexpressed or selectively expressed
by particular cells or tissue components. These may include cell-surface carbohydrates
(carbohydrate targeting), cellular antigens for antibodies (antibody targeting), and cell surface
receptors (receptor targeting).41 Carbohydrates coat the surfaces of cells and have been used
for cell recognition in antibacterial drug development. 3-deoxy-D-manno-2-octulosonic acid
(KDO) and heptoses are examples of unique carbohydrates present on the cell surface of
bacteria, that have been used in research for the development of antibiotics.42 In research and
development for cancer therapy, antibody and receptor targeting are the most commonly
explored potential targets. Antibodies bind to their targets with high specificity and binding
efficiency, which makes them ideal candidates for targeted drug delivery. Antibody-drug
conjugates (ADCs) are designed to direct a cytotoxic drug to cells expressing a cell-surface
antigen recognized by an antibody.43 The approval of brentuximab vedotin in 2011, an ADC
that targets tumour cells expressing the CD30 antigen in relapsed Hodgkin's lymphoma, and
the approval of ado-trastuzumab emtansine in 2013, an ADC that targets the human
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epidermal growth factor receptor 2 in HER2-positive metastatic breast cancer, have sparked
vigorous research in the field, with >65 ADCs currently in clinical evaluation.44
An alternative strategy for developing a targeted drug is to design a receptor-targeted delivery
system, which can identify and target tumour-associated receptors. These tumour-associated
receptors or antigens can be derived from proteins synthesized by the tumour cell and are
relatively restricted to or overexpressed in cancer cells when compared to the corresponding
normal tissue.45 Folate receptors have been extensively studied as targets because of their
high-affinity for the vitamin folic acid. These receptors are expressed in higher levels in
cancer cells, and hence, appear to be promising targets for cancer treatment.41 The folate
receptor is the target used in this study and will be discussed later in more detail.
The specific ligand-receptor interaction can be utilized to concentrate a therapeutic agent at
the diseased tissue, producing a preferred distribution profile.46 Successfully developed
therapeutic agents are tailored to target specific receptors and can selectively attack malignant
cells and avoid, for the most part, normal cells. As a result, these agents are expected to have
very little associated toxicity. These therapeutic strategies have been shown to sensitize
tumour cells to the effects of chemotherapy and radiotherapy.47 Efficient ligand-receptor
interaction is dependent upon a variety of factors, such as the extent of expression of the
receptor on targeted cells relative to non-target cells, receptor availability on the target cell
surface, and the rate of internalization of that surface receptor following ligand binding.
Furthermore, the expression of a promising tumour-targeting receptor may not be
homogenously distributed within a tumour or may change its surface expression over time.39
Receptor targeting involves attaching drugs to a ligand that binds to receptors expressed on
the cell surface, thereby initiating receptor-mediated endocytosis.41 The development of
receptor-targeted delivery systems is based on the direct coupling of an anti-cancer drug to a
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ligand or on encapsulation of the drug into a ligand-directed drug carrier.48 Figure 1.4 below
shows the structure of ligand-directed/receptor-targeted drug conjugates. The construction of
ligand-directed drug conjugates involves the association of targeting ligands to the drug using
a linker system, or the drug can be encapsulated into a targeted drug-carrier through either
chemical conjugation or physical interaction.48

A

B
Figure 1.4. Ligand-directed drug delivery systems. (A) The drug is directly linked to the
ligand through a linker system,49 or, (B) a drug-carrier system is used.50

The carrier is a vehicle required to transport the loaded drug to the diseased tissue. Ideally,
these systems should be non-toxic, non-immunogenic, biodegradable and stable, and should
restrict drug distribution to target cells or tissues, through a molecular marker present in that
site. In addition, the drug release rate should be controllable and predictable, and should not
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affect the drug action.51 Their size and shape properties should be ideal for tissue penetration,
cellular trafficking and facile control of cargo release.52 Several different materials have been
used as carriers for the purpose of delivering chemotherapeutics to tumours. These materials
include cyclodextrins, lipids such as liposomes and exosomes, carbon such as nanotubes,
graphene and nanocrystals, porous silica, polymers dendrimers, carbohydrates, iron oxide and
proteins such as albumin or antibodies.53 Figure 1.5 depicts some of these materials. Each
material has unique structural properties. For example, porous silica has uniform surface
pores that allow easy functionalization of the surface to control drug loading and release.54
Lipids have shown effective size-dependent properties and a high degree of biocompatibility
and versatility.55 Cyclodextrins can form inclusion complexes with guest molecules to
increase their solubility, stability and bioavailability.56 Hybrid material such as silica and
cyclodextrins, for example, have also been studied for drug delivery and other applications. 57
Cyclodextrins are the proposed carrier used in this study and are discussed in more detail
below.

Figure 1.5. A range of drug delivery vehicles.53
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1.3 Cyclodextrins as carriers
Cyclodextrins (CDs) were first identified in 1891 when Villiers isolated a crystalline
substance from a culture medium of Bacillus amylobacter grown in the presence of
starch.58,59 CDs are oligosaccharides that are produced by the cyclodextrin glucanotransferase
(CGTase) enzyme in the degradation of starch. Their glucopyranose units form a truncatedcone shaped structure and are linked by α-(1,4) bonds. α-Cyclodextrin consists of six of these
glucose units while β-cyclodextrin and γ-cyclodextrin consist of seven and eight respectively.
β-cyclodextrin is the most accessible and most used sub-type.
X-ray studies identified that, in the cone-shaped structure of CD, primary hydroxyl groups
(C6) are on the narrower edge of the structure while the secondary hydroxyl groups (C2, C3)
are on the wider edge of the structure, as seen in figure 1.6 below, while ether-like oxygen
atoms and hydrogen atoms, at C3 and C5, are on the inside of the cone. This arrangement of
atoms results in CDs having a hydrophobic cavity and hydrophilic exterior. These properties
enable CDs both to form inclusion complexes and to dissolve in water.59

A

B

Figure 1.6. (A) Chemical structure of β-cyclodextrin and (B) a truncated-cone representation
of cyclodextrins.60
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For the formation of inclusion complexes, a guest molecule can be totally or partly included
in the cavity and the weak non-covalent bond between the CD host and the guest results in
the easy release of the guest molecule at the required site. The inclusion of a guest molecule
in the CD cavity consists of the substitution of water molecules by a less polar molecular
guest and is an energetically favoured process.61
Because of their unique structure and properties, CDs have been used for different
applications in industry. In the pharmaceutical industry, CDs have been used to increase drug
solubility, bioavailability and stability, reduce irritation, prevent incompatibility and to mask
odour and taste. Examples of the use of cyclodextrins in medicines on the European market
are β-CD in cetirizine tablets, used to mask the unpleasant taste of the cetirizine
dihydrochloride62 and γ-CD in minoxidil solution, used to increase drug solubility.63
Cetirizine or zyrtec is an antihistamine and minoxidil is an antihypertensive vasodilator.
Examples of β-cyclodextrin derivatives include SBE-β-CD (sodium salt of sulfobutylether-βcyclodextrin) used with intravenous antimycotic voriconazole to increase drug solubility64
and RM-β-CD (randomly methylated β-CD) used in a nasal spray for hormone replacement
therapy with 17β-estradiol for better drug absorption and enhanced bioavailability.65,66 CDs
have also been used in the food and beverage industry as they can bind certain bitter materials
or flavours in their cavity and stop them being perceived by the senses of taste and odour. For
example, in non-alcoholic beverages based on green tea, cyclodextrins are used to mask the
bitter taste of catechin, an antioxidant found in this type of tea.67 CDs have also been used in
the agricultural industry to trap pesticides or herbicides and avoid the compound being lost
through evaporation, hydrolysis, inactivation by wetness or degradation by light, and
therefore, reduce the amount of pesticide needed in the formulation.68,69
CDs can be derivatised through a multitude of hydroxyl groups and bound to other molecules
which can then act as ligands, making these molecules interesting for targeted drug delivery.
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For example, complexation of the drug doxorubicin with 2-hydroxypropyl-β-CD (HP-β-CD)
was applied to increase permeability across the blood-brain barrier.70 Doxorubicin (DOX)‐
loaded β‐CDs equipped with multivalent mannose target units were efficiently taken up via
receptor‐mediated endocytosis by MDA‐MB‐231 breast cancer cells that overexpress the
mannose receptor.71 Diverse research groups have been working with the development and
biological evaluation of folate derivatives of cyclodextrins. For example, Khattabi et al
(2017) have worked on the synthesis and evaluation of a folic acid-carboxymethyl-βcyclodextrin aminated silica nanoparticle. These workers evaluated the activity of the CDconjugated nanoparticle with a combination of the anti-cancer drugs thymoquinone and
melatonin in HeLa and MCF-7 cells, and showed an increased effect compared to
unconjugated nanoparticles and the free drugs.72 Tao et al (2018) have investigated the in
vitro and in vivo toxicity of a docetaxel/folic acid-β-cyclodextrin inclusion complex in KB
cells and in mice, which indicated a favourable anti-tumour effect by inducing mitochondrialmediated apoptosis.73

1.4 Folic acid as a ligand
Folate is the generic term for a family of compounds that include folic acid and derivatives,
such

as

tetrahydrofolate

(THF),

5-methyltetrahydrofolate

(5-methylTHF),

5-

formyltetrahydrofolate (5-formylTHF or folinic acid) and 5,10-methyleneTHF. Folic acid is
the oxidized, synthetic form which does not exist in nature and its structure is displayed in
figure 1.7 below. The terms folic acid and folate are sometimes used interchangeably.
However, folic acid refers to the synthetic form of the molecule, while the term folate is used
for naturally occurring folates, such as 5-methylTHF, shown in figure 1.8, which is a
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biologically active form of folate. 5-MethylTHF is the most abundant form found in plasma
and it is also the predominant active metabolite of ingested folate.74

Figure 1.7. Chemical structure of folic acid.

Figure 1.8. Chemical structure of sodium 5-methyltetrahydrofolate.

Folate is one of the B vitamins and is essential for humans because of its important role in
DNA synthesis and repair. Folate, amino acids and CO2 are the molecules required for the de
novo synthesis of purines and pyrimidines, which are nitrogenous-ring, subunit structures of
the nucleotides found in polymeric nucleic acids.75 The structures of purines and pyrimidines
are displayed in figure 1.9 and are the nitrogenous bases paired as A-T and C-G within the
DNA structure shown in figure 1.1. The synthesis of purines and pyrimidines is part of the
DNA replication process, and therefore, folate is important for the cellular processes of cell
replication and proliferation. In addition, the methylation of DNA, which is also a result of
folate metabolism, plays a role in controlling gene expression and is important for cell
differentiation.76
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Figure 1.9. Purines and pyrimidines represent the nitrogenous bases within DNA.

Natural folates must be enzymatically hydrolysed in the intestine to be absorbed, while folic
acid can enter directly into the cell. As displayed in figure 1.10, after entering the cell, folic
acid is converted into dihydrofolate (DHF) and then into tetrahydrofolate (THF) by the
enzyme dihydrofolate reductase (DHFR). The natural folate, 5-methylTHF, is also converted
into THF, which is the active form that carries one-carbon units required for DNA synthesis
and repair. This conversion also generates methyl groups, which are required to regenerate
methionine from homocysteine and are necessary for all genomic and non-genomic
methylation reactions in the form of S-adenosyl methionine (SAM). The folate and the
methionine cycles are essential to cellular function via interactions with other pathways.77
Deficiencies in folate or aberrations in its metabolism can be a problem during pregnancy
when the embryonic cells are differentiating and proliferating constantly and as a result,
neural tube defects can occur.78 Folate deficiency can also be a problem for normal cell
replication and can cause diseases, such as cancer.79 There are two principal mechanisms
through which folate deficiency appears to be associated with the risk of cancer. The reduced
intracellular levels of S-adenosylmethionine (SAM) in folate deficiency can alter cytosine
methylation in DNA, leading to the activation of genes that are related to cancer
development. Alternatively, folate deficiency may cause an imbalance in DNA precursors, or
19
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the wrong incorporation of nucleotides into DNA, causing DNA damage.80 Results from
animal studies on colorectal cancer suggest that folate plays a dual role. While it may protect
against the initiation of cancer, it can also enhance the growth and progression of existent
neoplastic cells.81

Figure 1.10. Schematic of folate-mediated one-carbon metabolism. DHF =
dihydrofolate, THF = tetrahydrofolate, DHFR = dihydrofolate reductase, MTHFD =
methylenetetrahydrofolate dehydrogenase, MTHFR = methylenetetrahydrofolate reductase,
dUMP = deoxyuridine monophosphate, dTPM = deoxythymidine monophosphate, SAM =
S-adenosyl methionine and MS = Methionine synthase.82

In situations where cancer is already present, folate will contribute to rapid cell growth.
Proliferating tumour cells have unique metabolic requirements characterized by enhanced
nutrient uptake and metabolic pathways to support the biosynthesis of macromolecules
needed for cell growth and division.83 This requirement of cancer cells for high levels of
folate has made folate receptors (FR) the object of study for drug targeting purposes. FRs
have been identified as molecular markers that have a higher expression in cancer cells than
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in healthy cells.49,84–88 Folate has been used as a ligand associated with different carriers and
chemotherapeutic drugs for DDS in cancer treatment and is the ligand used in this research.

1.5 Folate receptors and reduced folate carriers
Cells can uptake folate and antifolates (folate antagonists) through folate receptors (FRs) and
reduced folate carriers (RFCs), although their transport kinetics and affinities differ. The FR
is a membrane-bound protein with high binding affinity for folic acid. The RFC is an integral
plasma membrane protein that has a high affinity for antifolates, such as methotrexate, but
low affinity for folic acid.89,90 While the RFC is expressed by various normal cells, there is a
small proportion of FR in normal tissues. In contrast, FR is highly expressed on the
membranes of many types of epithelial cancer, such as ovarian, cervical, lung, kidney,
colorectal, and brain tumours.41
The role of FR expression in tumours is not completely clear, but studies have suggested
parallel roles for this receptor in both cell-growth regulation and signalling functions.
According to Boshnjaku et al (2012), following uptake and internalization, FR can
translocate to the nucleus and act as a transcription factor, which may directly regulate the
expression of key developmental genes in cancer cells.91 Cells treated with an inhibitor of FR
reduced their cell surface expression and showed subsequent impaired tumour cell
proliferation, reduced colony formation and deregulated adhesion.92 Furthermore, folate
uptake can promote cancer cell proliferation, migration and loss of adhesion through downregulation of the cell-cell adhesion molecule, E-cadherin, promoting cell motility and
metastasis.93 FR expression may also induce drug resistance by enhancing the anti-apoptotic
ability of tumour cells.94 Therefore, considering that FR levels are reported to be high in
specific malignant tumours compared to normal cells, are positively associated with tumour
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progression and are significantly expressed in a limited number of non-malignant cell types,
FRs are considered to be promising anti-tumour targets.
Several FR-targeting anticancer therapies have been developed, which include two main
strategies, 1) synthesise conjugate compounds that use folic acid as a ligand or 2) humanized
monoclonal antibodies (mAbs) that are reactive to FRs or that can be conjugated to a drug
molecule.95 An example of a mAb reactive to human FR is farletuzumab (Morphotek, USA).
In January 2018, the Food and Drug Administration (FDA) accepted an Investigational New
Drug (IND) application for MORAb-202, an antibody-drug conjugate (ADC), that uses a
cathepsin-cleavable linker to combine farletuzumab with the microtubule inhibitor, eribulin.
A phase 1 dose-escalation study will be conducted in the U.S. to evaluate the safety and
preliminary efficacy of MORAb-202 in patients with solid tumours that express FR. The
solid tumours to be studied include metastatic endometrial, ovarian, lung and triple-negative
breast cancer.96 An example of a folic acid conjugate drug compound that is in development
as a chemotherapeutic agent is vintafolide, which is composed of folic acid and the vinca
alkaloid desacetylvinblastine hydrazide (DAVLBH, Endocyte Inc., USA). EC1456 is another
conjugate molecule that targets FRs and consists of a folic acid molecule covalently linked to
the cytotoxic agent, tubulysin B hydrazide (Tub-B-H, Endocyte Inc., USA).97
Unlike FRs, which have a known key role in cancer development and can be used as
biomarkers for targeted drug delivery, the RFC has not been as well investigated. However, it
is known that RFC is a transport protein that is expressed, ubiquitously, in healthy tissues and
tumours and is the major transporter for natural folates (5-methylTHF) and folate antagonists.
RFC transports folate cofactors from the blood into cells of peripheral tissues. In human
tissues, highly elevated human RFC transcripts are detected in placenta and liver, with
significant levels in other tissues, including leukocytes, kidney, lung, bone marrow, intestine,
and portions of the central nervous system and brain.49
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Loss of RFC expression or function may have pathophysiologic consequences, including
cancer. When antifolates are used for cancer treatment, loss of RFC transcripts and proteins
results in antifolate resistance due to incomplete inhibition of cellular enzyme targets and
insufficient substrate for polyglutamate synthesis.98 RFC transport is, therefore, a critical
determinant of the anti-tumour efficacy of cytotoxic antifolates, such as the clinically relevant
drugs currently used for cancer treatment, including MTX (methotrexate), PMX (pemetrexed)
and pralatrexate.99 Given the importance of RFC to in vivo folate homoeostasis and the
impact of folate deficiency on human health and disease, there is an interest in the study of
RFC regulation in relation to exogenous folate levels. Liu et al (2005) have suggested a
broad-reaching regulatory adaptation of mammalian cells to conditions of folate depletion or
excess, involving mechanisms critical to folate cofactor uptake and retention.100 Hou et al
(2014) demonstrated a novel post-transcriptional regulation of human RFC involving
increased RFC transcripts and proteins, accompanying increased extracellular folates,
attributable to differences in RFC transcript stabilities and also increased retention of RFC in
the cell under conditions of folate excess, because of impaired intracellular trafficking and
plasma membrane targeting.99 While antifolate drug conjugates are developed to selectively
target FRs, RFC levels are nonetheless important determinants of the anti-tumour activities of
these agents, since RFC impacts cellular folate pools, which compete for polyglutamylation
and binding to intracellular enzyme targets. FR and RFC expression levels in different cell
lines, regulation in response to a low folate environment, as well as the correlation between
gene and protein levels of each receptor are discussed in detail in Chapter 2.
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1.6 Uptake and internalisation of drug delivery systems
Understanding the mechanisms of cellular uptake and internalisation is critical in developing
drug delivery systems. An improved understanding of intracellular trafficking mechanisms
allows for effective binding to specific locations within the targeted cells and can contribute
to successful drug absorption, increasing the efficacy of certain drugs.39 Targeting cell
surface receptors allows not only a drug carrier to deliver the therapeutic agent directly to the
targeted site, but it also facilitates efficient internalisation. Research has demonstrated that
targeting receptors that internalise can result in increased therapeutic activity in some tumour
models.101 For example, Park et al (2002) demonstrated that anti-HER2 immunoliposomes
containing doxorubicin bind efficiently to HER2-overexpressing cells in vitro, resulting in
intracellular drug delivery and produce enhance antitumor efficacy in animal models.102,103
Liposomal doxorubicin-loaded nanoparticles, that target the CD19 surface antigen on a B-cell
lymphoma line, showed significant improvement over nanoparticles coupled to a noninternalising receptor.104 Similar results were achieved with folate receptor-targeted
cyanoacrylate nanoparticles, which were internalised more efficiently in folate receptor
expressing tumour cells than cells lacking the receptor.105
The molecular mechanisms mediating the internalisation of particles are mainly dependent on
their size. Large particles can be internalised via an energy-dependent process, which is
inhibited by drugs that affect membrane vesicle formation. Smaller particles are generally
internalised via protein (clathrin)-coated pits, while larger particles are internalized via
caveolae membrane invaginations. In addition, there are mechanisms mediating the
internalisation of particles that are independent of both clathrin and caveolae.101 These
internalisation pathways are described in detail in Chapter 4. Membrane specific receptors
most frequently enter the cell through endocytosis following the binding of a high-affinity
ligand. Endocytosis is a mechanism common to all human cells because of the fluidity of the
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plasma membrane surrounding cells. Macromolecules are internalised by a change in
phospholipid plasma membrane structure which invaginates inwards and then separates into
distinct transport vesicles with the macromolecules contained inside the vesicle. These
vesicles then traffic along the endolysosomal scaffold.106 Figure 1.11 displays different
internalisation pathways involved in the uptake of drugs. Through passive diffusion, drug
molecules move from an area of high concentration to one of low concentration, in a process
that requires no energy to proceed. Other particles are too large to use small channels to
transport by passive diffusion through the plasma membrane. In this case, cells engulf the
larger particles through endocytosis, which is an active energy requiring process that includes
phagocytosis, pinocytosis and receptor-mediated endocytosis.107 Phagocytosis is a process
wherein a cell binds to the particle on the cell surface and draws the item inward while
engulfing it. Pinocytosis, also known as fluid endocytosis, is a mode of endocytosis in which
small particles suspended in extracellular fluid are brought into the cell through
an invagination of the cell membrane. In receptor-mediated endocytosis, a specific receptor
on the cell surface binds tightly to its specific ligand and the plasma-membrane region
containing the receptor-ligand complex then undergoes endocytosis, becoming a transport
vesicle.108
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Figure 1.11. Processes leading to cellular internalisation of delivered drugs. (A) Passive
diffusion of free drug. (B) Non-specific phagocytosis of a nanoparticle. (C) Drug entrapped
in fluid and uptake by pinocytosis. (D) Receptor-mediated endocytosis.101

CDs are large hydrophilic molecules and cannot directly pass through the lipophilic plasma
membranes of cells. Studies suggest that, in general, CD is only slightly absorbed in the
stomach and small intestine.109 In the large intestine, it is absorbed after fermentation into
smaller saccharides by colonic microbial flora. However, Fenyvesi et al (2014), demonstrated
that fluorescently-labelled methyl-β-cyclodextrin was able to enter the intestinal epithelial
cells, CaCo-2, by fluid-phase endocytosis from the apical side of the cell.110,111 Although CDs
are generally not able to enter the cell through a passive mechanism, the use of a receptortargeted ligand coupled to the CD can trigger the endocytosis process. In that case, the cell is
able to engulf and internalise a macromolecule such as the CD. The internalisation of the
folate derivative of the β-cyclodextrin drug delivery system is further discussed in Chapter 4.
As MTX is generally internalised through the RFCs and folic acid binds with high affinity
and enters the cell through the FRs, the pathway for internalisation of a drug delivery system
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that includes both MTX and folic acid should be characterised. The pathways for molecule
internalisation can be investigated through different methodologies. These include the use of
fluorescent markers that can label molecules related to internalisation pathways and
methodologies that involve the inhibition of genes and proteins responsible for these
processes.

1.7 Drug development approaches: In vitro and in vivo studies
In drug development, pre-clinical tests include in vitro experiments with cell lines, followed
by in vivo studies to verify pharmacological toxicity and safety. Cancer cell lines established
and maintained in vitro have been effectively used in drug discovery and development, for
example, to identify promising receptors for active drug targeting, to evaluate cytotoxic effect
of compounds, or to analyse the mode of action of drugs. Understanding the cellular uptake
and internalisation processes of a drug-conjugate candidate is important for the development
of an effective drug delivery system. This can be analysed in vitro by using fluorescent
molecules that can mark intracellular trafficking, which can then be detected through
techniques such as flow cytometry, fluorescent microscopy and confocal microscopy. For
analysis of a receptor-mediated uptake process, receptors can be inhibited using
pharmacological inhibitors, which are chemicals that can block a protein function, or using
methods that can inhibit gene and protein expression, such as gene knockdown or gene
knockout methods. After inhibiting the expression or blocking the function of the receptor,
the effect of the drug-conjugate candidate can be analysed to assess if the blocked receptor is
responsible for the uptake.112,113 Assays that measure proliferation, viability and cytotoxicity
are commonly used to monitor the response and health of cells after treatment with new drugs
or drug delivery systems. After evaluating the cytotoxic effect of the drug to a range of cell
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lines, animal models can be selected for screening of the toxicity effect, primarily to assess
safety and biocompatibility.114
The use of in vivo pre-clinical trials is essential to predict the clinical outcome of a specific
drug in development. Adequate design, execution and reporting of animal model results, help
to make pre-clinical data more reproducible and translatable to the clinic.115 Therefore,
animal in vivo studies are performed to examine the preliminary efficacy, toxicity and
pharmacokinetics of new drugs. Early in vivo testing specifically aims to demonstrate safety,
which is important to determine whether a candidate drug has scientific merit to proceed with
further development.116 In vivo pre-mammal models can be used for early in vivo screens and
can be valuable in reducing problems when linking in vitro findings to in vivo readouts.117
Animal testing is typically conducted in rodents, such as mice, followed by drug safety
testing and certain efficacy evaluations in larger mammals, such as rabbits and dogs. When
testing in mammalian models, large amounts of the drug candidate are necessary, which is
not always feasible in the early stage of drug development. 118 In addition, drug candidates
may fail due to absorption, distribution, metabolic, elimination and toxicological properties.
Invertebrate animal models have been used at this stage of pre-clinical trials as their use does
not require specialised laboratory facilities, they are easy to manipulate, and do not require
ethical approval. This makes invertebrate models ideal for use as in vivo models in place of or
in advance of using mice and other vertebrate mammalian models. These models have
demonstrated interesting use in toxicity and efficacy testing of new pharmaceuticals, sparing
vertebrate animals from preliminary testing.119 Invertebrate organisms such as insects
combine genetic amenability, low cost, and culture conditions compatible with large-scale
screens. On the downside, protein divergence between invertebrates and humans causes a
high rate of false negatives. Nevertheless, invertebrate models are a tool to bridge the gap
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between in vitro and pre-clinical animal assays.120 Table 1.2 summarises some of the
advantages and disadvantages of using invertebrate models in pre-clinical research.

Table 1.2. Advantages and disadvantages of the invertebrate screening systems.120
Advantages
Numerous biological processes are conserved
between mammals and invertebrates

Disadvantages
Some diseases cannot be modelled with
invertebrates because the gene or organ does
not exist

Many genes are conserved between mammals
and invertebrates

Problems of molecule penetration

Studies occur in a physiological context

Concentration within an animal is unknown

Low cost

Protein conservation at the amino acid level
is poor

Genetics allow the identification of a drug
effector pathway

False negatives

Insects such as the larvae of the wax moth, Galleria mellonella, have been used as screening
tools in drug discovery as they are cheaper and easier to maintain when compared to
mammalian models such as mice, rats and rabbits. They also have a convenient size for
housing and manipulation, which makes them ideal for high-throughput studies.121
Furthermore, although vertebrates have developed an adaptive immune response, their innate
immune response still retains remarkable similarities with the immune response in insect
models. In mammals and insects, the communication between and regulation of immune cells
is carried out by cytokines.122 Therefore, similar pathogen recognition receptors and
signalling pathways activate the immune response in both animals. In addition, in insects and
mammals, the recognition of non-self cells and molecules happens through pathogenassociated molecular patterns. Moreover, challenges in recognising and fighting pathogens
are the same for any host.122 The similarities between the immune system in G. mellonella
and mammals are described in detail in Chapter 5. G. mellonella larvae were used in this
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work to assess drug tolerance. Although this is not a tumour model, a screening to evaluate
the organism’s tolerance to the compounds, especially to the drug carrier without the
chemotherapeutic agent is important to further confirm its biocompatibility and safety as a
targeted-drug delivery vehicle.

1.8 Aims of research
Over the past 20 years, significant expertise has been developed at DIT in the synthesis and
characterisation of cyclodextrin derivatives for various pharmaceutical applications. Recent
work has involved the development of a folate-modified cyclodextrin, 6-deoxy-6-[(1-(2amino)ethylamino)folate-β-cyclodextrin (CDEnFA) for drug delivery.123 Cyclodextrins were
chosen as carriers since they have a favourable structure as its hydrophobic cavity allows it to
form inclusion complex with poorly soluble drug molecules. In addition, they can be
modified so a ligand can be linked to it, which may increase the specificity of delivery. Folic
acid was chosen as the tether in order to target folate receptors on cell membranes which
provide a route for internalisation of folates into the cytosol of the cell. The literature is not
completely clear on the levels of expression of FR and RFC in various cells lines. Therefore,
the aim of this study was to assess FR and RFC levels in different cell lines and to evaluate
the effectiveness of the drug delivery system, CDEnFA:MTX, towards a range of cancer cell
lines. CDEnFA was used in this work as a targeted carrier to deliver the drug methotrexate
and figure 1.12 shows the proposed chemical structure of CDEnFA:MTX.
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Figure 1.12. The proposed structure of the targeted drug delivery system CDEnFA:MTX.
Folic acid is shown in blue, the cyclodextrin is shown in red and the drug, MTX, is included
in the CD cavity.

The specific objectives of this work were to:
1) Compare FR and RFC gene levels in a range of human cell lines grown in folatereplete and folate-free medium to standardise the culture conditions. Then, to assess
the gene and protein expression of FR and RFC in a range of untreated cell lines to
address the conflicting reports of expression of these transporters and allow for
selection of in vitro models for subsequent experiments using real-time PCR and flow
cytometry.
2) Evaluate the cytotoxicity of CDEnFA to certify that the carrier alone is not toxic to
the cells, and then evaluate the cytotoxicity of free MTX and the complex
CDEnFA:MTX towards selected cell lines with high, medium and low FR levels,
comparing the outcomes between the complex and the drug alone and confirm FR
targeting.
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3) Investigate the cellular route of uptake and internalisation of the drug complex
CDEnFA:MTX, using fumonisin-B1 and sulfasalazine as inhibitors of FRs and RFCs,
and with this, clarify the roles of each transporter in these processes.
4) Evaluate the in vivo toxicity of the targeted carrier CDEnFA to the larvae of the
greater wax moth Galleria mellonella, to assess its safety to be used in invertebrate
models, and assess its tolerance to the free drug and to the complex.
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2.1 Introduction
Cellular uptake of folate molecules is mediated by folate receptors (FRs) and reduced folate
carriers (RFCs), although their transport kinetics and affinity differ between these routes. FRs
bind with high affinity to folic acid (Km ~ 1 nM), 10 times higher than their affinity for
antifolates, while RFCs function with high affinity for antifolates such as methotrexate (Km =
5-10 µM) but low affinity for folic acid (Km = 200-400 µM).1–4 As mentioned in Chapter 1,
studies have demonstrated that over-expression of FRs may provide a growth advantage for
cancer cells through mechanisms related to folate uptake.5 FRs are highly expressed in a
variety of cancers such as ovarian, cervical, lung, kidney, colorectal, and brain tumours,
while their distribution in normal human tissues is restricted to low level expression on the
apical surfaces of some organs, such as the kidney, lung and choroid plexus.2,6,7 However,
levels of FRs differ between cell lines and contradictory reports of different levels are found
in the literature for the same cell line. For example, Zhang et al (2015) demonstrated that
MCF-7 cells (breast cancer cell line) express high levels of FR while Chen et al (2009)
reported no significant levels when compared to cell lines such as KB and HeLa.8 Hartmann
et al (2007) and O'Shannessy et al (2012) reported that breast cancer cell lines over-express
FRs while Kelley et al (2003) reported low expression in this tissue.9–11 Some authors have
used breast cancer cell lines such as MCF-7 and ZR75-1 as FR-negative controls.12–15 In
addition, it can be found in the literature that the cervical cancer cell line HeLa highly
expresses FR, as reported by Grove et al (2012), or that HeLa cells express low levels of FR,
as shown by Bongartz et al (2013).16,17 Therefore, more studies are required to identify the
cell lines which over-express these receptors and ideally identify the conditions required or
responsible for such gene and protein expression regulation.
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RFC is reported to have widespread tissue expression in mammalian cells. Whetstine et al
(2002) have demonstrated that human RFC is ubiquitously expressed and reported high levels
of RFC mRNA expression in placenta and liver tissue, followed by lower levels in kidney,
bone marrow, and intestine. Of the tumour cell lines analysed, the highest levels of transcripts
were detected in erythroleukaemia (K562) cells.18
The levels of proteins, such as receptors and transporters in a cell, reflect the balance between
synthesis and degradation. Protein synthesis starts at the transcription of DNA to RNA and
continues with the translation of RNA to protein, and the regulation of these two processes,
as well as post-translational modifications, are important in determining which proteins are
present in a cell and in what amounts. The expression of FRs, for example, can be regulated
in relation to intracellular homocysteine levels. Figure 2.1 illustrates folate metabolism and
shows that, when folic acid or the natural folate, 5-methyltetrahydrofolate (5-methylTHF), is
converted to tetrahydrofolate (THF), a methyl group is transferred to homocysteine. The
homocysteine can then be converted to methionine, which plays a role in DNA methylation,
or can be degraded to cysteine.19 When there is folate deficiency, homocysteine accumulates
in the cell and it mediates the translational regulation of FR expression. Homocysteine binds
covalently

to

the

mRNA

binding

protein,

hnRNP-E1

(heterogeneous

nuclear

ribonucleoprotein-E1), forming a protein-mRNA complex, for which FRs have high affinity.
This interaction between mRNA and protein triggers FRs biosynthesis.20 Figure 2.2 shows
how homocysteine accumulation stimulates folate receptor expression. Homocysteine buildup induces a direct post-translational homocysteinylation of the protein hnRNP-E1, which
results in the unmasking of a high-affinity FR-α mRNA cis-element binding site and leads to
increased translation of FR.21

43

Chapter 2

Expression of Folate Receptors and Reduced Folate Carriers

Figure 2.1. Overview of folate (one-carbon) metabolism. DHF=dihydrofolate;
THF=tetrahydrofolate; MTHFR=methylenetetrahydrofolate reductase; MS=methionine
synthase; SAH=S-adenosylhomocysteine; SAM=S-adenosylmethionine.19

Figure 2.2. Effect of homocysteine accumulation. (A) Post-translational homocysteinylation
of the protein hnRNP-E1 results in upregulation of FR mRNA. (B) mRNA-binding site in
hnRNP-E1 protein with the covalent binding of L-homocysteine, through the replacement of
a cysteine disulfide bond.21
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Folate receptors are cell-surface glycoproteins that mediate folate uptake through
endocytosis. There are three main subtypes of FR, FR-α, FR-β and FR-γ. FR-γ is a secretory
protein while FR-α and FR-β are membrane-associated forms. FR-β is expressed in normal
hematopoietic cells, but it is only functional for folate binding in activated monocytes and
macrophages.22 FR-α is the most widely expressed receptor isoform23 and since it is the focus
of this study, FR is used to refer to the FR-α form in this thesis. This receptor is a 38-40 kDa
molecule anchored to the cell membrane through a glycosylphosphatidylinositol moiety. 24
Investigators have demonstrated increased FR levels when extracellular levels of folate are
low.25–27 Moreover, Miao Guo et al (2011) evaluated the uptake of a folate-conjugated drug
delivery system in both folate-replete medium and folate-free medium and their results
indicated greater uptake by cells grown in a folate-free medium.28
The reduced folate carrier (RFC) is an integral plasma membrane protein with a molecular
mass of ~65 kDa. RFC is a bidirectional anion exchanger and it transports natural folates and
antifolates. The detailed mechanism of RFC transport is not firmly established but it is
expected to involve a physical translocation of the carrier within the plasma membrane which
occurs due to a large intra- to extracellular anion concentration gradient.29 Unlike the FR,
RFC is a bidirectional transporter and it is responsible for the efflux of folates to normalise
folate levels in the cell. Therefore, RFC can be regulated according to folate levels in the cell
or in the medium. Ilan Ifergan and colleagues (2008) have demonstrated that, when there is a
lack of extracellular folate, RFC becomes a unidirectional transporter and the efflux of folates
can cause cell death.4
This chapter will focus on the gene and protein expression levels of FRs and RFCs while the
uptake and internalisation processes of folate molecules through these receptors are discussed
in more detail in Chapter 4. In the first part of our work, gene expression of FR and RFC was
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assessed for a range of cell lines grown in a folate-replete and a folate-free medium. From the
results of this experiment, we expected to standardise the experimental conditions with
respect to the culture medium. A folate-free environment is favourable to avoid competition
for folate, though how a folate-free environment affects the cellular levels of folate
transporters should be evaluated. Then, both gene and protein levels of FR and RFC were
assessed in a range of untreated cell lines, including six cancer cell lines and also a healthy
(non-cancer) cell line, and the correlation between mRNA and protein levels is presented and
discussed. Quantifying the expression levels of these receptors is important, since the
literature is controversial, as discussed above. In addition, we can select a smaller range of
cell lines, based on FR levels, for the in vitro cytotoxicity evaluation, to demonstrate the
potential to selectively target FRs and to study the correlation between the levels of each
receptor and the cytotoxicity of our complex.
FOLR1 is the gene that encodes for the FR-α protein. FR-α is the most studied member of the
family of folate receptors, as it is present on epithelial cells, while other members of this
family, such as FR-β and FR-γ are selectively present in hematopoietic cells. The high
expression of FR-α in cancer tissues has led to extensive research regarding its potential role
as a target for receptor-specific drug delivery systems. As mentioned previously, in this study
FR refers to the FR-α, and therefore, FOLR1 is the gene used to assess gene expression of
FRs in the studied cell lines.30 The RFC is a member of the solute carrier (SLC) group of
membrane transport proteins. The SLC gene group includes 52 families and 395 transporter
genes in the human genome. The RFC is the member 1 of the family 19 of this group, and is
encoded by the SLC19A1 gene, and therefore, this is the gene used to assess gene expression
of RFCs in the studied cell lines.31
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2.2 Materials and methods
2.2.1 Cell lines and culturing conditions
A range of cancer cell lines was obtained from the RESC cell culture bank in DIT, having
previously been purchased from the American Type Culture Collection (ATCC) and
European Collection of Authenticated Cell Cultures (ECACC). These were SKOV-3 (ovarian
carcinoma), HeLa (cervical carcinoma) and MCF-7 (breast carcinoma), which were cultured
in both regular (folate-replete) RPMI-1640 (Sigma-Aldrich) and folate-free RPMI-1640
media (Life Technologies), supplemented with 10% Foetal Bovine Serum (FBS) (SigmaAldrich) and maintained in a sterile environment at 37 °C and 5% CO2 atmosphere. Gene
levels of FR and RFC in cells was investigated by real-time PCR.
From this, the folate-free RPMI-1640 medium was established as the optimum medium and
used for cell culture in all experiments. The cell lines KB (subline of HeLa cells, cervical
carcinoma), CaCo-2 (colorectal carcinoma), A549 (lung carcinoma) and BEAS-2B (normal
lung) were added to the range to investigate mRNA and protein expression levels of FR and
RFC by real-time PCR and flow cytometry, respectively. For this, all cells were cultured in
folate-free RPMI-1640 medium supplemented with 10% FBS in T75 cell culture flasks
(Sarstedt, Ireland) and also maintained in a sterile environment at 37 °C and 5% CO2
atmosphere.
In all experiments, when the cells reached 70–80% confluency, they were subcultured either
for routine maintenance or experimentation. Subculturing involved first removing the cell
culture medium from the monolayer of cells, then adding 10 mL of trypsin:EDTA (1:1)
(Invitrogen, Ireland) solution to wash and remove any dead or detached cells from the
population. A further 10 mL of trypsin solution was added and the cells were incubated at 37
°C for 2-4 min to detach cells from their monolayer on the base of the flask. Cells were then
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placed in 10 mL of fresh culture medium to deactivate the trypsin enzyme and produce a 20
mL stock cell suspension. This stock cell suspension was used to seed different cell densities
in T75 stock flasks to maintain the cells in culture. The stock cell suspension was also used
for the subsequent experiments of real-time PCR or flow cytometry described below.

2.2.2 Gene expression by real-time PCR
RNA isolation
KB, CaCo-2, SKOV-3, HeLa, MCF-7, A549 and BEAS-2B cells were cultured in 3 x T25
cell culture flasks (Starsedt, Ireland). When cells achieved 80% confluency, 1 mL of TRI
Reagent® (Sigma-Aldrich) was added to each flask, homogenised and transferred to a 1.5
mL centrifuge tube. For the phase separation step, 0.2 mL of chloroform was added,
incubated for 5 minutes at room temperature and then centrifuged at 4 ºC for 15 minutes at
12,000 g. The upper aqueous phase was transferred to a fresh tube and the same volume of 2propanol was added to give a 1:1 ratio, incubated for 10 minutes at room temperature, and
then centrifuged at 4 ºC for 10 minutes at 12,000 g. The supernatant was discarded and the
RNA pellet was washed with 75% ethanol. The RNA pellet was resuspended in 30 µL of
RNase-free water and incubated in a water bath at 55 °C for 10 minutes for RNA
solubilization.
RNA quantification
The purity and concentration of the RNA samples were measured using the micro-volume
spectrophotometer MaestroNano™ (MaestroGen, USA). After an initial blank with 0.1%
diethyl pyrocarbonate (DEPC) treated water, the concentrations, as well as the absorbance
ratios of the samples, were recorded to allow for the cDNA synthesis step. The ratio of
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absorbance at 260 and 280 nm (the A260/280 ratio) is used to assess the purity of nucleic
acid preparations, and according to the literature, an A260/A280 absorbance ratio of 1.8 to
2.1 is indicative of a pure, i.e. protein free, RNA sample,32 and therefore, this was the ratio
range considered acceptable for proceeding with the cDNA synthesis and further
experiments.
cDNA synthesis
Based on the RNA concentrations previously obtained, a standardised value of 435 ng of
RNA was chosen based on the smallest measured concentration, and all subsequent samples
were normalised to this concentration in a 5 μL volume. The same amount of total RNA from
each sample was reverse-transcribed in a 20 µL reaction using the qScript™ cDNA synthesis
kit (Quanta Biosciences). Briefly, a master mix was prepared using the qScript™ reaction
mix (4 µL/20 µL) and qScript™ reverse transcriptase (1 µL/20 µL). Then a 5 μL volume of
each RNA sample was added to 15 µL of master mix. The reverse transcription PCR was
performed in a Thermocycler (Techne, UK) and the program consisted of 5 min at 22 °C, 30
min at 42 °C, and 5 min at 85 °C.
Primer design for Real-Time qPCR
Gene-specific primers corresponding to the targets FOLR1 and SLC19A1, and housekeeping
genes (endogenous reference genes) β-tubulin and β-actin were designed in-house using
NCBI/Blast33 and Primer3 software,34,35 and purchased from Genosys (Sigma-Aldrich). Table
2.1 below shows the forward and reverse primer sequences for each gene primer set. All
primers used were desalted and scaled to 0.05 µM.
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Table 2.1. Primer sequences for quantification of the target genes folate receptor (FOLR1)
and reduced folate carrier (SLC19A1), and the housekeeping genes, β-tubulin and β-actin.
Primer

Direction

Sequence (5’ – 3’)

FOLR1 (FR)

Forward

ACTCCCTGCCTGTCTCCTAG

FOLR1 (FR)

Reverse

CAGCCACCCACACTAGAAGG

SLC19A1 (RFC)
SLC19A1 (RFC)

Forward
Reverse

ACTGACGTAGAATGAAGAACTGC
ACACTTCAGAAGGACAGACAGG

β-tubulin

Forward

TTGGCCAGATCTTTAGACCAGACAAC

β-tubulin

Reverse

CCGTACCACATCCAGGACAGAATC

β-actin

Forward

ACTCTTCCAGCCTTCCTTCC

β-actin

Reverse

GTTGGCGTACAGGTCTTTGC

Real-time quantitative PCR assay conditions
The real-time quantitative PCR (qPCR) reaction was standardised using the KAPA SYBR
FAST Universal 2X qPCR Master Mix (Kapa Biosystems), which consisted of 1 µL of each
primer (forward and reverse at 500 nM per µL), 10 µL of Kapa SYBR Master Mix (2X), and
6 µL of PCR-grade water. This master mix was used in a reaction with 2 µL of cDNA
template for a total reaction volume of 20 µL. Four PCR master mixes were prepared, one for
each gene primer set (forward and reverse) including the target genes FOLR1 and SLC19A1,
and the housekeeping genes β-tubulin and β-actin, which were used as reference genes to
normalise the data. Each sample was aliquoted in duplicate, in a 96 well plate (plate design
can be seen in Appendix 1) and read using the 7500 Fast Real-Time PCR System (Applied
Biosystems®). The amplification program consisted of 1 cycle of 95 °C with a 5-minute hold
followed by 45 cycles of 95 °C with a 10-second hold, 60 °C with a 30-second hold and 72
°C with a 10-second hold. A negative control without cDNA template was run with every
assay to assess the overall specificity.
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qPCR data analysis
Real-time qPCR is based on the use of dyes to monitor and report DNA amplification and the
SYBR® family of cyanine dyes is widely used for this purpose. Briefly, the SYBR® green
dye fluoresces when bound to double-stranded DNA and the cycle of amplification in which
significant fluorescence is detected above a threshold is then reported. The reported cycle of
amplification is called the CT value (threshold cycle). The CT value is inversely proportional
to the amount of nucleic acid in the sample. Therefore, lower CT values indicate high
amounts of nucleic acid, while higher CT values mean lower amounts of nucleic acid.36
Amplification plots are created when the fluorescence signal from each sample is plotted
against cycle number. Therefore, amplification plots represent the accumulation of product
over the duration of the real-time PCR experiment.37
Relative quantitative PCR can be used to determine gene expression when analysing the
effect of a treatment or to compare two different conditions such as disease and non-disease.
In such cases, the PCR signal of the target transcript in the treated sample is quantified
relative to that of an untreated or non-disease control.38 In this work, the data was analysed
using the relative 2

-CT

method, described by Livak and Schmittgen (2001).39 In this

method, the PCR data are normalised to an endogenous reference gene and are relative to a
calibrator control. CT, the threshold cycle, is the cycle number at which the amount of
amplified target reaches a fixed threshold. The equation below describes the 2

CT

XT = X0 • (1 + EX)

=K

Equation 2.1

where XT = threshold number of target molecules
X0 = initial number of target molecules
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EX = efficiency of target amplification
CT = threshold cycle number for target
K = constant
In our work CT is normalised with respect to β-tubulin and β-actin as endogenous reference
genes (internal control genes, also called housekeeping genes) and therefore the equation for
these references is:
CTR

RT = R0 • (1 + EX)

=K

Equation 2.2

where RT = threshold number of reference molecules
R0 = initial number of reference molecules
ER = efficiency of reference amplification
CTR = threshold cycle number for reference
K = constant

Therefore, if EX = ER
CTX - CTR

XT/ RT = X0/ R0 • (1 + E)

Equation 2.3

And
ΔCT

XN • (1 + E)

=K

Equation 2.4

Or
XN = K • (1 + E)

-ΔCT

Equation 2.5

where XN = X0/ R0 = amount of target normalised to the endogeneous reference
ΔCT = CTX - CTR = difference in threshold cycle of target and endogenous reference
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In each experiment, a calibrator sample was used as the basis for comparing results. Thus, to
measure the difference in the gene expression levels of FR and RFC in cells grown in folatereplete and folate-free media, samples of cells grown in folate-replete medium were used as
calibrator samples. To measure the difference in the gene expression levels of FR and RFC in
different cancer cell lines, the normal cell line BEAS-2B was used as calibrator.
Therefore,

XNS/ XNC = K • (1 + E)

-ΔCTS

/ K • (1 + E)

-ΔCTC

= (1 + E)

-ΔΔCT

Equation 2.6

where -ΔΔCT is the difference in threshold cycle of the sample target and endogenous
reference genes relative to the calibrator. Normally the efficiency is close to one, giving:

XNS/ XNC = 2

-ΔΔCT

Equation 2.7

Therefore, the amount of target normalised to the endogenous reference and relative to the
calibrator sample is given by 2

-ΔΔCT

which is referred to as the fold change or fold

difference. Values of the fold change above 1 indicate that the target sample is upregulated in
relation to the calibrator sample while values under 1 indicate that it is downregulated.
To determine significant upregulation and significant downregulation, a t-test was performed,
and to calculate significant difference between cell lines, a 2-way ANOVA was performed
using GraphPad Prism® software. Post-ANOVA Bonferroni’s test was used in multiple
comparisons, i.e. to assess the significant difference in the gene expression between each cell
line, as in the Bonferroni’ test, the significance level applies to the entire family of
comparisons. Statistical significance was accepted as p ≤ 0.05 at 95% confidence levels for
all tests. The standard deviation was calculated according to the method described in Applied
Biosystems User Bulletin No. 2 (P/N 4303859).40
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2.2.3 Protein expression by flow cytometry
The number of cells per mL for each cell line KB, CaCo-2, SKOV-3, HeLa, MCF-7, A549
and BEAS-2B, was counted using the particle counter Beckman COULTERTM Z1 Coulter®
(Beckman-Coulter, USA) and 1 mL of cell suspension was placed into 20 mL of isoton
electrolyte solution (BD, Ireland). The volume required to give a cell solution with a
concentration of 5 x 105 cells/100 µl was calculated and the cell suspension was aliquoted
into three centrifuge tubes: (1) unstained cells with no antibodies, (2) negative control with
secondary antibody, and (3) immunoassay sample with both primary and secondary
antibodies for FR or RFC detection.
For the immunoassay, cells were incubated at 4 °C for 1 hour with the primary antibody, i.e.
a mouse monoclonal anti-folate receptor antibody, LK26 purchased from Abcam (ab3361), at
a final concentration of 2 µg/100 µL for FR detection, or with a chicken polyclonal antireduced folate carrier SLC19A1 antibody, purchased from Thermo Scientific (PA1-9553), at
a final concentration of 2 µg/100 µL for RFC detection. Flow cytometry staining (FCS)
buffer, containing PBS, 1% bovine serum albumin (BSA) and 0.1% sodium azide, was used
in the dilution of the antibodies. After incubation, the cells were washed and incubated at 4
°C for 30 minutes in the dark with the respective secondary antibodies, i.e. a goat anti-mouse
Alexa Fluor® 488-conjugated from Life Technologies (A11017) at a 1:800 final dilution, and
a goat anti-chicken Alexa Fluor® 488-conjugate from Fisher Scientific (10286672) at a 1:800
final dilution. After incubation, the cells were washed and examined on the Accuri C6 (BD
Biosciences) flow cytometer. The unstained cells sample was incubated with FCS buffer
only. Negative controls were samples of cells with the secondary antibody which were
incubated with FCS buffer without the primary antibody, to define positive populations and
to eliminate any background fluorescence from the conjugated secondary antibody. All
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antibodies were previously titrated to determine the optimal dilution for the assay. 1% BSA
was used in the staining buffer to avoid non-specific binding. Three independent experiments
were carried out for all samples. In the flow cytometer, an excitation laser line of 488 nm,
filter 530/30 and FL-1 detector were used for excitation and detection of fluorescence from
the green dye Alexa Fluor® 488. All samples were gated to eliminate debris and undesired
subpopulations. Aggregates were removed by gating single cells on the analysis of the height
versus the area of the forward scattered light (FCS-H x FCS-A) and 10,000 events were
recorded as single cells. All cells were healthy and alive at the moment of detection, which
was determined through analysis of the cell size and complexity in the side scattered light
versus forward scattered light (SSC x FSC) histograms and with the use of propidium iodide
(PI), a dye which binds to the DNA that is exposed from dead cells. Data were analysed using
BD Accuri C6 software.

2.3 Results and discussion
2.3.1 Folate-replete and folate-free media
To confirm the upregulation of FR gene expression levels and to assess if RFC levels were
also regulated by the lack of extracellular folate, three cell lines, SKOV-3, HeLa and MCF-7,
were grown in both folate-replete and folate-free RPMI-1640 media. Gene (mRNA) levels
were quantified by real-time quantitative PCR and cells grown in the folate-replete RPMI1640 medium were used as calibrator samples to calculate the relative fold change in the
expression levels of the genes for cell lines grown in a folate-free medium. Figure 2.3 below
shows the relative fold change in the mRNA levels of these cells when grown in folate-free
medium, compared to their mRNA levels when grown in folate-replete medium.
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Figure 2.3. Relative fold-change in (A) folate receptor and (B) reduced folate carrier gene

expression levels. Fold-change = 2-Ct where CT = CT of folate-free medium sample CT of folate-replete medium sample. Error bars represent standard deviation. Asterisks
indicate results which are significantly different to the calibrator sample where * is p<0.05
and ** is p<0.01 at 95% confidence.

It can be seen from figure 2.3A that there is an upregulation (fold-change > 1) of FR for all
cell lines grown in folate-free medium, with a statistically significant difference for SKOV-3
and MCF-7 cells. The complete statistical analysis is given in Appendix 2. The fold increase
observed in FR levels confirms the findings indicated in the literature. For example, Luhrs et
al (1992) found that FRs are upregulated in mouse embryonic fibroblast cells grown in low
folate conditions. They proposed that these conditions stimulate the cells to upregulate its FR
levels in order to maintain the necessary levels of intracellular folate. This is also supported
by Necela et al (2014) who reported higher FR expression in triple negative breast cancer
cells grown in low folate conditions, and Yang et al (2007) who reported an upregulation of
FR expression after human bone osteosarcoma cells were transferred to low-folate media.41–43
According to Antony et al (2004), folate deficiency results in homocysteine cellular
accumulation, and since homocysteine interacts with a protein-mRNA complex which
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stimulates FR expression, there are higher levels of FR in the membrane to capture folate
molecules and to normalise the cellular levels of folate.20 Folate-free medium was used in
subsequent experiments since the drug delivery system studied in this work is proposed to
specifically target FR.
From figure 2.3B, it can be seen that there is a significant upregulation of RFC for SKOV-3
but downregulation (fold-change < 1) for HeLa and MCF-7 cells, although this is not
significant. The complete statistical analysis is given in Appendix 3. Reports of both up and
downregulation can be found in the literature. Hou et al (2014) found less expression of RFC
mRNA and protein in RFC-expressing HeLa cells grown in low extracellular folate levels,
and found that it increased when folate was added to the medium.44 Subramanian et al (2003)
found upregulation of RFC mRNA and protein in CaCo-2 cells while Ilan Ifergan et al (2008)
found downregulation of RFC levels in MCF-7 cells in response to folate deficiency. Ifergan
suggests that when there is a lack of extracellular folate, the cellular efflux of folates needs to
decrease for cell survival and that can trigger RFC downregulation.45,46

2.3.2 Folate receptor and reduced folate carrier gene expression
The expression levels of FR (FOLR1) and RFC (SLC19A1) genes were examined in KB,
CaCo-2, SKOV-3, HeLa, MCF-7, A549 and BEAS-2B cells. β-Tubulin and β-actin were the
housekeeping genes used in this study as reference gene controls for data normalisation. The
aim of using quantitative PCR here is to measure the abundance of FR and RFC mRNA in
this range of untreated cell lines. Table 2.2 shows the data for FR and RFC gene expression
normalised to the endogenous controls (CT) in the seven cell lines analysed. As stated by
Ramon Goni et al (2009), in every cycle of PCR (CT value) the amount of DNA is
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approximately duplicated. CT is in the logarithmic scale and inversely proportional to the
quantity of DNA or RNA. Therefore high ∆CT values represent low expression, while highly
expressed genes have low ∆CT.47

Table 2.2. Folate receptor (FR) and reduced folate carrier (RFC) mRNA expression values
(CT ± standard deviation) normalised to the endogenous controls. Asterisks indicate results
which are significantly different to the BEAS-2B normal cell line where *** is p<0.001, ** is
p<0.01 and * is p<0.05 at 95% confidence.
Cell line

FR

RFC

KB

4.65*** ± 0.86

5.60*** ± 1.02

CaCo-2

9.58*** ± 0.38

7.56 ± 0.47

SKOV-3

10.56*** ± 0.18

7.58* ± 0.95

HeLa

13.65* ± 0.53

5.26*** ± 0.10

MCF-7

13.90 ± 0.59

6.08*** ± 0.44

A549

14.44 ± 1.76

6.74** ± 0.97

BEAS-2B

15.78 ± 0.47

9.75 ± 0.42

KB, CaCo-2 and SKOV-3 are the cell lines that express the highest levels of FR when
compared to the other cell lines. KB, HeLa, MCF-7 and A549 cell lines express significantly
higher levels of RFC than the other cell lines. BEAS-2B, the normal cell line, shows the least
abundance of mRNA levels of both receptors. A complete statistical analysis, which includes
a one-way ANOVA test comparing BEAS-2B cells to all other cell lines, is given in
Appendix 4 and a one-way ANOVA with a Tukey’s multiple comparison test, which
compares all cell lines, is given in Appendix 5.

To better visualise the difference in FR and RFC levels between the cancer cell lines and the
normal cell line, Ct was calculated using BEAS-2B as the calibrator sample.39 This
difference (fold-change) is shown in figure 2.4.

58

Chapter 2

A

Expression of Folate Receptors and Reduced Folate Carriers

B

Figure 2.4. (A) Folate receptor and (B) reduced folate carrier gene expression in KB, CaCo2, SKOV-3, HeLa, MCF-7, A549 and BEAS-2B cell lines represented by the 2-Ct method.
The red line represents the normal cell line BEAS-2B used as the calibrator. Error bars
represent standard deviation and asterisks indicate results which are significantly different to
the calibrator sample where *** is p<0.001, ** is p<0.01 and * is p<0.05 at 95% confidence.

It can be seen from the figures above that both FR and RFC are upregulated in all the cancer
cell lines analysed, compared to the normal cell line BEAS-2B. A significantly higher
expression is found for FR in KB, CaCo-2 and SKOV-3. Statistics can be seen in Appendices
6 and 7. HeLa and MCF-7 cells can also be considered as having FR low expressing mRNA
when compared to KB cells. As mentioned previously, there are conflicting reports in the
literature with respect to expression of FR in cancer cell lines. However, some investigators
have reported a similar overexpression of FR in cancer cells when compared to healthy cells.
Siu et al (2012) reported overexpression of FR in various ovarian cancer cells and its
association with tumour progression, demonstrating a progressive increase in FR levels from
non-tumour tissues, benign and borderline tumours to carcinomas.48 The high FR (FOLR1)
gene expression found here for KB, CaCo-2 and SKOV-3 is also consistent reports from
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Sadasivan et al (1989), who found high mRNA expression in KB cells, particularly higher
when grown in a folate-deficient environment, as in this study.49 Doucette and Stevens
(2001), reported high FR mRNA levels in CaCo-2 cells and correlated this with cell growth,
and Yang et al (2007) showed positive FR mRNA levels using real-time PCR data and a gel
of the PCR product.43,50 Bongartz et al (2013) also found low levels of FRs mRNA in A549
cells, which showed lower levels than in HeLa cells. At present, no information was found
for FR gene expression in BEAS-2B cells but several authors have reported a low expression
of FR in normal tissues, for example Parker et al (2005) and O’Shannessy et al (2015) found
negligible FR expression in normal ovarian tissue.7,51
RFC is ubiquitously expressed in normal mammalian tissues and tumours.28 From figure
2.4B it can be seen that RFC is upregulated in the cancer cell lines compared to the BEAS-2B
normal cell line with a significantly higher expression for HeLa cells. RFC (SLC19A1) gene
expression has not been as widely investigated as the FR (FOLR1) gene. Hou et al (2014)
describe HeLa as an RFC-expressing cell line, which is consistent with this work since HeLa
was found to be the highest RFC mRNA-expressing cell line analysed. In addition, Westerhof
et al (1995) describe KB cells as a RFC-expressing cell line, which also compares favourably
with this work since KB cells were the second highest RFC mRNA-expressing cell line.44,53
However, investigators, such as Siu et al (2012) and Ifergan et al (2008), reported
downregulation of RFC in cancer cells.4,48 The normal cell line used here is the human lung
cell line BEAS-2B, and no information was found in the literature about its expression of
levels of RFC. Therefore, it is possible that BEAS-2B expresses lower levels than other
normal cell lines, and thus, the cancer cells analysed may express high levels of RFC but only
in comparison to this cell line in particular.
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2.3.3 Folate receptor and reduced folate carrier protein expression
Flow cytometry experimentation was performed to confirm FR and RFC protein expression
levels and to identify the correlation with their gene mRNA levels. Figures 2.5 and 2.6
display the median fluorescence intensity for FR and RFC protein detection, respectively, in
the seven cell lines analysed.

Folate Receptor
1,200,000

***

1,000,000
800,000
600,000

MFI

400,000
150,000
100,000
50,000
6,000
4,000
2,000

A5
49
BE
AS
-2
B

F7
C
M

H

eL
a

V3

SK
O

C

aC

o2

KB

0

Cell line

Figure 2.5. Folate receptor protein expression in KB, CaCo-2, SKOV-3, HeLa, MCF-7,
A549 and BEAS-2B cells where MFI=Median Fluorescence Intensity. Asterisks indicate the
results which are significantly different to the rest of the cell lines where *** is p<0.0001 at
95% confidence.

Figure 2.5 shows that there is a variation in FR protein expression for the seven cells lines,
with KB cells displaying significantly higher expression (MFI = 1,039,696), and the normal
BEAS-2B cells displaying the lowest expression (MFI = 490) (statistics can be seen in
Appendix 8). These results compare favourably with the literature. Forster et al (2007)
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analysed KB, IGROV-1 (ovarian carcinoma) and JEG-3 (choriocarcinoma) cells and also
found higher protein expression of FR in KB cells. Bongartz et al (2013) analysed HeLa and
A549 cells and also found low expression of FR protein in A549 cells. Chen et al (2009) also
described HeLa and MCF-7 as tumour cells with lower FR density on their surface when
compared to KB cells. There is little information found in the literature with respect to FR
protein expression in BEAS-2B, but authors have reported low expression in other healthy
cell lines, for example, Weitman et al (1992) found low FR protein expression in MA104
normal renal epithelium cells and in a number of normal tissues such as liver, intestines and
muscle.54
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Figure 2.6. RFC protein expression in KB, CaCo-2, SKOV-3, HeLa, MCF-7, A549 and
BEAS-2B cell lines where MFI=Median Fluorescence Intensity. Asterisks indicate results
which are significantly different to the other cell lines where * is p<0.05 at 95% confidence.

Figure 2.6 shows that the cell lines studied all express RFC, which agrees with reports in the
literature. Matherly et al (2008) and Whetstine et al (2002) reported that RFC is ubiquitously
expressed between cell lines and tissues, such as placenta and liver.18,55 In this work, MCF-7
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has the highest expression of RFC protein (MFI = 5,446.17) although there is no significant
difference between the cell lines (statistics can be seen in Appendix 9). SKOV-3 displays the
lowest abundance of RFC (MFI = 1,436).
RFC levels vary less than FR levels between the cell lines, which may suggest that RFC is
required by all cells and is related to some physiological properties.32 RFC is called a folate
transporter because of its important role in the uptake of natural folates such as 5methyltetrahydrofolate, while FR has higher affinity for folic acid, the synthesised oxidised
form of folate.33 RFC is also responsible for balancing the intracellular levels of folate by
mediating its efflux transport. Therefore, these results may indicate that RFC is necessary for
folate internalisation when normal levels are required, and when higher levels of this vitamin
are required, such as when there is lack of extracellular folate or a greater need for rapid cell
replication, FR can be upregulated for higher uptake of folates.
Using the results presented in figures 2.5 and 2.6, the fluorescence obtained for each cell line
was compared with that obtained for unstained cells and control cells to which no primary
antibody was added, as described in the Materials and Methods section. The results are
presented in figure 2.8 for FR and figure 2.9 for RFC and show the fluorescence (filter
530/30 for Alexa Fluor® 488) on the x-axis and the number of events (cell count) on the yaxis.
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Figure 2.7. Fluorescence levels for unstained cells (black peak), no primary antibody control
(blue peak) and folate receptor levels (red peak) in KB, CaCo-2, SKOV-3, HeLa, MCF-7,
A549 and BEAS-2B.
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Figure 2.8. Fluorescence levels for unstained cells (black peak), no primary antibody control
(blue peak) and reduced folate carrier levels (orange peak) in KB, CaCo-2, SKOV-3, HeLa,
MCF-7, A549 and BEAS-2B.
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In figures 2.7 and 2.8, the x-axis indicates the fluorescence intensity, and therefore, the more
the peak shifts to the right, the higher is the fluorescence intensity and the higher is the
amount of protein present in the sample. Each peak is represented by the number of cells
(count) that display a determined amount of fluorescence. The results showed in the figures
2.5 and 2.6 are represented by the median of fluorescence intensity while the figures 2.7 and
2.8 show the distribution of this fluorescence between the cells analysed individually.

2.3.4 Comparison of gene and protein expression levels
Gene and protein levels were compared, and figure 2.9 shows the distribution of the cell lines
according to their expression levels of mRNA and protein for FR and RFC. These levels were
determined to be low, medium and high, which are relative terms, only comparing the cell
lines analysed in this study.

A

B

Figure 2.9. Distribution of the cell lines analysed according to their relative levels of
expression. (A) Folate receptor (FR) mRNA and protein expression levels. (B) Reduced
folate carrier (RFC) mRNA and protein expression levels.
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Figure 2.9A above shows the difference between the levels of FR in the seven cells analysed.
Gene and protein levels of FR were well correlated in KB, CaCo-2, A549 and BEAS-2B
cells. MCF-7 and HeLa expressed higher protein than mRNA levels, which may be explained
by different rates of protein synthesis in relation to the rates of mRNA synthesis in these cell
lines. As stated by Abreu et al (2009) one mRNA molecule in the cell can be translated into
protein several hundred to thousands of times before its degradation, eventually resulting in
higher amounts of protein than mRNA.34 This difference of gene and protein expression may
explain why contradictory reports can be found in the literature, particularly for FR
expression.
It can be seen from figure 2.9B that similar levels of RFC were found across all cell lines. As
discussed previously, RFC plays an important role in maintaining intracellular concentrations
of folate, and therefore, it is responsible for the influx and efflux of this vitamin. However, a
poor mRNA-protein correlation is found between cell lines. According to Abreu et al (2009),
changes in the concentration of a protein depend on the mRNA concentration, translation
efficiency and degradation of the existing protein. Post-transcriptional and translational
regulation, as well as protein turnover and protein degradation control, can all influence
protein concentration which could explain the poor protein-mRNA correlation.58,59 According
to Maier et al (2009), the correlation between mRNA and protein abundances in complex
systems are known to be notoriously poor and the processes of transcription from DNA to
RNA and translation from RNA to protein are far from having a linear relationship. There are
regulatory proteins and small RNAs that can act as translational modulators by specifically
binding to their mRNAs to stop translation. In addition, ribosomal density and ribosome
occupancy, which denote the number of ribosomes per transcriptional unit and the individual
mRNA fraction engaged in translation on ribosomes, are important measures for translational
efficiency. The translational efficiency is the number of proteins synthesized per mRNA, and
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different translation efficiencies for mRNA molecules directly influence the mRNA-protein
correlation.60 Fortelny et al (2017) indicate that protein levels cannot be accurately predicted
from mRNA levels and gene-specific translation rates, also demonstrating a poor correlation
between mRNA and protein levels.61

2.4 Conclusion
The study presented in this chapter elucidated the gene and protein levels of FRs and RFCs in
different cell lines. First, an upregulation in FRs was found when cells are grown in folatefree media. Then, after comparing the gene expression levels in a range of cell lines, real-time
PCR showed that FRs are more abundant in KB cells followed by CaCo-2 and SKOV-3 cells.
RFC has higher expression in HeLa cells, followed by KB cells. BEAS-2B showed the least
abundant mRNA levels of both receptors and, as it is a non-cancer cell line, seemed to be a
good calibrator cell line to compare with the cancer cell lines. Cancer cells displayed
upregulation of both FRs and RFCs when compared to the normal cell line BEAS-2B.
The protein expression levels of FR and RFC assessed by flow cytometry showed that KB
cells express significantly higher levels of FRs than all the other cell lines while BEAS-2B
cells showed the lowest levels. HeLa cells showed the highest levels of RFCs while SKOV-3
showed the lowest levels.
The levels of FRs vary between very high and very low expression in different cell lines
when compared to the levels of RFC, which are mostly in a lower range of expression. That
can be an indicator that FRs are regulated according to the cell requirements. Therefore, even
though FR is upregulated when folate is present in low concentrations, the function depends
on the requirements of the cell during cell replication.50
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The role of FRs and RFCs in the uptake of folic acid and antifolates is important in this work,
since in the drug delivery system CDEnFA:MTX, folic acid and the antifolate, MTX, are
present in the same complex. From their FR levels analysis, KB, CaCo-2, MCF-7, A549 and
BEAS-2B cells were selected to be used in the cytotoxicity evaluation of the drug delivery
system.
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3.1 Introduction
From the results of the work described in Chapter 2, five cell lines were selected for an in
vitro cytotoxicity analysis according to their FR expression levels. These cell lines are KB,
CaCo-2, MCF-7, A549 and BEAS-2B. KB and CaCo-2 cells were chosen due to their high
levels of FR, MCF-7 cells were chosen due to their medium levels of both FR and RFC,
while A549 and BEAS-2B cells were chosen due to their low levels of FR. These cells were
tested against the carrier CDEnFA, drug methotrexate (MTX), and the inclusion complex
CDEnFA:MTX.
CDEnFA was developed by Tofzikovskaya et al (2012) at DIT, to be used as a drug vehicle
that can target folate receptors on cancer cells and deliver the MTX. 1 CDEnFA is a βcyclodextrin carrier vehicle, developed through a three-step synthesis that starts with the
preparation of 6-o-monotosyl-6-deoxy-β-cyclodextrin (CDTs), which method was published
by Potter et al (2007).2 The synthesis method and the characterisation of CDTs are presented
in the supplementary information, Chapter 7, and figure 3.1 provides a schematic of the
synthesis of the CDTs.

Figure 3.1. Synthesis of 6-o-monotosyl-6-deoxy-β-cyclodextrin, CDTs.

The second step in the synthesis involves the addition of an amino group to the CDTs,
forming the derivative 6-deoxy-6-[1-(2-amino)ethylamino]-β-cyclodextrin, CDEn. This
amino group functions as a linker between the β-CD and the folic acid. CDEn was prepared
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according to the method published by Potter et al (2007).2 The synthesis method and the
characterisation of CDEn are presented in the supplementary information, Chapter 7, and
figure 3.2 gives a schematic of the synthesis.

Figure 3.2. Synthesis of 6-deoxy-6-[1-(2-amino)ethylamino]-β-cyclodextrin, CDEn.

The third step in the synthesis involves the addition of the folic acid to the CDEn, forming the
6-deoxy-6-[(1-(2-amino)ethylamino)folate]-β-cyclodextrin, CDEnFA. This procedure was
published by Tofzikovskaya et al (2012)1 and the full method and the characterisation of
CDEnFA are given in the supplementary information, Chapter 7. Figure 3.3 below depicts the
synthetic route to CDEnFA.

Figure 3.3. Synthesis of 6-deoxy-6-[(1-(2-amino)ethylamino)folate]-β-cyclodextrin,
CDEnFA.
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MTX is the model drug that was used in conjunction with the carrier CDEnFA
(CDEnFA:MTX) for this work. As described in Chapter 1, MTX is a well-known drug, used
worldwide for treating rheumatoid arthritis and cancers, such as acute lymphoblastic
leukaemia (ALL), osteosarcoma, breast, head and neck cancers, lymphoma, lung cancer,
bladder cancer, and trophoblastic neoplasms.3 MTX acts by inhibiting the enzyme
dihydrofolate reductase and potentially other enzymes in the one-carbon metabolism, which
results in the inhibition of purine nucleotide synthesis, and consequently, DNA synthesis.4
CDEnFA:MTX is the inclusion complex of CDEnFA and MTX. Although the CD cavity is
hydrophobic, it normally contains 11 H2O molecules per cavity. Non-covalent bonds are
involved in the inclusion complex formation in aqueous solution and it is energetically
favourable for a less polar molecule, such as MTX, to replace the water molecules and
preferentially bind to form the inclusion complex. The method for preparation of
CDEnFA:MTX is described in the supplementary information, Chapter 7. Figure 3.4 displays
the proposed structure of CDEnFA:MTX.

Figure 3.4. The proposed structure of the targeted drug delivery system CDEnFA:MTX.
Folic acid is shown in blue, the cyclodextrin is shown in red and the drug, MTX, is included
in the CD cavity.
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The work presented in this chapter provides an in vitro evaluation of the cytotoxicity of
CDEnFA:MTX compared to the drug MTX alone, towards cell lines expressing varying
levels of folate receptors. The carrier CDEnFA was also evaluated in terms of its
biocompatibility. A correlation between cytotoxicity data and the expression levels of FR
and RFC (from Chapter 2) in each cell line is analysed.

3.2 Materials and methods
3.2.1 Cell lines and cell culture
The cell lines KB, CaCo-2, MCF-7, A549 and BEAS-2B were selected for the in vitro
cytotoxicity analysis according to their FR expression levels. All cells were cultured in folatefree RPMI-1640 medium (Life Technologies) supplemented with 10% FBS, grown to 80%
confluency in T75 cell culture flasks (Sarstedt) and maintained in a sterile environment at 37
°C and 5% CO2 atmosphere. Cells were then trypsinised with protease enzyme trypsin in
EDTA solution (0.25%). Cells were neutralised with 1:1 trypsin EDTA:culture medium,
centrifuged for removal of trypsin and retained as a cell suspension in culture medium for the
cytotoxicity testing. Cells were counted using the Beckman Z1 Coulter Counter, as described
in the section 2.2.3 of Chapter 2. For the purpose of achieving a uniform methodology, all
cells were seeded at a density of 5,000 cells per well in 96 well plates, in a 100 μL volume.
The plates were incubated at 37 °C in a 5% CO2 humidified atmosphere for the cells to attach
to the culture plates, and after 24 hours, they were then exposed to each test compound
CDEnFA, MTX and CDEnFA:MTX.
Stock solutions of each test compound were prepared in NaOH (0.1 M pH 12). All solutions
were then diluted in supplemented folate-free RPMI-1640 medium for a concentration range
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of 1, 5, 10, 50 and 100 µM. Cells were seeded in 6 wells for each concentration of each
compound and on triplicate plates for statistical validity. Fresh folate-free RPMI-1640
medium was added to untreated cells as a negative control. After treating the cells, the plates
were incubated at 37 °C in a 5% CO2 humidified atmosphere for 48 hours, which was the
drug-exposure time chosen for this range of concentrations and this range of cell lines
followed experimental optimisations.

3.2.2 Cell viability assay
The MTT assay was used to assess the cell viability after treatments with each test
compound. The MTT assay, developed by Tim Mosmann (1981), is a rapid colourimetric
assay that measures cell viability based on cell function. The assay detects living cells and the
signal generated is proportional to the degree of activation and metabolic function of the
cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) is a tetrazolium
salt and its cleavage by the enzyme succinate-dehydrogenase results in the production of
purple formazan crystals which accumulate in endosomal and/or lysosomal compartments of
cells. These purple crystals can then be dissolved using an alcohol or dimethyl sulfoxide
(DMSO) to produce a homogeneous solution suitable for measurement of cell viability by
absorbance spectrophotometry.5
For the procedure, the MTT salt was prepared in Phosphate Buffered Saline (PBS) at 5
mg/mL as a stock solution and this was diluted 1:10 as a working (10 μL of MTT solution to
90 μL of medium). Cells were incubated with MTT working solution at 37 °C in a 5% CO2
humidified atmosphere for 3 hours. After incubation, the MTT was removed by washing with
PBS. 100 μL of DMSO was added to each well, the plate was shaken for 10 minutes and the
absorbance read on a SpectraMax® Plus384 Absorbance Microplate Reader at 570 nm.
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Cell viability was calculated as a percentage of control groups according to the following
formula:
cell viability (%) = (OD of the test group/ OD of the control group) ×100
where OD = optical density and test and control group are treated and non-treated cells,
respectively.

3.2.3 Statistics
Cytotoxicity data were expressed as mean percentage cell viability relative to control (100%)
± standard deviation (SD). Statistical analysis was carried out using two-way analysis of
variance (ANOVA) followed by a post-ANOVA Dunnett’s test for assessing the difference
between each sample concentration relative to the control. The two-way ANOVA compares
the mean differences between groups that have been split on two independent variables and
the Dunnett's test is a multiple comparison procedure used to compare each of a number of
treatments with a single control. The post-ANOVA Bonferroni’s test was used to assess the
difference between the same concentrations of two different compounds. Bonferroni
correction is used when multiple comparisons need to be performed following two-way
ANOVA as it can reduce the threshold for significance taking in consideration the number of
comparisons to be made. With this, the significance level applies to the entire family of
comparisons, not to each individual comparison. Statistical significance was accepted as p ≤
0.05 at 95% confidence levels for all tests. Statistical data and IC50 values were calculated
using the GraphPad Prism software®.
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3.3 Results and discussion
3.3.1 Cytotoxicity of CDEnFA
The cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B cells after a 48-hour exposure
to the carrier CDEnFA was assessed using the MTT assay and the results are presented in
figure 3.5 below.

Figure 3.5. Effect of CDEnFA on the cell viability of KB, CaCo-2, MCF-7, A549 and
BEAS-2B cells. Results are expressed as percentage of untreated control (mean ± SD).
Asterisks denote significant differences to the control where * is p < 0.05 and ** is p < 0.01
at 95% confidence.
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The cell viability as a result of the effect of CDEnFA remains above 84% for all
concentrations studied for CaCo-2 and A549 cell lines. A statistically significant cytotoxic
effect of CDEnFA can only be seen at concentrations of 50 and 100 µM for KB cells, with a
cell viability of 86.1% and 84.2%, respectively, and at 100 µM for both MCF-7 and BEAS2B, with a cell viability of 84.3% and 87.6% (statistics can be seen in Appendix 10). The
international standard for biological evaluation of medical devices, ISO 10993-5, includes
that from quantitative evaluations, a cytotoxic effect is considered when there is a reduction
of cell viability more than 30%.6 The result obtained compares favourably with Varan et al
(2018), who obtained a cell viability range between 70% and 100% for a non-ionic
amphiphilic and a polycationic amphiphilic unloaded derivatives of β-CDs, exposed to a coculture of MCF-7 and the human dermal fibroblast cell line (HDF).7 Róka et al (2015) tested
high concentrations of derivatives of α-CDs in CaCo-2 cells and found that the effect of αCDs derivatives resulted in concentration-dependent cytotoxicity. These authors suggest that
the cytotoxicity may vary between cell types possibly due to the different mechanisms of
membrane constituent extraction.8 Leclercq (2016) reviews the interactions between CDs and
cellular components and suggests that the CDs have the capacity to draw phospholipids and
cholesterol out of the biological membrane. According to Irie et al (1997) and Huang et al
(2013), the suggested mechanism is that CDs interact with plasma membranes by the
extraction of different components into their cavity via inclusion complex formation.9 The
removal of cholesterol components from the cells may result in an increase in membrane
fluidity, which would lead to lysis of the cells.10 This can be a reason for the cytotoxicity seen
for KB, MCF-7 and BEAS-2B cells. However, it should be noted that CDs lose their abilities
to interact with cell membranes when their cavities are occupied with guest molecules.11
Therefore, the carrier CDEnFA possibly interact with the cell membrane, but when MTX is
included in the cavity, the cytotoxic effect is caused by the drug itself and CDEnFA has no
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longer a toxic effect towards the cells. In addition, as discussed in Gidwani’s review (2015),
although in vitro studies have reported haemolytic effects of CDs, the toxicological
implication of in vivo studies is considered negligible.12 The in vivo tolerance of CDEnFA to
the larvae of the greater wax moth Galleria mellonella is discussed in Chapter 5. Additional
information on the biocompatibility of CDEnFA from in vitro cell viability measured by flow
cytometry is presented in Chapter 4.

3.3.2 Cytotoxicity of MTX
The cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B cells after a 48-hour exposure
to the drug MTX was assessed using the MTT assay and the results are presented in figure
3.6 as follows.
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Figure 3.6. Effect of MTX on the cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B
cells. Results are expressed as percentage of untreated control (mean ± SD). Asterisks denote
significant differences to the control where * is p < 0.05, ** is p < 0.01 and, *** is p < 0.0001
at 95% confidence.

It can be seen from these results that MTX is significantly cytotoxic to all cell lines studied,
at least from concentrations above and including 50 µM (statistics can be seen in appendix
11). MTX displayed higher cytotoxicity towards KB, CaCo-2 and A549 cells even at low
concentration of 5 µM, and lower cytotoxicity towards MCF-7 and BEAS-2B. According to
the results reported in Chapter 2, KB, CaCo-2 and A549 express higher protein levels of
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RFC, than BEAS-2B. RFC is the receptor with high affinity for MTX, and therefore, higher
RFC levels could result in higher MTX cytotoxicity. MCF-7 cells, even though they were not
so sensitive to MTX, express the highest protein levels of this receptor. Ifergan et al (2008)
investigated the association between RFC levels and cytotoxicity, and suggested that high
RFC levels are associated to sensitivity to antifolates, such as MTX, while low RFC levels
are associated to the resistance to antifolates.13 However, some investigators such as Huang et
al (2008)14 and Kaufman et al (2004)15 have reported a low correlation between RFC levels
and MTX toxicity. In addition to RFC levels, the expression of enzymes such as
methylenetetrahydrofolate

reductase

(MTHFR),

responsible

for

the

reduction

of

methyleneTHF in the metabolism of folates may be correlated to MTX activity.16,17

3.3.3 Cytotoxicity of CDEnFA:MTX
The cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B cells after a 48-hour exposure
to the complex CDEnFA:MTX was assessed using the MTT assay and the results are
presented in figure 3.7 as follows.
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Figure 3.7. Effect of CDEnFA:MTX on the cell viability of KB, CaCo-2, MCF-7, A549 and
BEAS-2B cells. Results are expressed as percentage of untreated control (mean ± SD).
Asterisks denote significant differences to the control where * is p < 0.05, ** is p < 0.01 and,
*** is p < 0.0001 at 95% confidence.

The data shows that CDEnFA:MTX treatment results in cell viability significantly different
to the control for all cells with p < 0.0001 at concentrations higher than and including 50 µM
in all cases (statistics can be seen in appendix 12). CDEnFA:MTX demonstrated the greatest
cytotoxicity towards KB and CaCo-2 cells at all concentrations studied and least cytotoxicity
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towards BEAS-2B cells. KB and CaCo-2 cells express the highest levels of FRs while BEAS2B expresses the lowest. The results obtained for A549 and BEAS-2B compares favourably
to previous work from Tofzikovskaya et al (2015).18 The comparison between cell viability
after treatments with MTX alone and CDEnFA:MTX, as well as its correlation to FR levels
in the cells, is discussed in the following section.

3.3.4 Comparison of the cytotoxicity of MTX and CDEnFA:MTX
Figure 3.8 below shows a comparison of the cell viability for each of the cell lines studied
after a 48-hour exposure to MTX and CDEnFA:MTX. A figure which also includes the
results for CDEnFA and the solvent control, NaOH, can be seen in appendix 13.
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Figure 3.8. Effect of MTX (■) and CDEnFA:MTX (▲) on the cell viability of KB, CaCo-2,
MCF-7, A549 and BEAS-2B cells. Asterisks denote significant differences between the two
compounds where * is p < 0.05, ** is p < 0.01, *** is p < 0.0001 at 95% confidence.

After a 48-hour exposure to free MTX and to the complex CDEnFA:MTX, the antiproliferative effect was observed and it can be seen from figure 3.7 that the complex was
more cytotoxic towards the high-FR expressing cell lines, KB and CaCo-2, in comparison to
the free MTX. The IC50 value, which is the concentration causing 50% inhibition of cell
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proliferation, was calculated from the cell viability results. The IC50 value for KB cells was
53.75 ± 1.57 µM for free MTX and 6.91 ± 1.49 µM for CDEnFA:MTX. This means that the
complex was responsible for a 7.8 fold increase in the cytotoxicity of the drug towards this
cell line. The IC50 value obtained for CaCo-2 cells was 76.48 ± 1.28 µM for MTX and 48.03
± 1.16 µM for CDEnFA:MTX, which means that the complex resulted in a 1.6 fold increase
in the cytotoxicity of the drug. Other investigators have also reported higher cytotoxicity of
FR-targeted drug compounds towards high-expressing FR cell lines. For example, Chen et al
(2015) assessed the cytotoxicity of an MTX-loaded nanoparticle in A549 and KB cell lines
and also observed higher cytotoxicity of the complex than the free drug. 19 Roger et al (2012)
reported that, in the FR expressing cell line, CaCo-2, folic acid functionalized poly(D,Llactide-co-glycolide)-nanoparticles loaded with the drug paclitaxel, showed an 8-fold increase
in transport when compared to free drug.20 Anderson et al (2001) reported that the
incorporation of folic acid conjugated liposomes for drug delivery resulted in a 5.7-fold
increase in CaCo-2 cell uptake of the drug vancomycin.21
MCF-7 cells express medium levels of FRs when compared to the other cell lines analysed,
and no significant difference was observed in cell viability between the complex and the free
drug. The IC50 value obtained for this cell line was 79.72 ± 1.12 µM for MTX and 71.79 ±
1.11 for CDEnFA:MTX. As discussed in chapter two, MCF-7 cells showed a poor correlation
between mRNA and protein expression. FRs may be upregulated or downregulated
depending on the experimental conditions, such as extracellular folate availability,
intracellular homocysteine levels, and cell requirements of folate due to cell replication.22,23
A549 and BEAS-2B cell lines express low levels of FR, and as shown in figure 3.7, these
cells lines were more sensitive to free MTX than to the complex CDEnFA:MTX. The IC50
values obtained for A549 were 30.59 ± 1.15 µM for MTX and 56.61 ± 1.13 for
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CDEnFA:MTX. The IC50 values obtained for BEAS-2B were 82.46 ± 1.09 for MTX and
127.1 ± 1.15 for CDEnFA:MTX. This means that the free MTX was 1.8 and 1.5 fold more
toxic towards A549 and BEAS-2B, respectively, than CDEnFA:MTX. These are exciting
findings as there was a lower effect towards the non-cancer cell line BEAS-2B. Several
investigators have reported that cell lines expressing low levels of FRs are not as affected by
FR targeted drug delivery systems as cell lines expressing high levels and reports also suggest
that normal cell lines do not express significant levels of that receptor. For example, Oliveira
et al (2016) reported that folate-amino-functionalized silica nanoparticles were significantly
cytotoxic to a prostate cancer cell line (PC3 cells), whereas a normal prostate epithelial cell
line (PrEC cells) was much less affected by this drug delivery system.24 Yang et al (2015)
confirmed the significant tumour inhibition efficacy of drug-loaded poly(ethylene glycol)folate nanoparticles with lower cytotoxicity to the normal cells HEK293 (human embryonic
kidney cells) than the drug alone.25
The results presented here suggest that CDEnFA:MTX can selectively target FRs, enhance
drug toxicity towards the high FR expressing cell lines, and also reduce the cytotoxicity of
MTX against cells expressing low levels of this receptor. Barar et al (2015), also
demonstrated a higher cytotoxicity of a folic acid conjugated nanoparticle towards MCF-7
cells than A549.26 Sharma et al (2013) also found greater inhibition of CaCo-2 proliferation
by MTX loaded folic acid conjugated nanoparticle than the non-folic acid MTX loaded
nanoparticle.27 Muralidharan et al (2016) demonstrated that FR-targeted lipid nanoparticles
were significantly less toxic towards a normal lung fibroblast cell line (CCD16 cells) than to
a high FR expressing cancer cell line (H1299 cells).28
These results indicate the potential of the drug delivery system CDEnFA in improving the
cytotoxicity of the drug MTX in cell lines overexpressing FR, suggesting that a lower
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concentration may be required to achieve the same dose response. Furthermore,
CDEnFA:MTX was not as toxic as free MTX to the cell lines which express low levels of
FRs, suggesting that the drug delivery system has some specificity towards cell lines that
express high levels of FRs.
The cell lines analysed express reduced folate carrier (RFC) protein levels as follows, MCF-7
> KB > A549 > CaCo-2 > BEAS-2B and it did not seem to influence the cytotoxicity of
MTX or CDEnFA:MTX. He et al (2014) analysed whether a polymorphism of the RFC gene
(SLC19A1) may influence MTX acute toxicity in pediatric lymphoblastic leukaemia (ALL)
and concluded that there is no correlation between RFC polymorphism and MTX toxicity in
pediatric ALL.29 Chattopadhyay et al (2006) demonstrated an inverse relationship between
RFC function and pemetrexed activity. Pemetrexed is also an antifolate that inhibits enzymes
responsible for the folate metabolism. The author suggests that this inverse correlation may
occur due to a cellular folate pool contraction which results in partial preservation of
pemetrexed polyglutamylation and increased target enzyme inhibition.30 However, Matherly
and Hou (2008) reviewed RFC structure and function and reported that loss of RFC
expression results in antifolate resistance due to incomplete inhibition of cellular enzyme
targets. Therefore, more studies are needed to investigate the correlation between RFC
expression and antifolates activity.31

3.4 Conclusion
The results presented in Chapter 3 demonstrated that the drug delivery vehicle CDEnFA has a
low cytotoxicity towards the cell lines analysed, suggesting that it is a good potential
candidate as a novel drug delivery system. The inclusion complex CDEnFA:MTX showed
greater cytotoxicity than free MTX towards the high FR expressing KB and CaCo-2 cells,
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indicating that it has potential to target this folate receptor, enhancing the specificity and the
efficiency of the MTX drug. Free MTX is more toxic towards cell lines expressing low levels
of FR, such as the normal cell line BEAS-2B, than the complex CDEnFA:MTX, suggesting
that the inclusion complex can potentially cause fewer side effects than the drug alone. The
levels of RFC do not seem to influence MTX or CDEnFA:MTX activity.
These are exciting findings and indicate that CDEnFA can be used as a drug delivery system
to specifically target FR in cancer cells with better efficacy. Furthermore, the inclusion
complex offers a system that causes less damage than the drug alone to cells that express low
levels of FRs, such as healthy cells.
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4.1 Introduction
It has been previously demonstrated that folic acid enters the cell preferentially through the
folate receptors (FRs) while methotrexate enters the cell preferentially through the reduced
folate carriers (RFCs).1 Therefore, FRs may be responsible for the uptake of CDEnFA:MTX
by the ligand, folic acid. Due to the relatively large size of the cyclodextrins (molecular
weight >1000 Da), as well as hydrophilicity, it is predicted that these molecules, in general,
are not able to permeate biological membranes. A guest molecule may be absorbed but only
an insignificant amount of cyclodextrin is able to dissolve in lipids and is considered to be
absorbed from the gastrointestinal tract.2 Therefore, it is thought that in general, the
cyclodextrin delivers the drug to the surface of cell membrane, and the free form of the drug
molecule is dissociated from the cyclodextrin complex and is internalised through the
lipophilic membrane while the cyclodextrin remains extracellular.3,4 However, in vivo studies
measured a high amount of β-cyclodextrins that were absorbed via the rectum of rats and
excreted in the urine, suggesting that not only the free form of dissociated drugs but also
cyclodextrin complexes may be absorbable through the rectal mucosa.5 In addition, Fenyvesi
et al (2014), investigated the internalisation of fluorescently-labelled methyl-β-cyclodextrin
by CaCo-2 cells and concluded that the compound was able to enter the intestinal epithelial
cells by fluid-phase endocytosis from the apical side of the cell.4
Although the cell membrane is naturally impermeable to complexes larger than 1000 Da,
there are active mechanisms, such as a process called endocytosis, that allow for the
internalisation of large molecules. In this process, the cell membrane invaginates to engulf
molecules in an intracellular membrane-bound vesicle, or endosome, which will subsequently
traffic through the cell. Molecules may reside near the membrane or directly interact with
membrane proteins to enable their retention in these vesicles.6 Thus, in drug delivery
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applications, the endocytotic pathway has always held significant promise for the
investigation of targeted drug delivery systems and cellular uptake of macromolecules.7
In the process of endocytosis, the macromolecules to be internalized first bind to specific cell
surface receptors, which are usually concentrated in specialized regions of the plasma
membrane, called clathrin-coated pits. These pits bud from the membrane to form small
clathrin-coated vesicles containing the receptors and their bound macromolecules (ligands).8
The clathrin-coated vesicles then fuse with early endosomes, in which their contents are
sorted for transport to lysosomes or recycling to the plasma membrane. Another protein that
is often needed in the endocytosis process is the GTPase dynamin, which is responsible for
membrane fission which results in the pinching off of the vesicle from the parent membrane.9
Clathrin- and dynamin-dependent endocytosis are endocytic pathways that are grouped
according to the cell requirement for the self-polymerizing vesicle coated protein clathrin and
the large enzyme GTPase dynamin.10,11 However, there are also many other pathways of
clathrin-independent endocytosis. For example, those which have distinct coats called
caveolae, formed by caveolin proteins, and others which function in the absence of
specifically coated intermediates. Some clathrin-independent pathways are also independent
of dynamin. Some of these routes likely overlap in their molecular requirements and their
cargo.12 Most internalised cargo is delivered to early endosomes via vesicular (clathrin- or
caveolin-coated vesicles) or tubular intermediates called clathrin- and dynamin-independent
carriers (CLICs) that are derived from the plasma membrane.13 Some pathways may first
direct
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to

intermediate

glycosylphosphatidylinositol

compartments,

(GPI)-anchored

such

as

protein-enriched

the

caveosome

early

or

endosomal

compartments (GEECs), en route to the early endosome.14 GEECs result from fusion of the
CLICs, which are directly derived from the cell surface, in a process termed the CLIC/GEEC
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pathway. A variety of GPI-anchored proteins are internalized by this pathway, including the
FRs.12 Figure 4.1 below illustrates these types of endocytosis.

Figure 4.1. Endocytic pathways present in cells. The left-side section shows dynamindependent pathways. Clathrin- and caveolae-mediated endocytosis, along with endocytosis of
the interleukin-2 receptor (IL2R) require dynamin. The right-side section shows dynaminindependent trafficking pathways, including the clathrin-independent carrier and
glycophosphatidylinositol-enriched endocytic compartment (CLIC/GEEC) pathway.15

FRs are expressed at the cell surface and anchored in the cell membrane by a GPI domain,
and therefore are examples of GPI-anchored proteins. Hence, FRs are GPI-anchored proteins
selectively endocytosed via a non-clathrin, non caveolar, and dynamin-independent pinocytic
(fluid) pathway to the recycling endosomal compartment of the cell.16 The RFC is an integral
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membrane protein that belongs to the solute carrier family of transporters and functions as a
bidirectional anion transporter of organic phosphates that are synthesised and retained within
cells.17 This is an antiport transport system in which the downhill flow of organic phosphates
is linked to the uphill transport of folate substrates into cells via the same mechanism at
neutral pH.18 According to Hou and Matherly (2014), membrane transport of folate molecules
by RFC is expected to involve a physical movement of the carrier within the plasma
membrane. In addition, its substrate-binding cavity accessibility alternates between the intraand extracellular compartments, allowing the efflux or the influx of reduced folates,
respectively. For this carrier, transport is driven by extrusion of anions down a large
concentration gradient.19 Sabharanjak and Mayor (2004) suggested that understanding the
relationship between the FR and the RFC, and the nature of the compartment where the two
come together for coordinating efficient folate uptake is an important issue that remains to be
addressed. Furthermore, understanding the detailed mechanisms of the sorting propensities of
FR will provide insight into the delivery of folate into cells, and may help in designing
therapeutics based on folate-conjugates.20
The inhibition of receptors, transporters and enzymes is a good strategy for the investigation
of cellular uptake, internalisation processes and intracellular trafficking pathways. The use of
uptake or endocytosis inhibitors can selectively knock-off individual mechanisms and the
mode of uptake for a specific molecule, such as a drug carrier.21 Here, the FR was inhibited
by the drug fumonisin-B1 (FB1) to confirm the drug targeting and cellular uptake process of
FR. Stevens et al (1997) demonstrated that FB1 can inhibit FR function by causing changes
in the membrane lipid composition. In their study, there was a decrease of 90% in the uptake
by FRs in FB1-treated cells. Their findings suggest that FB1 treatment results in the depletion
of cholesterol and sphingolipid levels vital for the structure of the cell membrane, and this
appeared to decrease the total amount of FRs in the cells in a time- and concentration101
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dependent manner.22 Nour et al (2007) also used FB1 to investigate the expression of both FR
and RFC and folate uptake. They demonstrated that FR levels are decreased after FB1
treatment, while RFC levels are increased, as a potential protective effect in a folate-replete
environment. However, the levels of both receptors decrease after FB1 exposure in a folatefree environment.23
According to Vandana and Sahoo (2012), the inhibition or loss of RFC leads to decreased or
impaired transport of antifolates, which in turn, decreases the intracellular concentration and
reduces the cytotoxic effect of the antifolates on cancer cells.24 In this work, the drug
sulfasalazine (SSZ) was used as an inhibitor of RFC to investigate if the cytotoxicity caused
by the drug-complex CDEnFA:MTX is affected. According to Jansen et al (2004), SSZ is an
effective non-competitive inhibitor of RFC. These authors have demonstrated a marked loss
of MTX efficacy when it was co-administered with SSZ. According to their findings, RFC
protein expression appeared to be down-regulated in cell lines treated with SSZ in a dosedependent manner.25
The primary objective of the work presented in this chapter is to elucidate the route of
cellular uptake and internalisation of the complex CDEnFA:MTX. A possible route would be
the total internalisation of the complex by the FR, triggered by the specific ligation of the
folic acid to this receptor. This model is demonstrated in figure 4.2. Here, after the uptake and
internalisation of the complex by the FR, the cyclodextrin releases the drug MTX into the
endocytic vesicle in the intracellular compartment. The release of the MTX can be triggered
by competitive compounds against the drug, such as the target enzyme, dihydrofolate
reductase (DHFR).26 Another possible route would be the uptake of the MTX by the RFC.
This model is demonstrated in figure 4.3. Here, the ratio of FR to RFC presumably needs to
be ≈1 so that the CDEnFA can target FR and then deliver the MTX to be uptaken and
internalised through the RFC.
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Figure 4.2. Possible route of uptake of the complex CDEnFA:MTX through the folate
receptor. The whole complex is internalised and the drug is released in endocytic vesicles
(adapted from Endocyte, inc).27

Figure 4.3. Possible route of uptake of the complex CDEnFA:MTX. Folic acid targets the
folate receptor and, the cyclodextrin remains extracellular while MTX is internalised through
the reduced folate carrier.
The work described in this chapter utilises FB1 and SSZ to inhibit and reduce the levels of
FR and RFC respectively. After treating the cervical carcinoma KB cells with FB1 and SSZ,
and thereby, inhibiting FR and RFC, a comparison of the cytotoxic effect caused by the free
drug and the complex is analysed to confirm the probable route of internalisation and release
of the MTX from the complex CDEnFA:MTX.
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4.2 Materials and Methods
4.2.1 Cell culture and treatments
KB cells were selected for this mechanistic study due to their previously demonstrated high
levels of both FRs and RFCs compared to the other cell lines. The cells were cultured in
folate-free RPMI-1640 medium (Life Technologies) supplemented with 10% foetal bovine
serum (FBS) (Sigma-Aldrich), grown to 80% confluency in T75 cell culture flasks (Sarstedt)
and maintained in a sterile environment at 37°C and 5% CO2 atmosphere. Cells were then
trypsinised with protease enzyme trypsin made in Hanks Balanced Salt Solution (0.25%) with
EDTA (1:1). Cells were neutralised in culture medium (1:1) and centrifuged. The supernatant
was removed and the cell pellet was suspended in fresh culture medium. Cell counts were
determined using the Beckman Z1 Coulter Counter, as described in section 2.2.3 of Chapter
2.
Cells were then seeded in 24-well plates at a concentration of 50,000 cells per well and
incubated at 37°C and 5% CO2. After 24 hours, cells were exposed to FB1 for 48 hours at a
concentration of 27.7 µM and to SSZ for 72 hours at a concentration of 250 µM (SigmaAldrich for both). These were described as the optimum times and concentrations for
inhibition of the receptors without any major cytotoxic effects, according to Stevens & Tang,
and Jansen et al.22,25 The cells were then harvested with a trypsin-EDTA solution and
prepared for detection of FR and RFC levels on the flow cytometer, as described below in
section 4.2.2.
For cytotoxicity evaluation of MTX, CDEnFA:MTX or CDEnFA, the cells were first treated
with FB1 and SSZ as above and then exposed to each compound at concentrations of 10, 100
and 1000 µM for 48 hours and then cell viability was measured using the flow cytometer and
propidium iodide as a marker of dead cells as described in section 4.2.3 below.
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4.2.2 FR and RFC protein expression
Following treatment with FB1 or SSZ, the cells were prepared for protein detection analysis
using flow cytometry. This procedure is detailed in section 2.2.3 in Chapter 2. Briefly, 5x105
KB cells were resuspended in 100 µL of FCS buffer and incubated at 4°C for 30 minutes with
a mouse monoclonal anti-folate receptor antibody LK26 (Abcam) at a final concentration of 2
µg/100 µL for FR detection, or with a chicken polyclonal anti-reduced folate carrier
SLC19A1 antibody (Thermo Scientific) at a final concentration of 2 µg/100 µL for RFC
detection. After incubation, the cells were washed and incubated at 4°C for 30 minutes in the
dark with the respective secondary antibodies, goat anti-mouse Alexa Fluor® 488-conjugated
at a 1:800 final dilution and goat anti-chicken Alexa Fluor® 488-conjugated at a 1:800 final
dilution. After incubation, the cells were washed and examined on the flow cytometer Accuri
C6 (BD Biosciences). Each cell solution was divided into 3 samples (a) unstained sample, (b)
negative control and (c) FR or RFC sample. Negative controls were samples of cells run with
the secondary antibody without including a primary antibody, to define positive populations
and to eliminate any background fluorescence from the conjugated secondary antibody. A
total of 10,000 events of single cells were recorded for analysis. In the flow cytometer, the
excitation laser line of 488 nm, filter 530/30 and the FL-1 detector was used for excitation
and detection of fluorescence from the green dye Alexa Fluor® 488. Data was analysed using
BD Accuri C6 software. Data from triplicate samples, run in parallel, were used for statistical
analysis where a t-test was used to assess the significant difference between treated and
untreated samples. GraphPad Prism software® was used for statistical analysis.
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4.2.3 Cell viability
KB cells were cultured in folate-free RPMI-1640 medium, supplemented with 10% FBS,
seeded in 96-well plates at a concentration of 5,000 cells per well and incubated at 37°C and
5% CO2. After 24 hours, the cells were treated with FB1 at a concentration of 27.7 µM for 48
hours, or with SSZ at a concentration of 250 µM for 72 hours, or with a co-treatment FB1 +
SSZ (where FB1 was added after 24 hours for a 48-hour treatment). The cells were then
exposed to the compounds MTX, CDEnFA:MTX and CDEnFA for 48 hours at
concentrations of 10, 100 and 1000 µM. The cells were harvested with a 1:1 trypsin-EDTA
solution as before and centrifuged at 1800 rpm for 3 minutes. The supernatant was removed
and 100 µL of flow cytometry staining (FCS) buffer (PBS, 1% BSA, 0.1% sodium azide) was
added to each well. For the staining of dead cells, 4 µg/mL of propidium iodide (PI) was
added to each well prior to analysis, incubated at room temperature for 1 minute in the dark.
The samples were put through the Accuri C6 flow cytometer until 1,000 events were
recorded for each sample. The experiment was performed with triplicate samples, run in
parallel, for all treatment samples or control samples. The control samples are described in
detail in table 4.1 below and consisted of live cells, dead cells, and cells treated with FB1,
SSZ or FB1 + SSZ without further exposure to MTX, CDEnFA:MTX or CDEnFA.

Table 4.1. Description of the control samples.
Live cells

Untreated KB cells

Dead cells

KB cells were incubated with 4% paraformaldehyde
(PFA) for 20 minutes at room temperature (PFA is a
polyoxymethylene that kills cells by quickly denaturing
its proteins).
(a) KB cells treated with FB1 with no further exposure.

No exposure to MTX,
CDEnFA:MTX or
CDEnFA

(b) KB cells treated with SSZ with no further exposure.
(c) KB cells treated with a co-treatment of FB1 and
SSZ, with no further exposure.
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4.2.4 Data analysis
The median fluorescence intensity (MFI) from PI was recorded. PI binds to the DNA of
damaged cells, and therefore, the amount of PI fluorescence detected is proportional to the
amount of dead cells in the sample, equivalent not only to the number of dead cells but also
to how damaged the affected cells are. The data presented in the figures of sections 4.3.2
onwards, represent the mean of three replicates ± standard deviation. Statistical analysis was
performed using GraphPad Prism software®. T-test or one-way analysis of variance
(ANOVA) followed by a post-ANOVA Dunnett’s test was used to assess the significant
difference between live cells in control samples. Two-way ANOVA, followed by a postANOVA Bonferroni’s test, was used to assess the significant difference between the
untreated and treated samples for different concentrations. Statistical significance was
accepted as p ≤ 0.05 at 95% confidence levels for all tests.

4.3 Results and Discussion
4.3.1 Protein levels of FR and RFC after treatment with fumonisin-B1 (FB1) and
sulfasalazine (SSZ)
KB cells were treated with FB1 and SSZ, followed by a protein detection assay for measuring
FR and RFC levels on a flow cytometer. The ratios FSC-H/FSC-A and SSC-A/FSC-A plots
are given in where FSC-H and FSC-A are the forward scattered light height and area,
respectively, and SSC-A is the side scattered light area. These plots, from each analysed
sample, report the particle’s size and complexity, and were used to discriminate cell debris
and doublets or clumps of cells from single cells. Plots representing how samples are gated to
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exclude debris or clumps and to determine positives are given in appendix 14. 10,000 events
of single cells were recorded for each sample.

FR levels after FB1 and SSZ treatments
Figure 4.4 presents the results obtained for the determination of the FR protein levels in KB
cells after treatment with FB1 and SSZ.

A

B

Figure 4.4. Folate receptor protein levels in (A) fumonisin-B1 treated (red peak) and (B)
sulfasalazine treated (pink peak) KB cells, determined by flow cytometry. Untreated samples
are shown in green.

As regards the effect of FB1 on FR levels, it can be seen from figure 4.4A that the red peak,
representing FB1-treated samples, shifts to the left when compared to the green peak, which
represents untreated samples. This indicates that less fluorescence is detected from the FB1-
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treated samples, and therefore, there are lower amounts of FRs in the KB cells. This is also
indicated by the MFI (median fluorescence intensity) of the FB1-treated samples compared to
the untreated samples, with a significant decrease of 64% in FR levels for FB1-treated KB
cells. A complete statistical analysis is given in Appendix 15A. This data is consistent with
literature and indicates that FB1 inhibits and reduces FR levels on cell membranes. Nour et al
(2007) investigated the effect of FB1 on the protein and also on the mRNA levels of FRs in
the human liver carcinoma (HepG2) cells, and found that in FB1-treated cells, both FR
protein and mRNA expression were inhibited in a concentration- and time-dependent manner.
They suggested that the decrease in FR levels occurred after the apoptosis event, confirming
that the inhibition was not caused by a direct effect of the FB1, but as a consequence of the
disruption of sphingolipid metabolism.23 Pellanda et al (2012) used a rat model to investigate
the effect of FB1 administration during rat pregnancy, including the effect of FB1 on the
mRNA levels of FRs. They also found that exposure to FB1 resulted in decreased FR mRNA
and supported the hypothesis that FB1 alters folate transport by interfering with the
metabolism of cell membrane lipids.28
As regards the effect of SSZ, it can be seen from figure 4.4B that both the pink peak
representing SSZ-treated samples, and the green peak representing untreated samples, cover
the same region of fluorescence, and therefore, SSZ treatment causes no shift in the
fluorescence peaks for FR levels. This is also indicated by the MFI of the treated versus the
untreated samples which show a non-significant difference in the fluorescence intensity for
the FR levels in KB cells (statistics are given in Appendix 15B). This indicates that SSZ does
not inhibit FR protein expression levels. No recent information could be found in the
literature describing the effect of SSZ directly on FR levels in cells. It was previously
reported that SSZ inhibited the absorption of folic acid in four of seven patients with
ulcerative colitis, although the process involved was not clear.29 Inoue et al (2008)
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demonstrated that SSZ (0.2 mM) inhibits folic acid uptake into everted sacs of rat jejunum at
pH 5.5. However, the proton-coupled folate transporter (PCFT) is responsible for the
internalisation of folates into the cell under a low pH environment, with an optimum transport
function at pH 5.5. Therefore, Inoue and colleagues suggest that SSZ can inhibit folic acid
absorption by inhibiting the function of the PCFT transporter and not FRs.30

RFC levels after FB1 and SSZ treatments
Figure 4.5 presents the results obtained for the determination of the RFC protein levels in KB
cells after treatment with FB1 and SSZ.

A

B

Figure 4.5. Reduced folate carrier levels in (A) fumonisin-B1 treated (purple peak) and (B)
sulfasalazine treated (orange peak) KB cells, determined by flow cytometry. Untreated
samples are shown in green.
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As regards the effect of FB1 on RFC levels, it can be seen from figure 4.5A that both the
purple peak, representing FB1-treated cells, and the blue peak, representing untreated cells,
cover the same region of fluorescence, and therefore, FB1 treatment causes no shift in the
fluorescence peak for RFC levels. This is also indicated by the MFI of treated versus
untreated samples which showed similar values for the RFC levels of both samples. Nour et
al (2007) studied whether FB1 modifies the expression of RFC levels in HepG2 cells grown
in both folate-replete and folate-free media. Their results indicate that in cells grown in
folate-replete media, protein expression of the RFC was increased while, when grown in
folate-free media, protein expression of the RFC was decreased after treatment with FB1.23 In
our work, KB cells were grown in folate-free medium, and a decrease in the levels of RFC is
observed, although it was not significant (statistics are given in Appendix 16A).
From figure 4.5B, it can be seen that the orange peak, representing SSZ-treated cells, shifts
slightly to the left when compared to the blue peak for untreated samples. This indicates that
less fluorescence is detected from the SSZ-treated sample, and therefore, there are lower
amounts of RFC in that sample. This is also indicated by the MFI of the SSZ-treated sample
compared to the untreated sample with a significant decrease of 14.5% in RFC levels for
SSZ-treated KB cells (statistics are given in Appendix 16B). This result is consistent with
Jansen et al (2004), who demonstrated that RFC protein expression was down-regulated in
the human leukemic (CCRF-CEM) cells. According to these authors, RFC transport activity
closely corresponded to RFC protein levels.25

4.3.2 Effect of FB1 and SSZ on the cytotoxicity caused by the study compounds
After confirming that FB1 and SSZ indeed affect FR and RFC levels respectively, KB cells
were exposed to a pre-treatment with these drugs as well as with a co-treatment with FB1 +
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SSZ, to assess if these pre-treatments affect the cytotoxicity caused by the compounds MTX,
CDEnFA:MTX and CDEnFA . Control samples are important in order to demonstrate that
any cytotoxic effect seen from the sample is not caused by the pre-treatments with FB1
and/or with SSZ. The concentrations of FB1 (27.7 µM) and SSZ (250 µM) used for the pretreatments are optimum concentrations for inhibiting the transporters, without causing major
damage to the cells, as determined by Stevens and Tang (1997) and Jansen et al (2004).22,25
Figure 4.6 below shows the cell viability for control samples that were not exposed to
CDEnFA, MTX or CDEnFA:MTX, and include untreated live KB cells and dead cells, which
were KB cells that were fixed with 4% paraformaldehyde (PFA).

Controls
100000

Live cells
Dead cells
FB1
SSZ
FB1+SSZ

***

MFI

80000
60000
40000
20000
0

Figure 4.6. MFI (Median Fluorescence Intensity) obtained for the controls where live
cells=untreated KB cells, dead cells=fixed KB cells (4% PFA), FB1=KB cells treated with
FB1 only, SSZ=KB cells treated with SSZ only, FB1+SSZ=KB cells treated with a cotreatment of FB1 and SSZ. Asterisks represent significant difference to the live cells control.

Median Fluorescence Intensity (MFI) of PI, detected by flow cytometry was used to measure
cell viability. PI binds to the DNA when the cell membrane is damaged, hence higher
fluorescence means higher cell death. There was no significant difference between untreated
live cells and FB1, SSZ or FB1 + SSZ treated control samples (Appendix 17). Therefore, it
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can be concluded that pre-treatment with FB1 and/or SSZ cause no cytotoxic effect on KB
cells.

4.3.2.1 Effect of FB1 on the cytotoxicity caused by the study compounds
Figure 4.7 below displays the effect of a pre-treatment of KB cells with FB1 on the
cytotoxicity of MTX, CDEnFA:MTX and CDEnFA, each at concentrations of 10, 100 and
1000 µM for 48 hours. MFI of PI, detected by flow cytometry, was again used as a measure
of cell viability.
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0
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Figure 4.7. Effect of pre-treatment with fumonisin B1 (FB1) on the cytotoxicity of (A) MTX,
(B) CDEnFA:MTX and (C) CDEnFA towards KB cells.
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The data shows that FB1 pre-treatment caused a decrease in the cytotoxic effect of MTX and
CDEnFA:MTX, although the change was not significant for MTX. As seen previously, FB1
treatment does not have a major effect on the expression levels of RFC protein, the
transporter responsible for the uptake of MTX, which can explain why the change in the
cytotoxicity of MTX was not significant. FB1 treatment caused a significant decrease in the
cytotoxicity of CDEnFA:MTX at 100 µM (p < 0.05) and 1000 µM (p < 0.01), statistics are
given in Appendix 18. As seen previously, FB1 treatment causes a down-regulation of FR
protein expression, and it was also demonstrated that FB1 treatment reduces the uptake of
folates by the cell.22,23 Therefore, this can explain the significant decrease in the cytotoxicity
caused by CDEnFA:MTX after treatment with FB1.
Figure 4.7C shows that CDEnFA was not toxic to the cells, as reported previously, and a pretreatment with FB1 did not exert a significant effect on cell viability. This confirms that the
carrier CDEnFA, without the drug, does not damage the cells, and also provides additional
evidence that FB1 itself is not responsible for cell death.

4.3.2.2 Effect of SSZ on the cytotoxicity caused by the study compounds
Figure 4.8 displays the effect of a pre-treatment of KB cells with SSZ on the cytotoxicity of
MTX, CDEnFA:MTX and CDEnFA, each at concentrations of 10, 100 and 1000 µM for 48
hours.
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Figure 4.8. Effect of pre-treatment with sulfasalazine (SSZ) on the cytotoxicity of (A) MTX,
(B) CDEnFA:MTX and (C) CDEnFA towards KB cells.

Figure 4.8A shows that SSZ treatment caused a decrease in the cytotoxic effect of MTX,
although not statistically significant (statistics are given in Appendix 19). It should be noted
that pharmacological inhibition only blocks the function of a protein but the protein is still
present, even if in reduced levels. Therefore, a pharmacologically inhibited protein lacks
activity, but may still interact with some binding partners or partially internalise a substrate.31
This may explain why the decrease was not statistically significant. In addition, MTX could
still enter the cell through a different route by using the proton coupled folate transporter
(PCFT). Although, MTX enters the cell through this route preferentially in an acidic
microenvironment, with optimum transport at pH 5–5.5.19
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From figure 4.8B it can be seen that the cytotoxicity of CDEnFA:MTX was increased at
concentrations of 10 and 100 µM and decreased at 1000 µM, after SSZ treatment, although
these changes were not statistically significant. Previously it was seen that SSZ pre-treatment
does not inhibit FR expression. However, it has also been reported that SSZ can partially
inhibit the uptake of folic acid when the concentration of folic acid is high.32 This may
explain why the cytotoxicity of CDEnFA:MTX decreases only at the highest concentration of
the compound.
Figure 4.8C shows that SSZ pre-treatment did not exert significant effect on the cell viability
of CDEnFA-treated cells, and also provides additional evidence that SSZ itself is not
responsible for cell death.

4.3.2.3 Effect of a co-treatment with FB1 + SSZ on the cytotoxicity caused by the study
compounds
Figure 4.9 displays the effect of a co-treatment of KB cells with FB1 and SSZ on the
cytotoxicity of MTX, CDEnFA:MTX and CDEnFA, each at concentrations of 10, 100 and
1000 µM for 48 hours.
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Figure 4.9. Effect of a co-treatment with fumonisin-B1 and sulfasalazine on the cytotoxicity
of (A) MTX, (B) CDEnFA:MTX and (C) CDEnFA towards KB cells.

Figure 4.9A shows that co-treatment with FB1 and SSZ did not significantly affect the
cytotoxicity of MTX (statistics are given in Appendix 20). Previously it was also shown and
discussed that, independently, FB1 and SSZ pre-treatments showed only a non-significant
decrease in MTX cytotoxicity, which may explain why co-treatment has also not caused
major changes in the cytotoxic effect of MTX towards the cells.
Figure 4.9B shows that co-treatment with FB1 and SSZ exerted an additive effect on the
internalisation of CDEnFA:MTX, resulting in a very significant decrease in its cytotoxic
effect towards KB cells. FB1 treatment is responsible for a decrease of FR levels on the cell
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membrane, and, therefore, FB1 may be playing a key role in the co-treatment effect by
reducing the number of sites for binding of CDEnFA. Once the CDEnFA is not able to bind
to the FRs on the cell, it is also not able to deliver the drug through the RFC, nor it can be
internalised through the FR itself. The effect of SSZ have certainly also contributed to the
significant decrease in the cytotoxicity of CDEnFA:MTX as the effect of the co-treatment
was remarkably stronger than the effect of the independent treatment with FB1. RFC is a
bidirectional transporter responsible for the influx and efflux of reduced folates. The free
intracellular levels of MTX and of reduced folates are determined by the relative activity of
both influx and efflux transport pathways. When the intracellular levels of MTX are high, the
influx of MTX through the RFC will stop, which may also happen due to the lack of folates
in the extracellular environment.33 SSZ may reduce the influx of MTX, and together with
blocking of FRs by FB1, the CDEnFA:MTX cannot exert its strong cytotoxic effect towards
the co-treated cells.
Figure 4.9C shows that the co-treatment of FB1 + SSZ, like the independent treatments with
these drugs, did not exert any significant difference in the cell viability of CDEnFA treated
cells. This also provides additional evidence that FB1 + SSZ co-treatment is not responsible
for cell death.
It is possible that, for cells treated with CDEnFA:MTX (with no other treatments), both FR
and RFC function as internalisation routes for the complex. Even if the influx of MTX via
RFC stops due to saturated intracellular levels of MTX, the cell may continue internalising
the drug through the endocytic pathway of FRs. Therefore, the results presented here indicate
that the complex, CDEnFA:MTX, can ameliorate the cytotoxic effect of the drug by using
both RFC direct transport and FR endocytosis.
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4.4 Conclusion
The results presented in this chapter have demonstrated that FB1 treatment results in a
decrease in FR protein levels in the cell, but it does not affect RFC protein levels.
Conversely, SSZ treatment does not affect FR protein levels in the cell, but it results in a
decrease in RFC protein levels.
FB1 treatment resulted in a decrease in the cytotoxic effect of MTX and CDEnFA:MTX,
although not significant for MTX, while it caused a significant decrease in the cytotoxicity of
CDEnFA:MTX at 100 and 1000 µM concentrations. SSZ treatment caused a decrease in the
cytotoxic effect of MTX, although not statistically significant. The changes caused by SSZ on
the cytotoxicity of CDEnFA:MTX were also not statistically significant.
The co-treatment of FB1 + SSZ has not affected significantly the cytotoxicity from MTX,
while it drastically inhibited the cytotoxic effect of CDEnFA:MTX. The results indicate that
FB1 prevents the CDEnFA:MTX to bind to FRs, reducing its potential to internalise the drug
MTX. SSZ have contributed likely by blocking the influx of MTX which was released from
the complex. Therefore, the data presented here indicate that the cytotoxic effect from the
complex can be a result of the drug uptake and internalisation from both hypothetic routes
displayed in figures 4.2 and 4.3 in the introduction: (1) the CDEnFA:MTX binds to the FR on
the cell membrane and this receptor internalises the whole complex. (2) After CDEnFA:MTX
binds to the folate receptor on the cell membrane, MTX is released from the cyclodextrin
cavity and internalised through the RFC. By using both of these routes of internalisation,
CDEnFA:MTX can amplify the cytotoxic effect of the drug MTX.
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5.1 Introduction
Animal models have contributed valuable insights that have permitted extensive growth in
our knowledge of biology and medicine, including the discovery and development of new
drugs.1,2 Traditional animal models such as mice, rats and rabbits require a specific laboratory
structure, adequate expertise for handling the animals so as to minimize animal stress, and
ethical approval for their use can be a lengthy process.3 In vivo tests in mammalian models
also require the administration of a large amount of the compound, which is not always
feasible at the early stage of drug development. 4 Moreover, about 40-60% of drug
candidates fail due to absorption, distribution, metabolic elimination and toxicological
properties in clinical development. To screen drug candidates and reduce the costs to market
for new drugs, a variety of complex in vitro models are applied as filters to select the most
suitable compounds for the in vivo models. However, further pre-mammal screens are
necessary in order to reduce problems when linking in vitro findings to in vivo readouts.5
Therefore, invertebrate animal models have been used to bridge the gap between the
traditional in vitro and pre-clinical animal assays. Invertebrate organisms combine genetic
amenability, low cost, and culture conditions compatible with large-scale screens. Their main
advantage is to allow high-throughput screening in a physiological context. On the down
side, protein divergence between invertebrates and humans causes a high rate of false
negatives.6 Despite these limitations, invertebrate models, including insect models, are a
much needed tool to fill the gap between in vitro and in vivo studies and have been used as
screening tools in drug discovery.
Insect models give a better prediction of in vivo absorption, distribution, metabolic
elimination and toxicological parameters than in vitro models, and at the same time are faster
and cheaper than traditional vertebrate in vivo models.5 Particularly, the larvae of the greater
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wax moth, Galleria mellonella, seen in figure 5.1, has become an increasingly popular model
for investigating pathogenicity and drug tolerance.7 G. mellonella, is an insect from the order
Lepidoptera and the family Pyralidae.8 The greater wax moth develops through four distinct
life stages, egg, larva, pupa, and adult. The larva is the stage used for the drug screenings.
When compared with traditional mammalian models, G. mellonella larvae are cheaper and
easier to maintain, as specialised laboratories or equipment are not required. They have a
convenient size for housing and manipulation, which makes them ideal for high-throughput
studies.7,9 Additionally, the use of G. mellonella does not require ethical approval and allows
the generation of high number of data in a short time.10

Figure 5.1. Larvae of the greater wax moth, Galleria mellonella.

Although vertebrates have developed an adaptive immune response, their innate immune
response still retains remarkable similarities to the immune response in insects. For example,
pathogens are recognized by mammalian innate immune cells in a very similar manner as in
insects via cellular pattern recognition receptors. Pathogen-associated molecular patterns
(PAMPs) are conserved structures of microbes, such as peptidoglycans, that allow for the
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recognition of the pathogen. Peptidoglycan recognition proteins (PGRPs) activate
intracellular pathways related to the immune response. Although the mechanisms of PGRPs
seem to be different between insects and mammals, these proteins activate the humoral and
cellular arm of the host defence in both of them.11 The pattern recognition molecule in
insects, apolopophorin III (apoLp-III), is similar to the apolipoprotein E (apoE) found in
mammals, which is involved in phagocytosis.12 Moreover, there are striking similarities
between insect and mammalian innate immune signalling pathways. Mammals use Toll-like
receptors (TLRs), which are transmembrane proteins that can directly recognize components
of the pathogen. TLRs are named for their homologous leucine-rich repeat structures that are
also present in insect Toll, to activate antibacterial and fungal immune responses.13 There is
an evident pattern when comparing the signal transduction throughout the homologous
pathway of insects and mammals due to their similar signalling components. However, the
terminal molecules, the initiating receptors and the molecules that are produced as a result of
gene expression, vary considerably.14 The innate immune cells of both insects and mammals
are efficient producers of antimicrobial peptides and proteins (AMPs). However, the innate
immune system of insects leads to the production of AMPs that fight the infection, whereas
mammals generate cytokines and chemokines that amplify the immune response and recruit
antigen-presenting cells that induce antibody production.15 Phagocytic cells engulf and kill
pathogens. In insects, these cells are called plasmatocyte, and they have receptors on the
surface which are similar to receptors on mammalian neutrophils. Neutrophils produce
extracellular traps (NETs) containing nucleic acids and proteins to immobilize and kill
pathogens.12 A similar process has been observed to occur in haemocytes of G. mellonella in
response to infection, although the extracellular nucleic acids in the larvae exhibit weaker
bacterial entrapment capacity.16
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The innate immune response of insects consists of two major parts, the cellular and the
humoral immune response. The cellular response is mediated by haemocytes, which are
phagocytic cells. These are found within the haemolymph, which functions in an analogous
manner to mammalian blood. Indeed, cellular responses within the haemolymph are often
activated by signal transduction systems comparable to those in mice, and results obtained
using insects strongly correlate with results obtained from murine testing.17,18 Haemocytes are
not only involved in phagocytosis, but also in encapsulation and clotting. Haemocytes can
recognize foreign material and also distinguish self from non-self during the cellular immune
response in a similar manner to human immune cells.19 The humoral response is orchestrated
by soluble effector molecules that immobilize or kill the pathogen and includes complementlike proteins, melanin, and anti-microbial peptides.20
Larval death, changes in haemocyte density, and an increase in the concentration of melanin
(melanisation) in the larvae are good indicators of virulence and of immune response or stress
responses. Visual changes can occur to the larvae through the course of drug exposure.
Throughout the exposure time period, the inoculated larvae may turn a brown/black colour,
which represents the onset of melanisation, an insect immune response driven by the cleavage
of prophenoloxidase to active phenoloxidase.21 Different stages of melanisation are shown in
figure 5.2 as follows.
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Figure 5.2. Photographic images of G. mellonella larvae showing different stages of
melanisation starting from (a) the typical creamy colour of healthy larvae through to (e)
complete melanisation. (Figure adapted from Ott et al22 representing melanisation as
described by Loh et al23, detailed in table 5.1).

The activity of the response is driven by a general damage to the organism where it responds
to limit the growth of a potential pathogen within the haemocoel.24 Other characteristic
changes can also be analysed in order to determine the effect of a drug, such as survival time
and activity, for example, a slow movement response to a stimulus and slow development
within the normal life-cycle.23 Besides similarities in immune response, the distribution and
metabolism of an agent in G. mellonella are also comparable to that in humans.12 This was
demonstrated by Hill et al (2013) and Thomas et al (2013), who used G. mellonella as a
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model system to test the pharmacokinetics of antibiotics against Pseudomonas aeruginosa
and Burkholderia pseudomallei infection, respectively. They determined pharmacokinetic
parameters, such as dose, drug concentration, elimination and half-life, of clinically relevant
antibiotics in this model, demonstrating that this model can be used for the initial screening of
novel antimicrobials.25,26 Paudel et al (2017) used a silkworm infection model to perform
structure-activity relationship studies on an antimicrobial agent, comparing the
pharmacokinetic parameters to the metabolism of these antimicrobial agents in human
liver fractions in vitro. They suggest that the therapeutic effectiveness of an antimicrobial
agent in the insect model reflects appropriate pharmacokinetic properties in humans.4
In this work, larvae of G. mellonella were used primarily to assess the larval tolerance to the
carrier CDEnFA, and thereby assessing its safety and biocompatibility to this in vivo model.
Larval response and overall health were assessed after treatments with CDEnFA, and also
with the drug MTX and the complex CDEnFA:MTX.

5.2 Materials and Methods
5.2.1 Galleria mellonella toxicity assay
In vivo toxicity of the carrier CDEnFA, MTX alone and the complex CDEnFA:MTX was
examined in the larvae of the greater wax moth Galleria mellonella larvae. G. mellonella
larvae of the 6th instar development stage were sourced from Livefoods Direct Ltd (Sheffield,
UK). All larvae were stored in the dark at 15 ⁰C prior to testing. Thirty-three healthy larvae
(average weight 0.3±0.05 g) with no cuticle discolouration were used for each experiment,
thirty for assessing the effect of the compounds on the larval health and three for the
haemocyte density assay. Fresh solutions of the test compounds were prepared immediately prior
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to testing under sterile conditions. Each compound (CDEnFA, MTX and CDEnFA:MTX) was
dissolved in NaOH (1 mL of 0.1 M) and added to sterile water (9 mL) to give a stock solution of 5
mg/mL. Each compound was tested across the concentration range 4 to 400 μg of compound per
larva. Three controls were also employed in all assays. The first consisted of undisturbed larvae,
maintained at the same temperature as the test larvae. The second, sham-inoculated larvae, was
larvae with the pro-leg pierced with an inoculation needle but no solution injected. The third
control was larvae that were inoculated with the solvent NaOH (0.1 M), following the dilutions as
used for the test compounds. 20 μL of each test solution was administered per larva and they were
inoculated by injection directly into the haemocoel through the last pro-leg (figure 5.3). Larvae
were then placed in sterile Petri dishes and incubated at 30 °C for 72 hours.

Figure 5.3. Procedure for inoculating G. mellonella larvae. The needle is inserted into the last
left pro-leg in order to inject the compound.27

Larvae were monitored after 24, 48 and 72 hours for the following attributes: activity, extent of
silk production (cocoon formation), melanisation, and survival. A score was provided for each
attribute that contributed toward an overall health index of an individual G. mellonella larva, as
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described by Loh, et al (2013). A healthy larva typically scores between 9 and 10, and a dead larva
typically scores 0. Scoring for each attribute has been summarised in table 5.1 below.

Table 5.1. Scoring system for overall health of larvae.23
Category

Activity

Cocoon
formation

Melanisation

Survival

Description

Score

No movement

0

Minimal movement on stimulation

1

Move when stimulated

2

Move without stimulation

3

No cocoon

0

Partial cocoon

0.5

Full cocoon

1

Black larvae
Black spots on brown larvae

0
1

≥3 spots on beige larvae

2

<3 spots on beige larvae

3

No melanisation

4

Dead

0

Alive

2

5.2.1.1 Measurement of haemocyte density
Haemocyte density was measured in larvae, 24 hours post inoculation with CDEnFA, MTX
and CDEnFA:MTX, along with the undisturbed, sham-inoculated and solvent controls. Three
larvae were selected at random. The larvae representing each control or each concentration of
each test compound were bled through the anterior region of the head (figure 5.4). The
extracted haemolymph was diluted 1:10 with mercaptoethanol (0.37% in distilled water)
(Sigma, Ireland). Cell counts were performed using a haemocytometer: 10 µL of the diluted
haemolymph were loaded onto each side of the haemocytometer (Neubauer Tiefe, 0.002
mm2), covered with a coverslip and visualised under the 40x objective lens of a light
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microscope. Cells were enumerated from five squares of each grid on the haemocytometer.
An average of three separate counts was obtained. The density was calculated by multiplying
the total average by the dilution factor of both haemolymph and the haemocytometer.

Figure 5.4. Piercing point (anterior portion) of the G. mellonella larvae for haemocyte
extraction indicated by the black arrow.

5.3 Results and Discussion

5.3.1 Galleria mellonella toxicity assay

G. mellonella larvae were exposed to CDEnFA, MTX, and CDEnFA:MTX, and the toxicity
was assessed by the mean mortality (%) after 24, 48 and 72 hours of drug exposure.
Undisturbed, sham-inoculated and solvent-inoculated controls were also assessed. Mortality
was not detected after 24 and 48 hours of exposure to the administered dosages of each
compound. Data for the survival of G. mellonella larvae (expressed as a %) as a function of
administered dosages of the test compounds 72 hours post inoculation are displayed in table
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5.2. No mortality was recorded at any time-point after incubation of undisturbed, shaminoculated and solvent (NaOH) controls.

Table 5.2. Mortality (%) of G. mellonella larvae 72 hours post inoculation with a range
of dosages of the test compounds. Non-marked percentages indicate larvae were active
(moving without stimulation).

CDEnFA

MTX

CDEnFA:MTX

% Mortality
μmol
mg kg-1

Administered amount (μg per larvae) /
% mortality
4
10
40
100
400
0
0
0
0
0
2.16
5.40
21.61
54.02
216.1
13.33
33.33 133.3
333.3
1,333

% Mortality
μmol
mg kg-1

0
8.80
13.33

0
22.00
33.33

0*
88.02
133.3

3*
220.0
333.3

3*
880.2
1,333

% Mortality
μmol
mg kg-1

0*
1.95
13.33

3*
4.87
33.33

3*
19.47
133.3

6*
48.68
333.3

6**
194.72
1,333

* Move only when stimulated
** Minimal movement on stimulation

All of the larvae treated with the carrier CDEnFA survived at all concentrations and all timepoints indicating in vivo tolerance to the carrier. Treatment with MTX caused the death of 3%
of larvae at concentrations of 100 and 400 μg after 72 hours of drug exposure.
CDEnFA:MTX was responsible for the death of 3% of larvae at concentrations of 10 and 40
μg, and 6 % at concentrations of 100 and 400 μg per larvae after 72 hours. It is important to
note that, even though there was still a high survival after 72 hours of drug exposure to MTX
and CDEnFA:MTX, the activity of the larvae and their ability to respond to stimulus was
strongly compromised. At that time-point, larvae were static after MTX treatment at
concentrations of 40 μg and above, and would only slowly move after stimulation by
touching. After CDEnFA:MTX treatment at concentrations from 4 to 40 μg, larvae would
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slowly move after stimulation, while at concentrations of 100 and 400 μg, larvae barely
responded to the stimulus with only minimum movement. When viewed in terms of
micromolar concentrations, it is clear that CDEnFA:MTX was more toxic than MTX. The
carrier CDEnFA, even with a higher molecular weight than MTX, was not toxic towards the
larvae at the concentrations tested. Because none of the inoculations resulted in the death of
50% or more, LD50 values, which represent the dose of a substance that kills 50% of a test
sample, could not be calculated.

The chemotherapeutic, cisplatin, was used alone as a reference standard and the mortality
caused, assessed by another PhD student at DIT, is presented in table 5.3 for comparison.28 At
a dosage of 100 μg of per larvae, approximately 90% larvae treated with cisplatin were dead
at all time-points. Thus, it is clear that cisplatin is considerably more toxic to G. mellonella
than both MTX and CDEnFA:MTX.

Table 5.3. Mean larval mortality (%) after 72 hours of inoculation
with 20 μL of cisplatin at a range of dosages of test compounds.28
Cisplatin (µg per larvae)
% Mortality
μmol
mg kg-1

4 µg
0
0.013
13.33

6 µg
0
0.019
19.99

8 µg
0
0.026
26.66

10 µg
6
0.033
33.33

100 µg
90
0.333
333.33

It is possible that G. mellonella is much less sensitive to MTX and CDEnFA:MTX than to
cisplatin, due to a low affinity of MTX for the enzyme, dihydrofolate reductase (DHFR), in
insects. In humans, antifolate drugs, such as MTX, can tightly bind to DHFR, inhibiting this
enzyme’s activity, consequently inhibiting DNA synthesis and cell proliferation. However,
Walker et al (2000) found that DHFRs in insects have significantly reduced sensitivity to

134

Chapter 5

In vivo Galleria mellonella Toxicity

inhibition by MTX, when compared with the enzyme in vertebrate animals. This reduction is
also reflected in the total binding energy of MTX to these enzymes. These authors
demonstrated that DHFRs in insects show the lowest affinity for this inhibitor of any wildtype DHFR, such as mammalian and chicken, studied to date. Four of the 17 amino acid
residues involved in MTX binding, Met32, Ala33, Thr36 and Cys60, are not well conserved
between the insect and mammalian or chicken enzymes and it is possible that these residues
contribute to the reduced sensitivity, by several orders of magnitude, of the insect DHFRs to
methotrexate.29

Although a low mortality was seen even for the highest concentrations of MTX and
CDEnFA:MTX, the activity of the larvae was compromised and some melanised lesions on
the cuticle were observed. These changes were particularly evident from CDEnFA:MTX.
Figures 5.5 and 5.6 display photographic images of the larvae at day 0 (just after inoculation)
and day 3 (72 hours after inoculation) at the highest administered concentration. In order to
obtain more subtle differences in larvae health status, the larvae were scored according to the
scoring index system displayed previously in table 5.1 for activity, cocoon formation,
melanisation, and survival.
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Day 0

Day 3

Figure 5.5. G. mellonella larvae on day 0 (immediately after inoculation, left) and on day 3
(72 hours post-inoculation, right) for (A) undisturbed control, (B) sham-inoculated control and
(C) solvent control.
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Day 0

Day 3

Figure 5.6. G. mellonella larvae on day 0 (immediately after inoculation, left) and on day 3
(72 hours post-inoculation, right) for (D) CDEnFA treated, (E) MTX treated and (F)
CDEnFA:MTX treated larvae.
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Higher activity and cocoon formation correspond to healthier larvae, though cocoon
formation was not observed as the three days of incubation were not enough for the larvae to
achieve this stage of development. Production of melanin by the larvae occurs as a result of
an immune response against infection, as melanin aids to trap and kill pathogens.30 As there
was no pathogenic infection, the effect of the compounds did not result in major melanised
lesions or major skin discolouration. Each G. mellonella larva was monitored based on the
characteristics presented in table 5.1 and an overall health index score was calculated for each
sample. Higher health index scores, which indicate healthy larvae, correlated well with the
control samples and samples inoculated with CDEnFA. Scores are an overall health
description after observing the larvae individually. After 72 hours of inoculation, undisturbed,
sham-inoculated, solvent control and CDEnFA inoculated larvae had an outcome score of 9,
MTX inoculated larvae had an outcome score of 7, while CDEnFA:MTX inoculated larvae
had an outcome score of 5. These scores are described in table 5.4 below.

Table 5.4. Health index scores calculated after 72 hours of inoculation with
the study compounds.
Compound

Category
Score
Description
Activity
3
Move without stimulation
Melanisation
4
No melanisation
Controls
Survival
2
Alive
Total
9
Activity
3
Move without stimulation
Melanisation
4
No melanisation
CDEnFA
Survival
2
Alive
Total
9
Activity
2
Move when stimulated
Melanisation
3
Cuticle discoloration
MTX
Survival
2
Alive
Total
7
Activity
1
Minimal movement when stimulated
2
Cuticle discoloration
CDEnFA:MTX Melanisation
Survival
2
Alive
Total
5
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The health of the larvae was more compromised after inoculation with CDEnFA:MTX than
inoculation with MTX alone, which was indicated mainly by lack of activity and/or slow
reaction to a stimulus. This indicates that CDEnFA:MTX may facilitate the delivery of MTX
and increase the intracellular amounts of the drug, which can contribute to the slightly
increased toxicity.

5.3.2 Measurement of haemocyte density

Haemocytes were enumerated from the haemolymph extracted from 3 larvae per treatment
(per dose at 24 h). The results are displayed in figure 5.7 below. Controls include undisturbed
larvae, sham-inoculated larvae, which were larvae pierced with an inoculation needle but with
no solution injected, and the solvent control, which was larvae that were inoculated with the
solvent NaOH (0.1 M) with the same dilutions used for the test samples. Significant differences
(p values) between the test samples and sham-inoculated control were obtained.

Undisturbed
Sham
NaOH
CDEnFA
MTX

Haemocytes density
Hemocyte density (cell/mL)

1.510 7

**
*

1.010 7

CDEnFA:MTX

5.010 6

4
10
40
10
0
40
0

4
10
40
10
0
40
0

4
10
40
10
0
40
0

4
10
40
10
0
40
0

0

Concentration (µg per larvae)

Figure 5.7. Haemocyte density 24 hours post-inoculation with CDEnFA, MTX,
CDEnFA:MTX and the controls (undisturbed larvae, sham-inoculated and solvent NaOH).
Asterisks represent significant difference where ** is p < 0.01 and * is p < 0.05, to both
undisturbed and sham-inoculated controls.
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No significant difference compared to the controls, was obtained in the haemocyte density for
24 hours post-inoculated G. mellonella, with both CDEnFA and MTX at all concentrations
studied. The haemocyte density, obtained for the 40 and 400 µg concentrations of the
complex CDEnFA:MTX were significantly different to both controls, which suggests that
treatment the complex may lead to activation of immune responses in larvae of G. mellonella.

A similar range of haemocyte count was obtained by Dubovsky et al (2013) using an
organophosphate as an insecticide, and they reported 1.1 x 107 cells/mL for the control and
1.5 x 107 cells/mL for 24 hours post-insecticide treated G. mellonella.31 According to these
authors, concentrations of drug compounds that are not lethal for all individuals in a sample
may stimulate the insect immunity and, as a consequence, enhance the larvae protective
response.32 Mowlds et al (2010) reported a range of 3 x 106 (control) to 0.75 x 107 for 24
hours post-β-glucan treated G.mellonella.33 Rochford et al (2018) assessed the toxicity of
Cu(II) phenanthroline-phenazine complexes in this in vivo model and reported a haemocyte

density with counts ranging from 3.8 to 4.5 x 107, 24 hours post inoculation with the copper
based complexes.28,34

Although there is only moderate toxicity towards the G. mellonella in vivo model observed at
high doses, compared to other therapeutics, the effect may be mediated by a role in the innate
immune response. From in vivo studies, it was reported that MTX acts on the immune
response with significant effects on neutrophil chemotaxis in a dose-dependent manner.35
Methotrexate is also known to suppress tumour necrosis factor (TNF) activity, in part related
to a reduction in the degradation and inactivation of an inhibitor of this factor, and probably
related to the release of adenosine, a potent endogenous anti-inflammatory mediator.36
Further investigation would be necessary to demonstrate the effect of CDEnFA:MTX on the
immune response of G. mellonella. In relation to the folate transporters or folate metabolism
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in insects, little information can be found in the literature. However, it has been reported that
folate intake has increased the growth of several insects, while some insects, such as the fruit
fly Drosophila melanogaster, do not require folate as they can synthesize it. Several studies,
using mice models, have demonstrated positive results for FR-targeted compounds. For
example, Güliz et al (2018) demonstrated that a folate receptor-targeted doxorubicin delivery
system was significantly more effective for therapy of xenografted nude mice than free
doxorubicin, based on tumour shrinkages and biochemical parameters.37 Peng et al (2017)
demonstrated using in vivo experiments that arsenic trioxide, loaded onto FA-labelled human
serum albumin, significantly alleviates side effects and improves the therapeutic efficacy of
arsenic trioxide on xenograft tumor models.38 And Alibolandi et al (2016) demonstrated that
the in vivo tumour inhibitory effect of folic acid quantum dots (QD) and doxorubicin (DOX)encapsulated PEG-PLGA nanopolymersomes showed an augmented therapeutic efficacy of
the targeted formulation over the non-targeted and free drug.39

5.4 Conclusion

The aim of this study was to assess the biocompatibility of the drug delivery system,
CDEnFA, using G. mellonella larvae and to assess the response of the larvae to the inclusion
complex, CDEnFA:MTX, to the free drug, MTX. The health of the larvae, assessed by a
health index score based on larvae activity, melanisation and survival, compared well among
undisturbed larvae, sham-inoculated or the solvent inoculated controls and CDEnFA treated
larvae. CDEnFA treatment did not cause larval death at any concentration or time-point and
did not result in any significant difference in haemocyte density compared to the controls.
This is an exciting result and indicates that CDEnFA is not toxic to the larvae, and therefore,
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is a safe drug carrier to be used in in vivo models. Further studies in mice could be used to
demonstrate the safety and biocompatibility of this targeted-drug vehicle in mammal models.

The mortality assay demonstrated that G. mellonella are tolerant to the drug MTX. MTX acts
by binding to and inhibiting the enzyme DHFR. However, this enzyme is not well conserved
between insect and mammalian enzymes and this may explain the reduced sensitivity of the
insect to this drug. The complex CDEnFA:MTX caused a slightly higher toxicity towards the
larvae, which was observed particularly in compromised activity, where the larvae were
barely responding to stimulus after 72 hours of treatment at the highest administered
concentration. Besides compromised activity, the haemocyte density was also higher for
CDEnFA:MTX treated G. mellonella, which can be an indicator of activation in immune
responses and an attempt to enhance the larvae protective response as a result of the
treatment. However, due to the high tolerance of the larvae to the drug MTX, mammal in vivo
studies would be necessary to further evaluate the in vivo response to CDEnFA:MTX and its
comparison to MTX alone.
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6.1 Conclusions
In this work, a new folate derivative of β-cyclodextrin has been evaluated in its potential to
target folate receptors (FRs) in cancer cells. The objectives of this work were successfully
achieved and they include:

1) Compare FR and RFC gene levels in a range of human cell lines grown in folate-replete
and folate-free medium to standardise the culture conditions. Then, to assess the gene and
protein expression of FR and RFC in a range of untreated cell lines to address the conflicting
reports of expression of these transporters and allow for selection of in vitro models for
subsequent experiments using real-time PCR and flow cytometry.
Folate-free culture medium was chosen as a standard culture medium for all experiments
since there was the interest of avoiding possible competition for folate in the environment. In
addition, a folate-free environment is favourable for the cellular expression of FRs. Real-time
PCR and flow cytometry were used to assess the gene and protein expression of FRs and
RFCs in the seven cell lines. The data from the real-time PCR experiments demonstrated that
FR mRNA (gene) levels are more abundant in KB cells followed by CaCo-2 and SKOV-3
cells. HeLa and MCF-7 cells express medium levels of FR mRNA while A549 and BEAS-2B
express low levels. RFCs mRNA has higher expression in HeLa cells, followed by KB cells,
and then by MCF-7, A549, SKOV-3 and CaCo-2. BEAS-2B showed the least abundant
mRNA levels of both receptors and, therefore, seemed to be a good normal control cell line to
compare with the cancer cell lines. Cancer cells displayed upregulation of both FRs and
RFCs when compared to the normal cell line BEAS-2B.
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The protein expression levels of FR and RFC assessed by flow cytometry showed that KB
cells express significantly higher levels of FRs than all the other cell lines and BEAS-2B
express the lowest levels. From highest to lowest levels of FR protein, the cell lines
expression order is as follows: KB > CaCo-2 > MCF-7 > HeLa > SKOV-3 > A549 > BEAS2B. MCF-7 cells showed the highest levels of RFCs while SKOV-3 showed the lowest levels.
From highest to lowest levels of RFC protein, the cell lines expression order is as follows:
MCF-7 > KB > HeLa > A549 > CaCo-2 > BEAS-2B > SKOV-3.
From their FR and RFC levels, five cell lines were selected for an in vitro cytotoxicity
analysis against the drug methotrexate (MTX), the carrier CDEnFA and the inclusion
complex CDEnFA:MTX. These cell lines are KB, CaCo-2, MCF-7, A549 and BEAS-2B.
KB and CaCo-2 cells were chosen due to their high levels of FR, MCF-7 cells were chosen
due to their medium levels of both FR and RFC, while A549 and BEAS-2B cells were
chosen due to their low levels of FR.

2) Evaluate the cytotoxicity of CDEnFA to certify that the carrier alone is not toxic to the
cells, and then evaluate the cytotoxicity of free MTX and the complex CDEnFA:MTX
towards selected cell lines with high, medium and low FR levels, comparing the outcomes
between the complex and the drug alone and confirm FR targeting.
The results from the cytotoxicity evaluation demonstrated that the drug delivery vehicle
CDEnFA has a low cytotoxicity towards the cell lines analysed, indicating it is biocompatible
and safe. The results also indicate that the inclusion complex CDEnFA:MTX can specifically
target FR in cancer cells enhancing the efficacy of the drug. This is because CDEnFA:MTX
showed greater cytotoxicity than free MTX towards the high FR expressing KB and CaCo-2
cells. Free MTX is more toxic towards cell lines expressing low levels of FR, such as the
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normal cell line BEAS-2B than the complex CDEnFA:MTX, suggesting that the inclusion
complex can potentially cause fewer side effects than the drug alone. These are exciting
findings and indicate that CDEnFA:MTX can be used as a drug delivery system to target FR
in cancer cells providing the treatment with a better efficacy. Furthermore, offering less
damage than the drug alone to cells that express low levels of FRs, such as healthy cells, as
demonstrated and as reviewed from the literature.
After the cytotoxicity evaluation, a study was conducted in order to investigate the route of
uptake and internalisation of the complex CDEnFA:MTX. FRs are responsible for the uptake
of CDEnFA:MTX due to the ligand, folic acid. However, whether the FR captures and
internalises the whole complex or the β-cyclodextrin remains extracellular and the RFC is the
responsible for the internalisation of the MTX, was a question to be elucidated.

3) Investigate the cellular route of uptake and internalisation of the drug complex
CDEnFA:MTX, using fumonisin-B1 and sulfasalazine as inhibitors of FRs and RFCs, and
with this, clarify the roles of each transporter in these processes.
FB1 treatment resulted in a decrease in the FR protein levels in the cell, but it did not affect
the RFC protein levels. SSZ treatment did not affect the FR protein levels in the cell, while
resulted in a decrease in the RFC protein levels. After inhibition with pre-treatments with
FB1, SSZ and a co-treatment with FB1 + SSZ, KB cells were treated with CDEnFA, MTX
and CDEnFA:MTX and the cytotoxicity was evaluated. The results demonstrated that
CDEnFA alone did not cause cell death confirming its biocompatibility to the cells. When
comparing the effect of the pre-treatments in the cytotoxicity caused by MTX and
CDEnFA:MTX, the results confirmed (a) the uptake of the complex through the FRs as FB1
treatment resulted in a significant decrease in the cytotoxic effect of high doses of
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CDEnFA:MTX; (b) the indicative internalisation of MTX through the RFC as SSZ treatment
caused slightly decreased cytotoxic effect of MTX; and (c) in addition, the results indicated
that the extensively increased cytotoxic effect from the complex CDEnFA:MTX in KB (FR+)
cells can be an additive result of the drug uptake and internalisation through two routes: (1)
after CDEnFA:MTX binds to the folate receptor on the cell membrane, MTX is released from
the cyclodextrin cavity and internalised through the RFC. (2) The CDEnFA:MTX binds to
the FR on the cell membrane and this receptor internalises the whole complex. By using both
of these routes of internalisation, CDEnFA:MTX can amplify the cytotoxic effect of the drug
MTX. This is indicated due to the dramatic decrease in the cytotoxic effect of CDEnFA:MTX
after a co-treatment with FB1 + SSZ.

4) Evaluate the in vivo toxicity of the complex in the larvae of the Galleria mellonella to
assess drug tolerance, and thereby proving its safety to be used in in vivo models.
The in vivo toxicity evaluation of CDEnFA, MTX and CDEnFA:MTX in the Galleria
mellonella larvae demonstrated that CDEnFA treatment did not cause larvae’s death and did
not increase the larvae’s immune response, which is an indicator that CDEnFA is not toxic
and therefore, is a safe drug carrier to be used in in vivo models such as invertebrates. The
mortality assay also demonstrated that G. mellonella are strongly resistant to the drug MTX.
This is because the enzyme targeted by MTX, dihydrofolate reductase, is not well conserved
between the insect and mammalian enzymes, so the sensitivity of the insect’s enzyme to
MTX is significantly reduced when compared to the mammal’s enzyme. The complex
CDEnFA:MTX caused slightly more toxicity towards the larvae, which was observed
through survival and particularly to a compromised activity where the larvae were barely
responding to stimulus after 72 hours of treatment at the highest administered concentration.
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Besides compromised activity, the haemocytes count indicated that CDEnFA:MTX may
activate the organism’s immune response in an attempt to enhance the larvae protective
response. However, due to the high resistance of the larvae to the drug MTX, mammalian in
vivo studies would be necessary to further evaluate the in vivo response to CDEnFA:MTX
and its comparison to MTX response.

6.2 Future scope and perspectives
From the 5th European Conference on Cyclodextrins in Lisbon, our group and researchers
from the Hungarian company Cyclolab demonstrated a mutual interest in developing a
collaborative work. Cyclolab is a Research & Development company based in Budapest,
specialised in the development of derivatives of cyclodextrins. Researchers at Cyclolab are
pioneers in Cyclodextrin R&D and have been working since 1972 in the fields of
pharmaceuticals, cosmetics and the food, agrochemical and environmental industries and also
analytical applications of cyclodextrins. The research plan for this collaborative work
involves the biological evaluation of a range of folate-modified cyclodextrins for delivery of
therapeutics. The cyclodextrins are synthesised and characterised by researchers at Cyclolab
while the biological work is being developed in-house. This work includes a biological
evaluation of folate derivatives of cyclodextrins and the chemotherapeutic agents as inclusion
complexes, which include native α-cyclodextrin, methylated cyclodextrins, sulfobutyl eter
cyclodextrin, as well as our complex CDEnFA. The chemotherapeutic agents to be used may
include 5-fluorouracil, tamoxifen, docetaxel, doxorubicin and pemetrexed. Assessing the
biological effect of these complexes will allow further investigation on the possibilities and
combinations of folate-derivatives of cyclodextrins with different drugs, expanding the work
on their use as targeted drug carriers for cancer treatment.
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The following experiments are suggestions and may be performed for the evaluation of these
new complexes:
A. Cytotoxicity screening of the complexes using MTT assays, as the work described in
Chapter 3 of this thesis, optimising concentrations and time-points for accurate
obtaining of IC50 values.
B. For the most promising drug-conjugate combinations, prove complex uptake through
FRs by inhibiting FR expression and assessing drug and complex effect, in a similar
way as described in Chapter 4. Although, using a gene knockdown method such as
RNA interference; or a gene knockout method such as CRISPR, could be a good
alternative as it would guarantee the lack of FR protein on the cell membrane.
C. Investigate intracellular trafficking by visualization of endosomes using confocal
microscopy. Endosomes are pockets of cellular membrane that form to internalise
components into the cell and form part of the endocytic pathway. Larger drug
molecules and/or drugs bound to receptors are internalised within cells by this
mechanism.1 The process of endocytosis can be investigated using CellLight® Early
Endosomes-GFP, BacMam 2.0 (Thermo Scientific) to observe early endosomes,
which serve as a focal point of the endocytic pathway.
D. Investigate if the drug-complex can help enhance the effect of the drug. This would
depend on each drug’s mode of action. For example, doxorubicin acts by damaging
the DNA in the cell. DNA damage can be measured as an indicator of genotoxicity
using an antibody against phosphorylated H2AX. When DNA damage, it forms
double-stranded breaks (DSBs), which is always followed by the phosphorylation of
the histone, H2AX.2 Therefore, the amount of H2AX is proportional to the amount of
damaged DNA in the cell and can be quantified by flow cytometry. The data
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comparison for complex vs drug alone and FR+ vs FR- cell line would allow
concluding whether the complex can facilitate drug activity.
E. Carry out an in vivo evaluation using the larvae of the insect Galleria mellonella to
assess toxic tolerance and cellular response as the work described in Chapter 5 of this
thesis.

6.3 General conclusion
CDs have an extensive potential for use in therapeutics, and the synthesis of derivatives of
CDs for targeted therapy has allowed the elaboration of more effective and stable drug
products with potentially reduced side effects. The work detailed in this thesis describes the
positive results obtained in the biological evaluation of the folate derivative of β-cyclodextrin
CDEnFA, and has recently opened the opportunity for collaborative work to test a broader
range of new complexes based on cyclodextrins for cancer therapy.
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7.1 Synthesis and characterisation of the carrier CDEnFA
The carrier, 6-deoxy-6-[(1-(2-amino)ethylamino)folate]-β-cyclodextrin (CDEnFA), is a
diaminoalkane

derivative

of

β-cyclodextrin,

6-deoxy-6-[1-(2-amino)ethylamino]-β-

cyclodextrin (CDEn), that was linked to folic acid (FA) by a covalent peptide bond. 1 The
synthesis involves the preparation of an aminoderivative of CD by using 6-o-monotosyl-6deoxy-β-cyclodextrin (CDTs) as an intermediate. Preparation of CDTs involves the reaction
of β-CD with p-toluenesulphonyl chloride in pyridine, with recrystallisation from water.2
The synthesis used in this study is a modified version of an aqueous-based method reported
by Brady et al (2000).3 From the CDTs, a diaminoalkane derivative 6-deoxy-6-[1-(2amino)ethylamino]-β-cyclodextrin (CDEn) was prepared according to the method published
by Potter et al (2007).4 Tofzikovskaya et al (2012) proposed to link CDEn to folic acid (FA)
by a simple covalent peptide bond for obtaining CDEnFA. This procedure involves the use of
N,N’-dicyclohexylcarbodiimide (DCC) as a coupling agent and N-hydroxysuccinimide
(NHS) as an acid activator. Hence, the activation of folic acid with N-hydroxysuccinimide to
produce the ester of folic acid, followed by the conjugation with the CDEn through an amide
bond formation with the ester of folic acid, results in the CDEnFA. The synthesis of
CDEnFA was firstly reported by Clementi et al (2001)5 with a 5% yield while
Tofzikovskaya et al (2012)1 achieved a 60% yield with this improved method. CDEnFA and
MTX are combined to form the inclusion complex, CDEnFA:MTX. The MTX replaces the
water molecules present in the CD’s cavity and forms non-covalent bonds for the guest–host
complex formation.
For the experimental procedures, all materials were purchased from commercial sources and
were used without further purification. β-cyclodextrin was supplied by Wacker Chemie UK.
The characterisation of CDTs, CDEn and CDEnFA was performed using nuclear magnetic
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resonance (NMR) spectroscopy, which is a technique that allows for a complete analysis of
the structure of organic compounds.
NMR is a phenomenon that occurs when the nuclei of certain atoms are immersed in a static
magnetic field.6 Some nuclei experience this phenomenon and others do not, depending upon
whether they possess a property called spin or angular momentum. Atomic nuclei with even
numbers of protons and neutrons have zero spin and all the other atoms with odd numbers
have a non-zero spin. In the NMR experiment, a spin flip between the energy levels occurs.
The energy difference between two states corresponds to the energy of the electromagnetic
radiation that causes the nuclei to change their energy levels. The energy absorbed by the
nuclear spins induces a voltage that can be detected, amplified, and the signal displayed as a
free induction decay.7 The most common types of NMR spectroscopy are carbon-13 NMR
(13C NMR) and proton NMR (1H NMR), which provide information on the amounts and
types of carbons and protons in the molecule, respectively. A 2D Heteronuclear SingleQuantum Correlation (HSQC) NMR experiment permits to obtain a 2D heteronuclear
chemical shift correlation between directly-bonded 1H and

13

C. The NMR characterisation

was performed on a Bruker (Boston, MA) Avance 400 NMR spectrometer operating at 400
MHz for 1H and 100 MHz for

13

C. Bruker Icon NMR software was used with a HP x1100

Pentium 4 workstation. 1H and 13C spectra of CDTs and folic acid were recorded in DMSOd6 due lack of solubility in D2O. All other samples were recorded in D2O and were referenced
to TMS at 0 ppm. Samples were of approximate concentrations of 15-50 x 10-3 mol dm-3.
Figure 7.1 shows the numbering system used for β-CD when assigning NMR shifts, while the
additional numbering systems for the substituents in its derivatives CDTs, CDEn and
CDEnFA are shown in the next figures in this section.
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Figure 7.1. Numbering system for the substituted glucose unit of β-cyclodextrin, where x is
the substitutent.

Step 1) Synthesis and characterisation of 6-o-monotosyl-6-deoxy-β-cyclodextrin (CDTs)
β-cyclodextrin hydrate β-CD (10.01 g, 7.61 mmol) was dissolved in NaOH (100 cm3 of 0.4
mol dm-3). The solution was cooled in ice and p-toluenesulfonyl chloride TsCl (3.0 g, 15.79
mmol) was added. The mixture was stirred for 3 hours at 0 – 4 oC. The mixture was then
filtered and the pH of the filtrate adjusted to 6.5 using HCl (1 mol dm-3, 20 cm3) and a
precipitate formed. The filtrate was then cooled at 4 oC for 24 hours. The product was
removed by filtration, washed with acetone and recrystallised from water several times. The
solid was recovered by filtration, washed with acetone and allowed to dry at 60 °C for 4
hours.
Yield 2.63 g, 24% (based on hydrated material).
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Figure 7.2. Numbering system for CDTs, where R is the glucose unit of the β-CD displayed
in figure 7.1.

1

H NMR (DMSO) δ (ppm): 7.7 (H8), 7.4 (H9), 5.8 (OH2, OH3), 4.8 (H1), 4.5 (OH6), 4.3

(H6b), 3.6 (H6), 3.6 (H3), 3.5 (H5), 3.3 (H4), 3.3 (H2), 2.5 (H11).
13

C NMR (DMSO) δ (ppm): 144.7 (C10), 132.6 (C7), 129.8 (C9), 127.5 (C8), 102.1 (C1’),

101.8 (C1), 101.2 (C1’’), 81.4 (C4’), 81.1 (C4’’), 80.7 (C4), 73.0 (C3), 72.6 (C2’ or C3’),
72.3 (C2), 71.9 (C5), 68.8 (C6’), 69.8 (C5’), 59.8 (C6), 59.4 (C6’’), 21.1 (C11).

13

C NMR

158

Chapter 7

1

Supplementary Information

H NMR

HSQC

159

Chapter 7

Supplementary Information

Step 2) Synthesis and characterisation of 6-deoxy-6-[1-(2-amino)ethylamino]-βcyclodextrin (CDEn)
6-o-monotosyl-6-deoxy-β-cyclodextrin (CDTs 2.5 g, 1.74 mmol) was dissolved in 1,2diaminoethane (70 cm3, 1.05 mol) and refluxed under nitrogen for 24 hours at 70 oC. The
mixture was concentrated under vacuum and gave a pale yellow viscous oil. The oil was then
dissolved in a minimum volume of water: methanol (3:1) mixture. The solution was slowly
added to cold acetone and a precipitate formed. The precipitate was recovered by filtration,
washed with acetone and dried in air. The product was dissolved in a minimum volume of
water (60 °C). A minimum volume of acetone was added to just initiate crystallisation and
the mixture was cooled to 4 °C. The product was recovered by filtration, washed with acetone
and dried at 60 °C for 4 hours.
Yield: 1.4g, 60% (based on hydrated material).

Figure 7.3. Numbering system for CDEn, where R is the glucose unit of the β-CD displayed
in figure 7.1.

1

H NMR (D2O) δ (ppm): 4.9 (H1β), 3.9 (H3), 3.8 (H6a,b), 3.8 (H5), 3.5 (H2), 3.5 (H4), 3.3

(H4’), 3.0 (H6’α), 2.7 (H6’β, H8), 2.6 (H7).
13

C NMR (D2O) δ (ppm): 101.7 (C1), 101.4 (C1’), 83.4 (C4’), 81.0 (C4) 80.8 (C4’’), 73.0

(C3), 72.9 (C2’/C3’), 71.9 (C2), 71.7 (C5), 70.3 (C5’), 60.1 (C6), 49.8 (C9), 49.1 (C6’), 39.3
(C8).
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HSQC

Step 3) Synthesis and characterisation of 6-deoxy-6-[(1-(2-amino)ethylamino)folate]-βcyclodextrin (CDEnFA)
Folic acid (0.075 g, 0.17 mmol) was dissolved in dimethylsufoxide (DMSO, 10 cm3) along
with N-hydroxysuccinimide (NHS, 0.021 g, 0.18 mmol). Dicyclohexylcarbodiimide (DCC,
0.038 g, 0.18 mmol) was then added, and the reaction mixture was stirred overnight in
darkness under nitrogen at room temperature. The insoluble by-product, dicyclohexylurea,
was removed by filtration. The filtrate contained the DMSO solution of the Nhydroxysuccinimide ester (NHS-FA) intermediate. CDEn (0.3 g, 0.22 mmol) was dissolved
in pyridine (2 cm3) and added to the NHS-FA solution. The reaction was performed under a
nitrogen atmosphere at 55 °C for 4 h. The resultant solution was diluted with a mixture of
acetone:diethylether (1:1 vol/vol, 45 cm3) and the product was recovered by filtration
followed by recrystallisation from water.
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Yield: 0.23 g, 55 % (based on hydrated material).

Figure 7.4. Numbering system for CDEnFA, where R is the glucose unit of the β-CD
displayed in figure 7.1.

1

H NMR (D2O) δ (ppm): 4.94 (H1β), 3.45 (H2), 3.79 (H3), 3.41 (H4), 3.71 (H5), 3.47

(H6a,b), 2.07 (H7), 2.67 (H8), 2.59 (H10), 2.15 (H11a), 2.00 (H11b), 4.18 (H12), 6.53
(H16/18), 7.51 (H17/19), 4.66 (H21), 8.46 (H23).
13

C NMR (D2O) δ (ppm): 102.4 (C1), 102.4 (C1’), 82.8 (C4’), 82.1 (C4) 82.1 (C4’’), 72.9

(C3), 72.9 (C2’/C3’), 72.4 (C2), 72.0 (C5), 69.9 (C5’), 59.8 (C6), 48.6 (C6’), 39.9 (C8),
165.3 (C9), 32.2 (C10), 30.7 (C11), 48.6 (C12), 161.6 (C13), 156.3 (C14), 122.3 (C15), 111.6
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(C16), 128.2 (C17), 111.6 (C18), 129.2 (C19), 150.5 (C20), 46.4 (C21), 148.2 (C22), 148.4
(C23), 128.2 (C24), 154.3 (C25), 156.3 (C26), 161.6 (C27).
13

1

C NMR

H NMR
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Preparation of the inclusion complex CDEnFA:MTX
The inclusion complex was prepared by combining CDEnFA and MTX in a 1:1 molar ratio
using the paste method. CDEnFA was placed in a glass beaker with a minimum volume of
water and stirred to achieve a homogeneous paste. Then, MTX powder was added slowly
and the mixture stirred for 45 minutes. The paste was dried in an oven at 45 oC for 48 hours.
The resulting solid was ground and stored in the dark. The NMR characterisation of the
inclusion complex was reported by Tofzikovskaya et al (2012).8
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Appendix 1. Plate design for real-time PCR.

Figure A.1. Plate design for real-time PCR. C=CaCo-2; S=SKOV-3; H=HeLa; A=A549;
B=BEAS-2B. 1, 2 and 3 represent biological triplicates. Two plates were used for assessing
all reference and target genes. (KB cells were added to another experiment).
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Appendix 2. Significant difference of folate receptor gene expression between folate-replete
and folate free media.
FOLATE RECEPTOR
Two-way ANOVA
Source of Variation

% of total variation

P value

Column Factor

96.3

0.0001

Row Factor

0.04

0.9702

Source of Variation

P value summary

Significant?

Column Factor

***

Yes

Row Factor

ns

No

Source of Variation

Df

Sum-of-squares

Mean
square

F

Column Factor

3

40.02

13.34

52.55

Row Factor

2

0.01546

0.007728

0.03044

Residual

6

1.523

0.2539

Bonferroni posttests
folate-replete vs HeLa folate free
Row Factor

folate-replete

HeLa folate free

Difference

95% CI of diff.

Row 1

1

2.313

1.313

-1.695 to 4.320

Row 2

1

3.062

2.062

-0.9455 to 5.070

Row 3
Row Factor

1
Difference

3
t

2

-1.008 to 5.008

P value

Summary

Row 1

1.313

1.842

P > 0.05

ns

Row 2

2.062

2.894

P > 0.05

ns

Row 3

2

2.807

P > 0.05

ns

Difference

95% CI of diff.

folate-replete vs Skov folate free
Row Factor

folate-replete

Skov folate free

Row 1

1

4.296

3.296

0.2887 to 6.304

Row 2

1

4.777

3.777

0.7698 to 6.785

Row 3

1

4.3

3.3

0.2924 to 6.308

Row Factor

Difference

t

P value

Summary

Row 1

3.296

4.626

P < 0.05

*

Row 2

3.777

5.301

P<0.01

**

4.631

P < 0.05

*

Difference

95% CI of diff.

Row 3

3.3

folate-replete vs MCF-7 folate free
Row Factor

folate-replete

MCF-7 folate free

Row 1

1

6.537

5.537

2.529 to 8.545

Row 2

1

5.11

4.11

1.102 to 7.117

Row 3

1

6

5

1.992 to 8.008

Row Factor

Difference

t

P value

Summary

Row 1

5.537

7.771

P<0.001

***

Row 2

4.11

5.767

P<0.01

**

Row 3

5

7.017

P<0.01

**
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Appendix 3. Significant difference of reduced folate carrier gene expression between folatereplete and folate free media.
REDUCED FOLATE CARRIER
Two-way ANOVA
Source of Variation

% of total variation

Column Factor
Row Factor

P value

90.05

0.0007

3.16

0.3183

Source of Variation

P value summary

Significant?

Column Factor

***

Yes

Row Factor

ns

No

Source of Variation

Df

Sum-of-squares

Mean square

F

Column Factor

3

9.606

3.202

26.5

Row Factor

2

0.3369

0.1684

1.394

Residual

6

0.725

0.1208

Bonferroni posttests
folate-replete vs HeLa folate free
Row Factor

reg rpmi

HeLa

Difference

95% CI of diff.

Row 1

1

0.2693

-0.7307

-2.806 to 1.344

Row 2

1

0.3687

-0.6313

-2.706 to 1.444

Row 3

1

0.3

-0.7

-2.775 to 1.375

Row Factor

Difference

t

P value

Summary

Row 1

-0.7307

1.486

P > 0.05

ns

Row 2

-0.6313

1.284

P > 0.05

ns

Row 3

-0.7

1.424

P > 0.05

ns

Difference

95% CI of diff.

folate-replete vs Skov folate free
Row Factor

reg rpmi

Skov

Row 1

1

2.874

1.874

-0.2009 to 3.949

Row 2

1

1.824

0.824

-1.251 to 2.899

Row 3

1

2.8

1.8

Row Factor

Difference

t

-0.2750 to 3.875

P value

Summary

Row 1

1.874

3.812

P < 0.05

*

Row 2

0.824

1.676

P > 0.05

ns

Row 3

1.8

3.662

P < 0.05

*

Difference

95% CI of diff.

folate-replete vs MCF-7 folate free
Row Factor

reg rpmi

MCF-7

Row 1

1

0.04126

-0.9587

-3.034 to 1.116

Row 2

1

0.07002

-0.93

-3.005 to 1.145

Row 3

1

0.8

-0.2

-2.275 to 1.875

P value

Summary

Row 1

-0.9587

1.95

P > 0.05

ns

Row 2

-0.93

1.892

P > 0.05

ns

Row 3

-0.2

0.4068

P > 0.05

ns

Row Factor

Difference

t
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Appendix 4. Significant difference of Ct values for FR and RFC gene expression between
each cell line and the BEAS-2B cell line.
Folate Receptor CT
One-way analysis of variance
P value
alue summary
Are means signif. different?
(P < 0.05)
Number of groups
F
R squared
ANOVA Table
Treatment (between columns)
Residual (within columns)
Total
Dunnett's Multiple Comparison Test
BEAS-2B vs KB
BEAS-2B vs CaCo-2
BEAS-2B vs SKOV
BEAS-2B vs HeLa
BEAS-2B vs MCF-7
BEAS-2B vs A549

< 0.0001
***
Yes
7
63.41
0.9645
SS
264.6
9.739
274.4

df
6
14
20

MS
44.11
0.6956

Mean Diff.

q

Significant?
P < 0.05?

Summary

95% CI of diff

11.13
6.199
5.215
2.128
1.880
1.333

16.34
9.103
7.658
3.124
2.761
1.957

Yes
Yes
Yes
Yes
No
No

***
***
***
*
ns
ns

9.143 to 13.11
4.216 to 8.183
3.232 to 7.199
0.1443 to 4.111
-0.1034 to 3.863
-0.6507 to 3.316

Summary

95% CI of diff

***
ns
*
***
***
**

2.202 to 6.112
-0.1948 to 3.715
0.2319 to 4.141
2.541 to 6.451
1.721 to 5.631
1.059 to 4.968

Reduced Folate Carrier CT
One-way analysis of variance
P value
P value summary
Are means signif. different?
(P < 0.05)
Number of groups
F
R squared
ANOVA Table
Treatment (between columns)
Residual (within columns)
Total

Dunnett's Multiple Comparison Test
BEAS-2B vs KB
BEAS-2B vs CaCo-2
BEAS-2B vs SKOV-3
BEAS-2B vs HeLa
BEAS-2B vs MCF-7
BEAS-2B vs A549

0.0001
***
Yes
7
10.96
0.8245
SS
44.45
9.459
53.91

df
6
14
20

Mean Diff.

q

4.157
1.760
2.187
4.496
3.676
3.014

6.194
2.622
3.258
6.699
5.477
4.490
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MS
7.408
0.6757

Significant?
P < 0.05?
Yes
No
Yes
Yes
Yes
Yes
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Appendix 5. Significant difference of Ct values for FR and RFC gene expression between
all cell lines.
Folate Receptor CT
One-way analysis of variance
P value
P value summary
Are means signif. different?
(P < 0.05)
Number of groups
F
R squared
ANOVA Table
Treatment (between columns)
Residual (within columns)
Total

Tukey's Multiple Comparison Test
KB vs CaCo-2
KB vs SKOV
KB vs HeLa
KB vs MCF-7
KB vs A549
KB vs BEAS-2B
CaCo-2 vs SKOV
CaCo-2 vs HeLa
CaCo-2 vs MCF-7
CaCo-2 vs A549
CaCo-2 vs BEAS-2B
SKOV vs HeLa
SKOV vs MCF-7
SKOV vs A549
SKOV vs BEAS-2B
HeLa vs MCF-7
HeLa vs A549
HeLa vs BEAS-2B
MCF-7 vs A549
MCF-7 vs BEAS-2B
A549 vs BEAS-2B

< 0.0001
***
Yes
7
63.41
0.9645
SS
264.6
9.739
274.4

df
6
14
20

Mean Diff.
-4.928
-5.912
-8.999
-9.247
-9.794
-11.13
-0.9840
-4.071
-4.319
-4.866
-6.199
-3.087
-3.335
-3.883
-5.215
-0.2478
-0.7951
-2.128
-0.5473
-1.880
-1.333

q
10.23
12.28
18.69
19.20
20.34
23.11
2.043
8.455
8.970
10.11
12.87
6.412
6.926
8.063
10.83
0.5145
1.651
4.419
1.137
3.904
2.768

172

MS
44.11
0.6956

Significant?
P < 0.05? Summary
Yes
***
Yes
***
Yes
***
Yes
***
Yes
***
Yes
***
No
ns
Yes
***
Yes
***
Yes
***
Yes
***
Yes
**
Yes
**
Yes
***
Yes
***
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns

95% CI of diff
-7.253 to -2.602
-8.237 to -3.586
-11.32 to -6.674
-11.57 to -6.921
-12.12 to -7.469
-13.45 to -8.801
-3.309 to 1.341
-6.397 to -1.746
-6.645 to -1.994
-7.192 to -2.541
-8.525 to -3.874
-5.413 to -0.7621
-5.661 to -1.010
-6.208 to -1.557
-7.541 to -2.890
-2.573 to 2.078
-3.120 to 1.530
-4.453 to 0.1976
-2.873 to 1.778
-4.205 to 0.4454
-3.658 to 0.9927
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Reduced Folate Carrier CT
One-way analysis of variance
P value
P value summary
Are means signif. different? (P <
0.05)
Number of groups
F
R squared
ANOVA Table
Treatment (between columns)
Residual (within columns)
Total

Tukey's Multiple Comparison Test
KB vs CaCo-2
KB vs SKOV-3
KB vs HeLa
KB vs MCF-7
KB vs A549
KB vs BEAS-2B
CaCo-2 vs SKOV-3
CaCo-2 vs HeLa
CaCo-2 vs MCF-7
CaCo-2 vs A549
CaCo-2 vs BEAS-2B
SKOV-3 vs HeLa
SKOV-3 vs MCF-7
SKOV-3 vs A549
SKOV-3 vs BEAS-2B
HeLa vs MCF-7
HeLa vs A549
HeLa vs BEAS-2B
MCF-7 vs A549
MCF-7 vs BEAS-2B
A549 vs BEAS-2B

0.0001
***
Yes
7
10.96
0.8245
SS
44.45
9.459
53.91

Mean Diff.
-2.397
-1.971
0.3389
-0.4812
-1.144
-4.157
0.4267
2.736
1.916
1.254
-1.760
2.309
1.489
0.8270
-2.187
-0.8201
-1.483
-4.496
-0.6624
-3.676
-3.014

df
6
14
20

q
5.052
4.152
0.7141
1.014
2.410
8.760
0.8992
5.766
4.038
2.642
3.708
4.866
3.138
1.743
4.608
1.728
3.124
9.474
1.396
7.746
6.350
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MS
7.408
0.6757

Significant?
P < 0.05? Summary
Yes
*
No
ns
No
ns
No
ns
No
ns
Yes
***
No
ns
Yes
*
No
ns
No
ns
No
ns
Yes
*
No
ns
No
ns
No
ns
No
ns
No
ns
Yes
***
No
ns
Yes
**
Yes
**

95% CI of diff
-4.689 to -0.1056
-4.262 to 0.3211
-1.953 to 2.631
-2.773 to 1.810
-3.435 to 1.148
-6.449 to -1.866
-1.865 to 2.718
0.4445 to 5.028
-0.3756 to 4.208
-1.038 to 3.545
-4.052 to 0.5318
0.01778 to 4.601
-0.8023 to 3.781
-1.465 to 3.119
-4.478 to 0.1051
-3.112 to 1.472
-3.774 to 0.8092
-6.788 to -2.204
-2.954 to 1.629
-5.968 to -1.384
-5.305 to -0.7219
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Appendix 6. Significant difference of folate receptor gene expression between each cell line
and the calibrator sample BEAS-2B (relative fold-difference values).

FR sig dif to BEAS-2B (set to 1)
Two-way ANOVA
Source of Variation
Column Factor

% of total
variation

P value

97.98

< 0.0001

0.77

0.0922

P value summary

Significant?

Column Factor

***

Yes

Row Factor

ns

Mean
square
2582

156
3.054

Row Factor
Source of Variation

Column Factor

5

No
Sum-ofsquares
12910

Row Factor

2

101.1

50.56

10

165.6

16.56

BEAS-2B

KB

Difference

1.000

2557

2556

1.000

3915

3914

1.000

1117

1116

Source of Variation

Residual

Df

F

Bonferroni posttests
BEAS-2B vs KB
Row Factor
Row 1
Row 2
Row 3

95% CI of
diff.
-244.5 to
5357
1113 to 6714
-1685 to
3917

Difference

t

P value

Summary

Row 1

2556

3.421

P<0.001

***

Row 2

3914

5.238

P<0.001

***

Row 3

1116

1.493

P<0.001

***

BEAS-2B

CaCo-2

Difference

1.000

78.28

77.28

1.000

76.85

75.85

1.000

65.94

64.94

Difference

t

P value

Summary

Row 1

77.28

13.43

P<0.001

***

Row 2

75.85

13.18

P<0.001

***

Row 3

64.94

11.28

P<0.001

***

BEAS-2B

SKOV-3

Difference

1.000

46.63

45.63

Row Factor

BEAS-2B vs CaCo-2
Row Factor
Row 1
Row 2
Row 3
Row Factor

95% CI of
diff.
55.25 to
99.30
53.83 to
97.88
42.91 to
86.96

BEAS-2B vs SKOV-3
Row Factor
Row 1
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95% CI of
diff.
23.60 to
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67.66
Row 2
Row 3
Row Factor
Row 1

11.56 to
55.61
8.758 to
52.81

1.000

34.59

33.59

1.000

31.78

30.78

Difference

t

P value

Summary

45.63

7.929

P<0.001

***
***
***

Row 2

33.59

5.837

P<0.001

Row 3

30.78

5.349

P<0.001

BEAS-2B

HeLa

Difference

1.000

8.576

7.576

1.000

2.572

1.572

1.000

3.785

2.785

Difference

t

P value

Summary

Row 1

7.576

1.316

P > 0.05

ns

Row 2

1.572

0.2731

P > 0.05

ns

Row 3

2.785

0.484

P > 0.05

ns

BEAS-2B

MCF-7

Difference

1.000

7.742

6.742

1.000

2.106

1.106

1.000

3.059

2.059

BEAS-2B vs HeLa
Row Factor
Row 1
Row 2
Row 3
Row Factor

95% CI of
diff.
-14.45 to
29.60
-20.45 to
23.60
-19.24 to
24.81

BEAS-2B vs MCF-7
Row Factor
Row 1
Row 2
Row 3

95% CI of
diff.
-15.28 to
28.77
-20.92 to
23.13
-19.97 to
24.08

Difference

t

P value

Summary

Row 1

6.742

1.172

P > 0.05

ns

Row 2

1.106

0.1921

P > 0.05

ns

Row 3

2.059

0.3578

P > 0.05

ns

BEAS-2B

A549

Difference

1.000

0.9281

-0.07191

1.000

5.941

4.941

1.000

2.898

1.898

Difference

t

P value

Summary

-0.07191

0.0125

P > 0.05

ns
ns
ns

Row Factor

BEAS-2B vs A549
Row Factor
Row 1
Row 2
Row 3
Row Factor
Row 1
Row 2

4.941

0.8586

P > 0.05

Row 3

1.898

0.3298

P > 0.05
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95% CI of
diff.
-22.10 to
21.95
-17.08 to
26.97
-20.13 to
23.92
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Appendix 7. Significant difference of reduced folate carrier gene expression between each
cell line and the calibrator sample BEAS-2B.
RFC sig dif to BEAS-2B (set to 1)
Two-way ANOVA
% of total variation

P value

Column Factor

80.7

0.0014

Row Factor

2.47

0.504

P value summary

Significant?

Column Factor

**

Yes

Row Factor

ns

No

Df

Sum-of-squares

Column Factor

5

Row Factor

Source of Variation

Source of Variation

956.7

Mean
square
191.3

9.589

2

29.31

14.65

0.7344

10

199.5

19.95

BEAS-2B

KB

Difference

95% CI of diff.

Row 1

1.000

11.47

10.47

-20.05 to 40.98

Row 2

1.000

29.65

28.65

-1.868 to 59.16

Row 3

1.000

16.71

15.71

-14.80 to 46.22

Difference

t

P value

Summary

Row 1

10.47

1.286

P > 0.05

ns

Row 2

28.65

3.519

P < 0.05

*

Row 3

15.71

1.930

P > 0.05

ns

BEAS-2B

CaCo-2

Difference

95% CI of diff.

Row 1

1

3.317

2.317

-21.86 to 26.50

Row 2

1

4.563

3.563

-20.62 to 27.74

Row 3

1

6.354

5.354

-18.82 to 29.53

Difference

t

P value

Summary

Row 1

2.317

0.3668

P > 0.05

ns

Row 2

3.563

0.564

P > 0.05

ns

Row 3

5.354

0.8475

P > 0.05

ns

BEAS-2B

SKOV-3

Difference

95% CI of diff.

Row 1

1

9.863

8.863

-15.32 to 33.04

Row 2

1

1.993

0.9934

-23.18 to 25.17

Row 3

1

4.799

3.799

-20.38 to 27.98

Difference

t

P value

Summary

8.863

1.403

P > 0.05

ns

Source of Variation

Residual

F

Bonferroni posttests
BEAS-2B vs KB
Row Factor

Row Factor

BEAS-2B vs CaCo-2
Row Factor

Row Factor

BEAS-2B vs SKOV-3
Row Factor

Row Factor
Row 1
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Row 2

0.9934

0.1573

P > 0.05

ns

Row 3

3.799

0.6013

P > 0.05

ns

BEAS-2B

HeLa

Difference

95% CI of diff.

Row 1

1

21.75

20.75

-3.424 to 44.93

Row 2

1

16.59

15.59

-8.592 to 39.76

Row 3

1

31.85

30.85

6.669 to 55.03

Difference

t

P value

Summary

Row 1

20.75

3.285

P < 0.05

*

Row 2

15.59

2.467

P > 0.05

ns

Row 3

30.85

4.883

P<0.01

**

BEAS-2B

MCF-7

Difference

95% CI of diff.

Row 1

1

18.2

17.2

-6.979 to 41.38

Row 2

1

9.007

8.007

-16.17 to 32.19

Row 3

1

12.74

11.74

-12.44 to 35.92

Difference

t

P value

Summary

Row 1

17.2

2.723

P > 0.05

ns

Row 2

8.007

1.267

P > 0.05

ns

Row 3

11.74

1.858

P > 0.05

ns

BEAS-2B

A549

Difference

95% CI of diff.

Row 1

1

5.632

4.632

-19.55 to 28.81

Row 2

1

12.9

11.9

-12.28 to 36.08

Row 3

1

7.248

6.248

-17.93 to 30.43

BEAS-2B vs HeLa
Row Factor

Row Factor

BEAS-2B vs MCF-7
Row Factor

Row Factor

BEAS-2B vs A549
Row Factor

Difference

t

P value

Summary

Row 1

4.632

0.7333

P > 0.05

ns

Row 2

11.9

1.884

P > 0.05

ns

Row 3

6.248

0.9891

P > 0.05

ns

Row Factor
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Appendix 8. Significant difference for the folate receptor protein expression between each
cell line.
FR Protein expression
One-way analysis of variance
P value
P value summary
Are means signif. different?
(P < 0.05)
Number of groups
F
R squared
ANOVA Table
Treatment (between columns)
Residual (within columns)
Total
Tukey's Multiple
Comparison Test
KB vs CaCo-2
KB vs SKOV-3
KB vs HeLa
KB vs MCF-7
KB vs A549
KB vs BEAS-2B
CaCo-2 vs SKOV-3
CaCo-2 vs HeLa
CaCo-2 vs MCF-7
CaCo-2 vs A549
CaCo-2 vs BEAS-2B
SKOV-3 vs HeLa
SKOV-3 vs MCF-7
SKOV-3 vs A549
SKOV-3 vs BEAS-2B
HeLa vs MCF-7
HeLa vs A549
HeLa vs BEAS-2B
MCF-7 vs A549
MCF-7 vs BEAS-2B
A549 vs BEAS-2B

< 0.0001
***
Yes
7
62.82
0.9642
SS
2601000000000
96610000000
2698000000000

df
MS
6 433500000000
14
6901000000
20

Mean Diff.
q
896400
18.69
1035000
21.58
1021000
21.28
936300
19.52
1039000
21.67
1039000
21.67
138600
2.891
124500
2.595
39910
0.8322
142800
2.977
142800
2.978
-14160
0.2952
-98730
2.058
4138 0.08628
4208 0.08773
-84570
1.763
18300
0.3815
18370
0.3829
102900
2.145
102900
2.146
69.67 0.001453
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Significant?
P < 0.05? Summary
Yes
***
Yes
***
Yes
***
Yes
***
Yes
***
Yes
***
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns
No
ns

95% CI of diff
664800 to 1128000
803400 to 1267000
789200 to 1252000
704700 to 1168000
807500 to 1271000
807600 to 1271000
-92970 to 370200
-107100 to 356100
-191700 to 271500
-88830 to 374400
-88760 to 374500
-245800 to 217400
-330300 to 132900
-227500 to 235700
-227400 to 235800
-316200 to 147000
-213300 to 249900
-213200 to 250000
-128700 to 334500
-128700 to 334500
-231500 to 231700
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Appendix 9. Significant difference for the reduced folate carrier protein expression between
each cell line.
RFC protein expression
One-way analysis of variance
P value
P value summary
Are means signif. different?
(P < 0.05)
Number of groups
F
R squared

0.0298
ns
No
7
3.331
0.5881

ANOVA Table
Treatment (between columns)
Residual (within columns)
Total

SS
43410000
30410000
73820000

df
6
14
20

Tukey's Multiple
Comparison Test
KB vs CaCo-2
KB vs SKOV-3
KB vs HeLa
KB vs MCF-7
KB vs A549
KB vs BEAS-2B
CaCo-2 vs SKOV-3
CaCo-2 vs HeLa
CaCo-2 vs MCF-7
CaCo-2 vs A549
CaCo-2 vs BEAS-2B
SKOV-3 vs HeLa
SKOV-3 vs MCF-7
SKOV-3 vs A549
SKOV-3 vs BEAS-2B
HeLa vs MCF-7
HeLa vs A549
HeLa vs BEAS-2B
MCF-7 vs A549
MCF-7 vs BEAS-2B
A549 vs BEAS-2B

Mean Diff.
992.3
3399
124.0
-611.2
899.7
3112
2407
-868.3
-1604
-92.67
2120
-3275
-4010
-2499
-286.8
-735.2
775.7
2988
1511
3723
2213

q
1.166
3.995
0.1457
0.7183
1.057
3.658
2.828
1.021
1.885
0.1089
2.491
3.849
4.713
2.937
0.3371
0.8640
0.9116
3.512
1.776
4.376
2.600
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MS
7235000
2172000

Significant?
P < 0.05? Summary 95% CI of diff
No
ns -3117 to 5101
No
ns -709.9 to 7508
No
ns -3985 to 4233
No
ns -4720 to 3498
No
ns -3209 to 5009
No
ns -996.7 to 7221
No
ns -1702 to 6516
No
ns -4977 to 3241
No
ns -5712 to 2505
No
ns -4202 to 4016
No
ns -1989 to 6229
No
ns -7384 to 833.9
No
ns -8119 to 98.74
No
ns -6608 to 1610
No
ns -4396 to 3822
No
ns -4844 to 3374
No
ns -3333 to 4885
No
ns -1121 to 7097
No
ns -2598 to 5620
No
ns -385.6 to 7832
No
ns -1896 to 6321
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Appendix 10. Significant difference in cell viability between control (fresh medium: 100%
cell viability) and CDEnFA treatment.
Control vs CDEnFA treatment
Two-way ANOVA
Source of Variation
Interaction
Column Factor
Concentration

% of total variation
17.29
29.42
9.48

P value
0.2988
< 0.0001
0.0177

Source of Variation
Interaction
Column Factor
Concentration

P value summary
ns
***
*

Significant?
No
Yes
Yes

Source of Variation
Interaction
Column Factor
Concentration
Residual

Df
20
5
4
60

Number of missing values

15

Sum-of-squares Mean square
876.1
43.81
1490
298.1
480.3
120.1
2219
36.98

F
1.185
8.060
3.247

Bonferroni posttests
Control vs KB
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
Control vs CaCo-2
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0

Control
100.0
100.0
100.0
100.0
100.0

KB
91.34
91.29
90.19
86.12
84.27

Difference
-8.665
-8.708
-9.806
-15.88
-19.53

95% CI of diff.
-25.01 to 7.685
-25.06 to 7.642
-26.16 to 6.543
-32.23 to 0.4676
-35.88 to -3.183

Difference
-8.665
-8.708
-9.806
-15.88
-19.53

t
1.745
1.754
1.975
3.199
3.934

P value
P > 0.05
P > 0.05
P > 0.05
P < 0.05
P<0.01

Summary
ns
ns
ns
*
**

Control
100.0
100.0
100.0
100.0
100.0

CaCo-2
93.91
95.69
91.88
95.21
93.82

Difference
-6.086
-4.310
-8.120
-4.793
-6.182

95% CI of diff.
-22.44 to 10.26
-20.66 to 12.04
-24.47 to 8.229
-21.14 to 11.56
-22.53 to 10.17

Difference
-6.086
-4.310
-8.120
-4.793
-6.182

t
1.226
0.8681
1.635
0.9652
1.245

P value
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns
ns
ns
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Control vs MCF-7
Concentration
1.000
5.000
10.00
50.00
100.0

Control
100.0
100.0
100.0
100.0
100.0

MCF-7
102.9
102.4
100.3
91.17
84.32

Difference
2.940
2.431
0.2626
-8.830
-15.68

95% CI of diff.
-13.41 to 19.29
-13.92 to 18.78
-16.09 to 16.61
-25.18 to 7.519
-32.03 to 0.6648

Concentration
1.000
5.000
10.00
50.00
100.0

Difference
2.940
2.431
0.2626
-8.830
-15.68

t
0.5922
0.4895
0.05289
1.778
3.159

P value
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P < 0.05

Summary
ns
ns
ns
ns
*

Control
100.0
100.0
100.0
100.0
100.0

A549
97.04
93.45
94.96
100.7
96.31

Difference
-2.958
-6.552
-5.045
0.6704
-3.686

95% CI of diff.
-19.31 to 13.39
-22.90 to 9.797
-21.39 to 11.30
-15.68 to 17.02
-20.04 to 12.66

Difference
-2.958
-6.552
-5.045
0.6704
-3.686

t
0.5958
1.320
1.016
0.1350
0.7423

P value
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns
ns
ns

Control
100.0
100.0
100.0
100.0
100.0

BEAS-2B
94.44
92.66
90.44
91.54
87.61

Difference
-5.558
-7.339
-9.563
-8.457
-14.85

95% CI of diff.
-21.91 to 10.79
-23.69 to 9.010
-25.91 to 6.786
-24.81 to 7.892
-31.20 to 1.494

Difference
-5.558
-7.339
-9.563
-8.457
-14.85

t
1.119
1.478
1.926
1.703
2.992

P value
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P < 0.05

Summary
ns
ns
ns
ns
*

Control vs A549
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
Control vs BEAS-2B
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
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Appendix 11. Significant difference in cell viability between control (fresh medium: 100%
cell viability) and MTX treatment.
Control vs MTX treatment
Two-way ANOVA
Source of Variation
Interaction
Column Factor
Concentration

% of total variation
24.52
34.34
37.14

P value
< 0.0001
< 0.0001
< 0.0001

Source of Variation
Interaction
Column Factor
Concentration

P value summary
***
***
***

Significant?
Yes
Yes
Yes

Source of Variation
Interaction
Column Factor
Concentration
Residual

Df
20
5
4
60

Sum-of-squares
11970
16760
18130
1953

Mean square
598.4
3352
4532
32.55

F
18.38
103.0
139.3

Number of missing values

15

Control
100.0
100.0
100.0
100.0
100.0

KB
57.52
59.40
60.41
56.53
57.87

Difference
-42.48
-40.60
-39.59
-43.47
-42.13

95% CI of diff.
-57.81 to -27.14
-55.94 to -25.26
-54.93 to -24.25
-58.80 to -28.13
-57.47 to -26.80

Difference
-42.48
-40.60
-39.59
-43.47
-42.13

t
9.119
8.716
8.499
9.331
9.045

P value
P<0.001
P<0.001
P<0.001
P<0.001
P<0.001

Summary
***
***
***
***
***

Control
100.0
100.0
100.0
100.0
100.0

CaCo-2
87.16
77.94
82.98
77.89
32.98

Difference
-12.84
-22.06
-17.02
-22.11
-67.02

95% CI of diff.
-28.17 to 2.502
-37.39 to -6.718
-32.36 to -1.685
-37.44 to -6.769
-82.36 to -51.68

Difference
-12.84
-22.06
-17.02
-22.11
-67.02

t
2.756
4.735
3.654
4.746
14.39

P value
P < 0.05
P<0.001
P<0.01
P<0.001
P<0.001

Summary
*
***
**
***
***

Bonferroni posttests
Control vs KB
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
Control vs CaCo-2
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
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Control vs MCF-7
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
Control vs A549
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
Control vs BEAS-2B
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0

Control
100.0
100.0
100.0
100.0
100.0

MCF-7
108.3
99.91
96.15
55.28
45.58

Difference
8.274
-0.09296
-3.847
-44.72
-54.42

95% CI of diff.
-7.065 to 23.61
-15.43 to 15.25
-19.19 to 11.49
-60.06 to -29.38
-69.76 to -39.09

Difference
8.274
-0.09296
-3.847
-44.72
-54.42

t
1.776
0.01996
0.8259
9.600
11.68

P value
P > 0.05
P > 0.05
P > 0.05
P<0.001
P<0.001

Summary
ns
ns
ns
***
***

Control
100.0
100.0
100.0
100.0
100.0

A549
91.02
80.15
67.36
38.24
36.23

Difference
-8.983
-19.85
-32.64
-61.76
-63.77

95% CI of diff.
-24.32 to 6.355
-35.18 to -4.508
-47.98 to -17.30
-77.10 to -46.42
-79.11 to -48.43

Difference
-8.983
-19.85
-32.64
-61.76
-63.77

t
1.929
4.260
7.007
13.26
13.69

P value
P > 0.05
P<0.001
P<0.001
P<0.001
P<0.001

Summary
ns
***
***
***
***

Control
100.0
100.0
100.0
100.0
100.0

BEAS-2B
98.21
100.3
91.17
56.72
48.38

Difference
-1.788
0.3266
-8.827
-43.28
-51.62

95% CI of diff.
-17.13 to 13.55
-15.01 to 15.66
-24.17 to 6.511
-58.62 to -27.94
-66.95 to -36.28

Difference
-1.788
0.3266
-8.827
-43.28
-51.62

t
0.3839
0.07012
1.895
9.291
11.08

P value
P > 0.05
P > 0.05
P > 0.05
P<0.001
P<0.001

Summary
ns
ns
ns
***
***
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Appendix 12. Significant difference of cell viability between control (fresh medium: 100%
cell viability) and CDEnFA:MTX treatment.
Control vs CDEnFA:MTX treatment
Two-way ANOVA
Source of Variation
Interaction
Column Factor
Concentration

% of total variation
16.31
42.86
39.04

P value
< 0.0001
< 0.0001
< 0.0001

Source of Variation
Interaction
Column Factor
Concentration

P value summary
***
***
***

Significant?
Yes
Yes
Yes

Source of Variation
Interaction
Column Factor
Concentration
Residual

Df Sum-of-squares
20
10030
5
26360
4
24010
60
1100

Number of missing values

15

Mean square
501.7
5272
6003
18.34

F
27.36
287.5
327.4

Bonferroni posttests
Control vs KB
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
Control vs CaCo-2
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0

Control
100.0
100.0
100.0
100.0
100.0

KB
52.22
46.33
48.65
39.50
38.50

Difference
-47.78
-53.67
-51.35
-60.50
-61.50

95% CI of diff.
-59.29 to -36.27
-65.18 to -42.16
-62.86 to -39.84
-72.02 to -48.99
-73.02 to -49.99

Difference
-47.78
-53.67
-51.35
-60.50
-61.50

t
13.66
15.35
14.69
17.30
17.59

P value
P<0.001
P<0.001
P<0.001
P<0.001
P<0.001

Summary
***
***
***
***
***

Control
100.0
100.0
100.0
100.0
100.0

CaCo-2
88.07
78.10
77.25
54.43
35.61

Difference
-11.93
-21.90
-22.75
-45.57
-64.39

95% CI of diff.
-23.44 to -0.4143
-33.42 to -10.39
-34.26 to -11.24
-57.09 to -34.06
-75.91 to -52.88

Difference
-11.93
-21.90
-22.75
-45.57
-64.39

t
3.411
6.265
6.507
13.03
18.42

P value
P<0.01
P<0.001
P<0.001
P<0.001
P<0.001

Summary
**
***
***
***
***
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Control vs MCF-7
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
Control vs A549
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0
Control vs BEAS-2B
Concentration
1.000
5.000
10.00
50.00
100.0
Concentration
1.000
5.000
10.00
50.00
100.0

Control
100.0
100.0
100.0
100.0
100.0

MCF-7
107.3
100.2
92.69
54.65
41.75

Difference
7.299
0.1645
-7.315
-45.35
-58.25

95% CI of diff.
-4.214 to 18.81
-11.35 to 11.68
-18.83 to 4.198
-56.86 to -33.84
-69.77 to -46.74

Difference
7.299
0.1645
-7.315
-45.35
-58.25

t
2.088
0.04705
2.092
12.97
16.66

P value
P > 0.05
P > 0.05
P > 0.05
P<0.001
P<0.001

Summary
ns
ns
ns
***
***

Control
100.0
100.0
100.0
100.0
100.0

A549
103.0
102.7
82.62
45.84
41.44

Difference
2.999
2.712
-17.38
-54.16
-58.56

95% CI of diff.
-8.514 to 14.51
-8.801 to 14.22
-28.89 to -5.864
-65.68 to -42.65
-70.07 to -47.04

Difference
2.999
2.712
-17.38
-54.16
-58.56

t
0.8576
0.7757
4.970
15.49
16.75

P value
P > 0.05
P > 0.05
P<0.001
P<0.001
P<0.001

Summary
ns
ns
***
***
***

Control
100.0
100.0
100.0
100.0
100.0

BEAS-2B
106.6
106.7
100.8
66.88
55.01

Difference
6.583
6.712
0.8202
-33.12
-44.99

95% CI of diff.
-4.930 to 18.10
-4.800 to 18.23
-10.69 to 12.33
-44.64 to -21.61
-56.50 to -33.47

Difference
6.583
6.712
0.8202
-33.12
-44.99

t
1.883
1.920
0.2346
9.474
12.87

P value
P > 0.05
P > 0.05
P > 0.05
P<0.001
P<0.001

Summary
ns
ns
ns
***
***
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Appendix 13. A comparison of the cell viability for each of the cell lines studied after a 48hour exposure to the solvent NaOH and to the compounds CDEnFA, MTX and
CDEnFA:MTX

Figure A.2. Effect of the solvent NaOH, the carrier CDEnFA, the drug MTX and the
complex CDEnFA:MTX on the cell viability of KB, CaCo-2, MCF-7, A549 and BEAS-2B
cells.
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Appendix 14. Plots representing how samples are gated to exclude debris or clumps and to
determine positives.
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Appendix 15. Significant difference in the folate receptor MFI, between KB untreated
sample and (A) FB1-treated or (B) SSZ-treated.

(A) Folate Receptor FB1
Column A
vs
Column B

(B) Folate Receptor SSZ

Untreated
vs
FB1 treated

Unpaired t test
P value
P value summary
Are means signif. different?
(P < 0.05)
One- or two-tailed P value?
t, df
How big is the difference?
Mean ± SEM of column A
Mean ± SEM of column B
Difference between means
95% confidence interval
R squared

0.0049
**
Yes
Two-tailed
t=5.634 df=4

1351000 ± 47170 N=3
637500 ± 117600 N=3
713900 ± 126700
362100 to 1066000
0.8881

Column A
vs
Column B

untreated
vs
SSZ treated

Unpaired t test
P value
P value summary
Are means signif. different?
(P < 0.05)
One- or two-tailed P value?
t, df
How big is the difference?
Mean ± SEM of column A
Mean ± SEM of column B
Difference between means
95% confidence interval
R squared

0.9841
ns
No
Two-tailed
t=0.02124 df=4

1245000 ± 91170 N=3
1247000 ± 89710 N=3
-2717 ± 127900
-357800 to 352400
0.0001128

Appendix 16. Significant difference in the reduced folate carrier MFI, between KB untreated
sample and (A) FB1-treated or (B) SSZ-treated.

Column A
vs
Column B

(A) Reduced Folate Carrier FB1
Untreated
vs
FB1

Unpaired t test
P value
P value summary
Are means signif. different?
(P < 0.05)
One- or two-tailed P value?
t, df
How big is the difference?
Mean ± SEM of column A
Mean ± SEM of column B
Difference between means
95% confidence interval
R squared

0.1202
ns
No
Two-tailed
t=1.970 df=4

15480 ± 291.5 N=3
14650 ± 303.8 N=3
829.3 ± 421.1
-339.5 to 1998
0.4924
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Column A
vs
Column B

(B) Reduced Folate Carrier SSZ
untreated
vs
SSZ treated

Unpaired t test
P value
P value summary
Are means signif. different?
(P < 0.05)
One- or two-tailed P value?
t, df
How big is the difference?
Mean ± SEM of column A
Mean ± SEM of column B
Difference between means
95% confidence interval
R squared

0.0469
*
Yes
Two-tailed
t=2.840 df=4

15780 ± 274.8 N=3
14380 ± 410.8 N=3
1403 ± 494.2
31.40 to 2775
0.6684

Appendix 17. Significant difference in the reduced folate carrier MFI, between KB untreated
sample and (A) FB1-treated or (B) SSZ-treated.
Controls
One-way analysis of variance
P value
P value summary
Are means signif. different?
(P < 0.05)
Number of groups
F
R squared
ANOVA Table
Treatment (between columns)
Residual (within columns)
Total
Dunnett's Multiple
Comparison Test
Live cells vs Dead cells
Live cells vs FB1
Live cells vs SSZ
Live cells vs FB1+SSZ

< 0.0001
***
Yes
5
70.12
0.9656
SS
13060000000
465500000
13520000000

df
4
10
14

Mean Diff.
-77290
-518.8
-8669
-6925

q
13.87
0.09313
1.556
1.243

MS
3264000000
46550000

Significant?
P < 0.05? Summary
Yes
***
No
ns
No
ns
No
ns

95% CI of diff
-93390 to -61190
-16620 to 15580
-24770 to 7433
-23030 to 9177

Appendix 18. Significant difference between untreated samples (test compound only) and
FB1-treated samples. (A) MTX; (B) CDEnFA:MTX and (C) CDEnFA.
(A) MTX FB1
Two-way RM ANOVA
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

% of total variation
6.64
12.39
17.40
32.3816

P value
0.4622
0.2624
0.2165
0.1760

P value summary
ns
ns
ns
ns

Significant?
No
No
No
No

Bonferroni posttests
No treatment (MTX only)
vs FB1 treated
Column Factor
10
100
1000

No treatment (MTX
only)
37290
54130
37820

Column Factor

Difference
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FB1 treated Difference
28210
-9088
33700
-20430
33880
-3941

95% CI of diff.
-38710 to 20540
-50050 to 9194
-33560 to 25680

P value

Summary

t

10 µM
100 µM
1000 µM

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

-9088
-20430
-3941

0.8527
1.917
0.3697

(B) CDEnFAMTX FB1
% of total variation
3.60
7.15
67.72
8.0849
P value summary
ns
ns
**
ns

P > 0.05
P > 0.05
P > 0.05

ns
ns
ns

P value
0.3869
0.1815
0.0044
0.3805

Significant?
No
No
Yes
No

Bonferroni posttests
No treatment (CDEnFA:MTX only)
vs FB1 treated
Column Factor
10
100
1000
Column Factor
10 µM
100 µM
1000 µM

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

(CDEnFA:MTX
only)

FB1 treated Difference

58430
60590
72490

41260
40020
43070

Difference
-17160
-20570
-29410

t
2.720
3.260
4.661

P value
P > 0.05
P < 0.05
P<0.01

Summary
ns
*
**

FB1 treated Difference
3461
180.2
2316
-41.00
3252
174.7

95% CI of diff.
-479.4 to 839.7
-700.5 to 618.5
-484.9 to 834.2

P value
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns

(C) CDEnFA FB1
% of total variation
1.01
76.42
1.05
7.0443
P value summary
ns
***
ns
ns

95% CI of diff.
-34700 to
-17160
373.8
-20570 -38110 to -3031
-29410 -46950 to -11880

P value
0.7629
0.0006
0.4839
0.4729

Significant?
No
Yes
No
No

Bonferroni posttests
No treatment (CDEnFA only)
vs FB1 treated
Column Factor
10
100
1000

No treatment (CDEnFA
only)
3281
2357
3077

Column Factor
10 µM
100 µM
1000 µM

Difference
180.2
-41.00
174.7
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t
0.7593
0.1728
0.7361

Appendix 19. Significant difference between untreated samples (test compound only) and
SSZ-treated samples. (A) MTX; (B) CDEnFA:MTX and (C) CDEnFA.
MTX SSZ
Two-way RM ANOVA
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

% of total variation
5.51
13.52
29.50
13.9067

P value
0.5787
0.2925
0.0435
0.5903

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

P value summary
ns
ns
*
ns

Significant?
No
No
Yes
No

Column Factor
10
100
1000

No treatment (MTX
only)
37290
54130
37820

SSZ treated
22830
30630
30310

Difference
-14460
-23500
-7508

95% CI of diff.
-42280 to 13360
-51320 to 4321
-35330 to 20310

Column Factor
10 µM
100 µM
1000 µM

Difference
-14460
-23500
-7508

t
1.445
2.348
0.7501

P value
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns

Bonferroni posttests
No treatment (MTX
only)
vs SSZ treated

CDEnFA:MTX SSZ
Two-way RM ANOVA

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

% of total
variation
35.86
7.70
0.44
39.0281

P value
0.0107
0.2241
0.8418
0.0320

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

P value summary
*
ns
ns
*

Significant?
Yes
No
No
Yes

Bonferroni posttests
No treatment
(CDEnFA:MTX
only) vs SSZ treated

Column Factor
10

No treatment
(CDEnFA:MTX
only)
58430

SSZ treated Difference
70900
12470
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95% CI of diff.
-23160 to 48100

100
1000
Column Factor
10 µM
100 µM
1000 µM

60590
72490

81300
46140

20710
-26340

-14920 to 56340
-61970 to 9288

Difference
12470
20710
-26340

t
0.9730
1.615
2.055

P value
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns

CDEnFA SSZ
Two-way RM ANOVA

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

% of total
variation
5.66
3.59
47.34
1.9799

P value
0.5993
0.7170
0.0006
0.9810

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

P value
summary
ns
ns
***
ns

Significant?
No
No
Yes
No

Column Factor
10
100
1000

No treatment
(CDEnFA only)
3281
2357
3077

SSZ treated
5159
6778
7764

Difference
1878
4421
4687

95% CI of diff.
-2996 to 6751
-452.6 to 9294
-186.9 to 9560

Column Factor
10 µM
100 µM
1000 µM

Difference
1878
4421
4687

t
1.071
2.521
2.673

P value
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns

Bonferroni posttests
No treatment (CDEnFA
only)
vs SSZ treated
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Appendix 20. Significant difference between untreated samples (test compound only) and
FB1+SSZ co-treated samples. (A) MTX; (B) CDEnFA:MTX and (C) CDEnFA.
MTX FB1+SSZ
Two-way RM ANOVA
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

% of total variation
10.21
19.39
6.80
22.8180

P value
0.4093
0.2110
0.3363
0.4117

P value summary Significant?
ns
No
ns
No
ns
No
ns
No

Bonferroni posttests
No treatment (MTX only)
vs FB1 + SSZ
Column Factor
10
100
1000
Column Factor
10 µM
100 µM
1000 µM

No treatment (MTX only) FB1 + SSZ Difference
37290
36970
-325.0
54130
39480
-14650
37820
36700
-1120

95% CI of diff.
-23130 to 22480
-37450 to 8154
-23920 to 21680

P value
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns

Difference
-325.0
-14650
-1120

t
0.03962
1.786
0.1365

CDEnFA:MTX FB1+SSZ
Two-way RM ANOVA
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

% of total variation
0.34
2.44
93.52
1.5049

P value
0.5599
0.0500
< 0.0001
0.3249

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

P value summary
ns
*
***
ns

Significant?
No
Yes
Yes
No

No treatment
(CDEnFA:MTX only)
58430
60590
72490

FB1 + SSZ
treated
3175
6952
10890

Bonferroni posttests
No treatment (CDEnFA:MTX
only) vs FB1 + SSZ treated
Column Factor
10
100
1000
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Difference
95% CI of diff.
-55250 -70950 to -39550
-53640 -69340 to -37930
-61600 -77300 to -45900

Column Factor
10 µM
100 µM
1000 µM

Difference
-55250
-53640
-61600

t
9.779
9.494
10.90

P value
P<0.001
P<0.001
P<0.001

Summary
***
***
***

CDEnFA FB1+SSZ
Two-way RM ANOVA
Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

% of total variation
17.16
25.42
34.65
8.2732

P value
0.0439
0.0174
0.0149
0.4029

Source of Variation
Interaction
Concentration
Column Factor
Subjects (matching)

P value summary
*
*
*
ns

Significant?
Yes
Yes
Yes
No

Column Factor
10
100
1000

No treatment
(CDEnFA only)
3281
2357
3077

FB1 + SSZ
treated
4510
3802
3090

Difference
1229
1445
13.17

95% CI of diff.
219.8 to 2238
436.4 to 2454
-995.7 to 1022

Column Factor
10 µM
100 µM
1000 µM

Difference
1229
1445
13.17

t
3.385
3.982
0.03627

P value
P < 0.05
P<0.01
P > 0.05

Summary
*
**
ns

Bonferroni posttests
No treatment (CDEnFA only)
vs FB1 + SSZ treated
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Appendix 21. Significant difference between the test samples and sham-inoculated control
for haemocytes count.
Haemocytes
Two-way ANOVA
Source of Variation
Interaction
Column Factor
Row Factor

% of total variation
12.90
65.88
4.71

P value
0.0059
< 0.0001
0.0041

Source of Variation
Interaction
Column Factor
Row Factor

P value summary
**
**
**

Significant?
Yes
Yes
Yes

Bonferroni posttests
Sham vs NaOH
Row Factor
4
10
40
100
400

Row Factor
4
10
40
100
400

Sham vs CDEnFA
Row Factor
4
10
40
100
400

Row Factor
4
10
40
100
400

Sham vs MTX
Row Factor
4
10
40

Sham
7500000
7500000
7500000
7500000
7500000

Difference
833300
666700
-666700
-1667000
1000000

Sham
7500000
7500000
7500000
7500000
7500000

Difference
0.0000
0.0000
0.0000
0.0000
0.0000

Sham
7500000
7500000
7500000
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NaOH Difference
8333000 833300
8167000 666700
6833000 -666700
5833000 -1667000
8500000 1000000

95% CI of diff.
-1739000 to 3406000
-1906000 to 3239000
-3239000 to 1906000
-4239000 to 905800
-1572000 to 3572000

P value
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns
ns
ns

CDEnFA Difference
7500000
0.0000
7500000
0.0000
7500000
0.0000
7500000
0.0000
7500000
0.0000

95% CI of diff.
-2572000 to 2572000
-2572000 to 2572000
-2572000 to 2572000
-2572000 to 2572000
-2572000 to 2572000

P value
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns
ns
ns

MTX Difference
5933000 -1567000
5667000 -1833000
6667000 -833300

95% CI of diff.
-4139000 to 1006000
-4406000 to 739100
-3406000 to 1739000

t
1.047
0.8375
0.8375
2.094
1.256

t
0.0000
0.0000
0.0000
0.0000
0.0000

100
400

Row Factor
4
10
40
100
400

Sham vs CDEnFA:MTX
Row Factor
4
10
40
100
400

Row Factor
4
10
40
100
400

7500000
7500000

6667000 -833300
9667000 2167000

-3406000 to 1739000
-405800 to 4739000

P value
P > 0.05
P > 0.05
P > 0.05
P > 0.05
P > 0.05

Summary
ns
ns
ns
ns
ns

Sham CDEnFA:MTX Difference
7500000
9333000 1833000
7500000
9833000 2333000
7500000
10670000 3167000
7500000
7833000 333300
7500000
10170000 2667000

95% CI of diff.
-739100 to 4406000
-239100 to 4906000
594200 to 5739000
-2239000 to 2906000
94190 to 5239000

t P value
2.303 P > 0.05
2.931 P > 0.05
P<0.01
3.978
0.4188 P > 0.05
P<0.05
3.350

Summary
ns
ns
**
ns
*

Difference
-1567000
-1833000
-833300
-833300
2167000

Difference
1833000
2333000
3167000
333300
2667000
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t
1.968
2.303
1.047
1.047
2.722

